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Duchenne muscular dystrophy (DMD) is a devastating primary muscle disease with pathological 
changes in skeletal muscle that are ongoing at the time of birth. Progressive deterioration in 
striated muscle function in affected individuals ultimately results in early death due to cardio-
pulmonary failure. Since affected individuals can be identified prior to birth by prenatal genetic 
testing for DMD, gene replacement treatment can be started in utero. This approach offers the 
possibility of preventing pathological changes in muscle that begin early in life.  
Previous studies with systemic in utero adenoassociated viral (AAV) vector serotype 1 
gene delivery to embryonic day 16 (E-16) pups resulted in high levels of transduction in 
diaphragm and intercostal muscles, but no detectable levels in limb muscle. Recently newer 
AAV serotypes such as AAV8 have demonstrated widespread and high transgene expression in 
skeletal muscles and diaphragm by systemic delivery in adults and neonatal mice. In this study I 
tested AAV8 vector gene delivery by intraperitoneal administration in E-16 mice in utero. Using 
an AAV8 vector carrying a lacZ transgene, I observed high level transduction of diaphragm and 
more moderate transduction of multiple limb muscles and heart. Encouraged with these results I 
tested in utero gene transfer in the mdx mouse model of DMD, a minidystrophin gene driven by 
the human cytomegalovirus promoter was delivered systemically by an intraperitoneal injection 
to the fetus at embryonic day 16. Treated mdx mice studied at 9 weeks after birth demonstrated 
widespread expression of recombinant dystrophin in skeletal muscle, restoration of the 
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dystrophin associated glycoprotein complex in dystrophin-expressing muscle fibers, improved 
muscle pathology, and functional benefit to the transduced diaphragm compared to untreated 
littermate controls. In order to further extend these studies, AAV9 carrying a minidytsrophin 
gene was also tested. Robust expression in heart and muscles were seen at 4 weeks post 
treatment by in utero gene delivery. Furthermore robust heart expression persisted as long as 3 
months post treatment. These results support the potential of AAV8 and AAV9 vectors to 
efficiently cross the blood vessel barrier to achieve systemic gene transfer to skeletal muscle in 
utero in a mouse model of muscular dystrophy, to significantly improve the dystrophic 
phenotype and to ameliorate the processes that lead to exhaustion of the skeletal muscle 
regenerative capacity. 
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FORWARD 
 
 
You cannot fail, if you resolutely determine that you will not. 
- Abraham Lincoln 
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1.0  INTRODUCTION 
This dissertation describes a fetal gene therapy approach to treat primary muscle disorders and 
focuses mainly on adeno-associated viral vectors (AAV) as the gene delivery vehicle. The main 
aim of this approach would be to test the potential of AAVs to provide in utero muscle gene 
therapy benefit that may ultimately lead to clinical testing of in utero gene therapy in humans. 
Many genetic diseases manifest ranging from asymptomatic transmission to lethal consequences. 
There are some genetic diseases which display lethal signs and symptoms primarily at later 
stages of life after birth. In such diseases these lethal complications debilitate the patients 
without any chance of recovery. Fetal gene delivery or in utero gene delivery is positioned at a 
unique position to not only deliver the therapeutic vector but also minimize the life-long 
complications of the treated disease when the target tissues are still immature. Duchenne 
muscular dystrophy (DMD) is an X-linked genetic progressive muscle disorder due to mutations 
in the dystrophin gene. The disease becomes lethal by the second or third decade of life. 
Currently although patients are provided multidisciplinary symptomatic treatment, there is no 
available curative treatment for DMD. Furthermore with the currently available gene vectors the 
drawbacks of unregulated non-specific muscle gene expression and lack of efficient gene 
delivery-mediated, muscle functional benefit, mandates more studies. 
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1.1 DUCHENNE MUSCULAR DYSTROPHY 
Among various primary muscle disorders DMD is one of the most common debilitating and 
progressive genetic muscle disorders affecting children (Blake, Weir, Newey, & Davies, 2002; 
A.E.H. Emery, 1993a). It affects 1 in 3600-6000 live male births and is due to mutations in the 
dystrophin gene (Drousiotou, et al., 1998; A. E. Emery, 1991). A milder allelic form of the 
disorder is Becker muscular dystrophy (BMD), where the disease has a later onset and is often 
due to in-frame deletions in the dystrophin gene. To date, dystrophin is one of the largest known 
genes and has a chromosomal location of Xp21. It is believed that the huge size could be one of 
the reasons for the high frequency of mutations in this gene in the human population. Mutations 
in other proteins associated with the dystrophin associated glyprotein complex (see below) can 
cause other forms of muscular dystrophy, such as limb-girdle muscular dystrophies and 
congenital muscular dystrophies. 
1.1.1 Dystrophin gene and protein 
Identification of the dystrophin gene was the first step towards a better understanding in DMD 
research. Studies in female DMD patients with balanced X autosome translocations with the 
translocation breakpoint in Xp21 helped researchers localize the dystrophin gene (Boyd & 
Buckle, 1986). DNA markers helped confirm this localization (Davies, et al., 1983) and the gene 
was finally identified from a patient with a large deletion who suffered from four X-linked 
phenotypes which included DMD (Francke, et al., 1985). Dystrophin is the largest gene 
identified to date spanning about 2.5 Mb of genomic sequence (Coffey, et al., 1992; Monaco, 
Walker, Millwood, Larin, & Lehrach, 1992) comprising of 79 exons (Coffey, et al., 1992; 
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Monaco, et al., 1992; Roberts, Coffey, Bobrow, & Bentley, 1993) with a full length mRNA 
transcript of 14-kb (Koenig, et al., 1987). This gene codes for the cytoskeletal dystrophin protein 
which is 427-kDa in size and has four domains: N-terminal actin domain, a middle rod domain 
which has 24 spectrin-like repeats, a cysteine-rich domain, and a C-terminal domain. The 
structure of the full-length dystrophin is illustrated in Figure 1.  
 
Figure 1. Structure of full-length dystrophin gene. 
The dystrophin gene codes for the cytoskeletal dystrophin protein (427-kDa in size) has four domains: N-terminal 
actin domain, a middle rod domain which has 24 spectrin repeats, a cysteine-rich domain, and a C-terminal domain. 
C: Carboxy-terminus; CR: Cysteine-rich region. Adapted from (Trollet, Athanasopoulos, Popplewell, Malerba, & 
Dickson, 2009). 
 
Full-length dystrophin is predominantly expressed in skeletal and cardiac muscle with 
small amounts also expressed in brain (Chelly, Kaplan, Maire, Gautron, & Kahn, 1988; Lidov, 
Byers, Watkins, & Kunkel, 1990). This protein forms a protein link between intracellular actin 
proteins and transmembrane/extracellular proteins forming a large structural protein complex. At 
the sarcolemmal level dystrophin along with other transmembrane proteins such as the 
sarcoglycan and the α and -dystroglycan proteins form the so called dystrophin associated 
glyprotein (DAG) complex. The important proteins associated with dystrophin are illustrated in 
Figure 2. 
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Figure 2.The dystrophin-associated glycoprotein complex (DAG complex) in skeletal muscle. 
The NH2 terminal of dystrophin binds to cytoskeletal actin and the COOH terminus is associated with a number of 
integral and peripheral membrane proteins that can be classified as the dystroglycan subcomplex, the sarcoglycan-
sarcospan subcomplex, together forming the DAG complex. (Adapated from (Blake, et al., 2002)) 
 
The N-terminal region, also called the NH2 terminus, binds to cytoplasmic actin along 
with part of the rod domain [reviewed in (Rybakova, Amann, & Ervasti, 1996)]. It constitutes the 
actin-binding domain 1 (ABD1), which contains two calponin homology (CH) domains that 
form hydrophobic interactions with -actin filaments. The middle rod domain which forms the 
major part of the dystrophin protein is composed of 4 hinges and 24 triple helical repeating units 
which are similar to spectrin (Koenig & Kunkel, 1990). The repeats 11-17 carry a basic charge 
and form an internal actin binding domain 2 (ABD2) that electrostatically interacts with actin. A 
domain located between the rod domain on one end and the cysteine-rich and C-terminal domain 
on the other, called the WW domain, (Bork & Sudol, 1994) has been reported and at least part of 
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the WW domain is believed to be involved in the binding of dystrophin and -dystroglycan 
(Rosa, Ceccarini, Cavaldesi, Zini, & Petrucci, 1996). The dystroglycan-binding domain (DgBD) 
is composed of a WW domain, a cysteine-rich (CR) domain containing two EF hand-like 
structures (EF1, EF2) and a zinc-finger “ZZ” domain. Neuronal NOS (nNOS) has been a 
component of the DGC complex and provides a regulatory role in skeletal muscle physiology. 
While studies have shown nNOS to be associated with syntrophin (Hillier, Christopherson, 
Prehoda, Bredt, & Lim, 1999; Tochio, Zhang, Mandal, Li, & Zhang, 1999) more recently it has 
been shown that spectrin-like repeats 16 and 17 in the rod domain also play an important role in 
anchoring nNOS to the sarcolemma (Y. Lai, et al., 2009). With the disruption of the DGC 
complex in DMD, the delocalization of nNOS results in loss of compensatory vasodilation 
during muscle contraction and subsequently leads to areas of ischemia and necrosis (Sander, et 
al., 2000; G. D. Thomas, et al., 1998). The C-terminal (CT) domain binds members of the 
syntrophin and dystrobrevin protein families at the indicated sites, SBD and DbBD (Blake, et al., 
1995; Sadoulet-Puccio, Rajala, & Kunkel, 1997).  
Detergent extraction and gel electrophoresis studies have shown that the DAG complex 
can be dissociated into (a) the sarcoglycan:sarcospan complex, (b) the dystroglycan complex, 
and (c) the cytoplasmic, dystrophin-containing complex (Yoshida, et al., 1994). The 
sarcoglycan:sarcospan complex consists of , , ,  sarcoglycan and sarcospan molecules. The 
dystroglycan complex which consists of ,  dystroglycans extends across the sarcolemma, 
binds extracellularly to laminin-2 and binds intracellularly to dystrophin forming a link 
connecting the intracellular cytoplasmic actin to the extracellular matrix. The cytoplasmic 
complex is comprised predominantly of dystrophin and other minor proteins such as syntrophins 
and -dystrobrevin.  
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Mutations in the dystrophin gene causes DMD, characterized by progressive muscle 
wasting and weakness. The high frequency of mutations is due to the large size of the dystrophin 
gene and leads to the high number of different independent mutations. Mutations causing DMD 
usually have highly reduced or complete absence of dystrophin protein levels, while BMD is 
associated with a reduced amount of functional or partially functional dystrophin protein. Studies 
have shown some association between the type of mutation and the resulting phenotype. It has 
been suggested that the size and the extent of the dystrophin gene mutation does not necessarily 
correlate with the clinical phenotype (Koenig, et al., 1989; Monaco, Bertelson, Liechti-Gallati, 
Moser, & Kunkel, 1988; Monaco, et al., 1985). According to the reading frame theory a 
functional dystrophin can be produced if the truncated transcript does not shift the open reading 
frame (Monaco, et al., 1988), which is most often observed in BMD. However if the deletion 
leads to a translational frame shift, this could lead to premature termination leading to an 
abnormal transcript with almost compete absence of dystrophin as is most commonly observed 
in DMD. Studying the correlations between the various mutations in the dystrophin gene and 
clinical phenotype enabled researchers to design truncated forms of a functional dystrophin gene 
for gene therapy (Amalfitano, Rafael, & Chamberalin, 1997). It has been observed that an in-
frame deletion of up to 46% of the dystrophin rod coding sequence in a patient resulted in a mild 
form of BMD, suggesting that the rod domain acts as a spacer between the N-terminal and the C-
terminal domains. Similarly large rod domain deletions were also observed in other BMD 
patients (Love, Flint, Genet, Middleton-Price, & Davies, 1991; Winnard, et al., 1993). Such 
findings have been the basis of constructing dystrophin mini-genes for retroviral, adenoviral and 
adeno-associated viral vectors for gene therapy (Acsadi, et al., 1991; Dunckley, Wells, Walsh, & 
Dickson, 1993; Ragot, et al., 1993; B. Wang, Li, & Xiao, 2000). 
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Mutations in DMD can broadly be categorized into large mutations and small mutations. 
Most of the large deletions in DMD and BMD are found to be concentrated around two regions 
(Koenig, et al., 1989; Koenig & Kunkel, 1990). They are believed to be around exons 45-53 
(Beggs, Koenig, Boyce, & Kunkel, 1990) which is part of the rod domain and exons 2-20 which 
removes part of the actin binding domain and the rod domain (Liechti-Gallati, et al., 1989). 
Nearly 1/3rd of the mutations causing DMD are small mutations which could involve point 
mutations and small deletions which end the protein due to a stop codon (Lenk, Hanke, Thiele, & 
Speer, 1993; Roberts, Gardner, & Bobrow, 1994). These small deletions are spread through out 
the dystrophin gene unlike the large deletions (Gardner, Bobrow, & Roberts, 1995; Prior, et al., 
1995; Roberts, et al., 1994). 
 Mutations in the dystrophin gene have also been noted in other regions; on the N-terminal 
region (Arg for Leu-54) (Prior, et al., 1995), at the cysteine rich region (Lenk, et al., 1996), and 
at the C-terminal region (Bies, Caskey, & Fenwick, 1992; Hoffman, et al., 1991). 
1.1.2 Clinical progression 
In humans the initial symptoms of DMD are most commonly observed between ages 2 and 5 
years (Dubowitz, 1978; Jennekens, ten Kate, de Visser, & Wintzen, 1991) with waddling gait or 
difficulty in climbing stairs. During this period the affected boys have delay in achieving motor 
milestones and delay in walking and difficulty in running. This is followed by 
pseudohypertrophy of the calf muscles; proximal limb muscle weakness and the development of 
the classical Gowers’ sign (the use of the child’s arms to climb up his body when going from a 
lying to standing position) (Gowers, 1879). Eventually reduced strength in lower limbs, joint 
contractures and progressive kyphoscoliosis debilitates the patient (A.E.H. Emery, 1993a). By 
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age 12 years most patients require the use of a wheelchair for mobility (A.E.H. Emery, 1993a) 
and most patients die due to respiratory complications due to intercostal muscle weakness. 
Cardiac dysfunction associated with cardiomyopathy and cardiac conduction abnormalities is 
also a common cause of death. Although 90% of the patients are still alive in their early 20s, 
DMD is a progressively deteriorating disease leading to death by 30s and 40s in the majority of 
the patients. The sequence of events in a muscular dystrophy patient is summarized in Figure 3a. 
Although the clinical signs in BMD are milder than DMD (Becker & Kiener, 1955), both DMD 
and BMD patients demonstrate mild forms of cognitive impairment suggesting certain brain 
functions are also affected (reviewed in (Blake & Kroger, 2000; Mehler, 2000) ). 
1.1.3 Histopathological features  
Normally skeletal muscle fibers are relatively uniform in size and well spaced as longitudinal 
tubes containing multiple nuclei with most nuclei being located at the periphery of a muscle 
fiber. However in adult postnatal DMD muscle, fibers are characterized by areas of necrosis seen 
usually in clustered areas (Gorospe, Nishikawa, & Hoffman, 1997; Schmalbruch, 1984). On 
sections these necrotic areas are filled and surrounded by inflammatory cells, composed largely 
of macrophages and CD4+ lymphocytes (McDouall, Dunn, & Dubowitz, 1990; Schmalbruch, 
1984) which can be seen as small basophilic myofibers with centrally placed nuclei (Bell & 
Conen, 1968; Bradley, Hudgson, Larson, Papapetropoulos, & Jenkison, 1972; Schmalbruch, 
1984). As the disease progresses the muscle loses its regenerative capacity resulting in 
replacement by adipose and fibrous tissue giving the appearance of hypertrophy finally leading 
to atrophy (reviewed in (A.E.H. Emery, 1993b)). This dual loss of muscle fiber and progressive 
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fibrosis results in debilitating muscle weakness The histological features are illustrated in Figure 
3b. 
Although the exact mechanisms of several physiological abnormalities within the DMD 
muscle remain unknown, the DMD muscle fiber is associated with several abnormalities such as 
altered calcium homeostasis, increased susceptibility to oxidative stress, and increased 
membrane permeability (reviewed in (Blake, et al., 2002)). 
3A 
 
 
3B 
 
 
 
 
 
 
 
 
 
 
 
birth diagnosis loss of
mobility
progressive onset of 
cardiorespiratory failure
death
3-5 8-12 10+ 20+
i ii
iii iv
Figure 3.Sequence of events and histopathology in a muscular dystrophy patient. 
Duchenne muscular dystrophy patients are usually diagnosed at age 3-5 years and they lose mobility by age 8-12
years of age (3A). In their first decade of life they develop cardio-respiratory complications and die in the 2nd –
4th decade of life. DMD muscle, fibers are characterized by areas of necrosis on H&E staining (i) and absence of
dystrophin (ii) by immunostaining, while a normal mature muscle has peripheral nuclei (iii) and positive
dystrophin staining (iv). 
Age (yrs)
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1.1.4 Current therapies 
Although DMD patients are living longer than before due to new treatments and 
multidisciplinary care, the treatment strategies have a long way to go for a permanent cure. Since 
inflammatory response is one of the main reasons for pathogenesis in DMD patients (Arahata & 
Engel, 1984) corticosteroids have been shown to improve muscle function in DMD children 
(Balaban, Matthews, Clayton, & Carry, 2005; Griggs, et al., 1991; Mendell, et al., 1989; Moxley, 
et al., 2005) and is the current treatment of choice. Thus with the use of corticosteroids, such as 
prednisone, muscle mass can be conserved and help synthesize protein to some extent (Tidball & 
Wehling-Henricks, 2004; Wagner, Lechtzin, & Judge, 2007; J. Zhao, Bauman, Huang, Caplan, 
& Cardozo, 2004). 
In addition the patients are treated symptomatically with positive-pressure ventilators due 
to weak respiratory muscles (Eagle, et al., 2002; Finder, et al., 2004) and standard heart failure 
strategies for dilated cardiomyopathy and arrythmias (Alexander, et al., 2007; Nigro, Comi, 
Politano, & Bain, 1990; Nohria, Lewis, & Stevenson, 2002; Pfeffer, et al., 1992; Pitt, et al., 
2000) and with supplemental calcium and vitamin D and occasionally, alendronate, to promote 
bone health and decrease fracture risk (Wagner, et al., 2007).  
Currently studies with advances in preclinical therapeutic strategies using viral and non- 
viral vectors are being tested with increasing hope for DMD patients. For preclinical gene 
therapy studies, the various vectors studied have included the retroviridae family of viral vectors 
(example: lentivirus, MLV-based retrovirus), adenovirus, AAV among other less-used vectors. 
Among the various viral vectors, AAV appears to show great promise for gene transfer in 
dystrophic animal models which will be discussed in detail later.  
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There are also several non-viral gene therapy approaches being tested for muscle 
disorders. The most common ones are naked plasmid DNA (Romero, et al., 2004), read-through 
of stop codons (Barton-Davis, Cordier, Shoturma, Leland, & Sweeney, 1999), exon skipping 
(Alter, et al., 2006; Mann, et al., 2001), and gene editing (Bertoni, Morris, & Rando, 2005; 
Bertoni & Rando, 2002; Rando, Disatnik, & Zhou, 2000). However each of these strategies is 
still at an experimental stage. 
1.1.5 Animal models of disease 
Therapeutic strategies to test treatment of DMD in humans first require animal models. The 
discovery of spontaneous mutations in dystrophin deficient animals such as mice, dogs and cats 
has allowed, to a great extent, study of the pathophysiological changes caused by dystrophin 
deficiency. The recent identification of dystrophic nematode models further enhanced the 
understanding of muscular dystrophy (Bessou, Giugia, Franks, Holden-Dye, & Segalat, 1998). 
More recently mutations in the zebrafish orthologue of the dystrophin gene have been identified 
in zebrafish (Bassett, et al., 2003). 
Mdx mice are one of the frequently used dystrophic animal models in DMD research. 
They were initially identified to have high serum creatine kinase levels and later discovered to 
have muscle pathology (Bulfield, Siller, Wight, & Moore, 1984). Further studies showed a point 
mutation in the exon 23 of the dystrophin gene results in a premature stop codon (Sicinski, et al., 
1989) leading to the absence of full length dystrophin (Hoffman, Brown, & Kunkel, 1987).  
Although the mdx mice display only a 20% reduction in lifespan (Chamberlain, Metzger, Reyes, 
Townsend, & Faulkner, 2007; Lynch, Hinkle, Chamberlain, Brooks, & Faulkner, 2001) and 
although obvious weakness is not a feature (Lynch, et al., 2001; Pastoret & Sebille, 1995), 
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muscle dysfunction has been shown in in vivo studies (Carlson & Makiejus, 1990; Rafael, Nitta, 
Peters, & Davies, 2000). Muscle fiber necrosis, a characteristic feature of dystrophic muscle, is 
observed beginning around 3-4 weeks of age (Tanabe, Esaki, & Nomura, 1986), followed by 
prominent muscle regeneration which is characterized by expression of the fetal myosin heavy 
chain isoform and centralized nuclei (Coulton, Morgan, Partridge, & Sloper, 1988; DiMario, 
Uzman, & Strohman, 1991; Hall-Craggs & Seyan, 1975). As the cycle of degeneration and 
regeneration continues further, it finally leads to atrophy and fibrosis (Pastoret & Sebille, 1993) 
with the diaphragm showing more prominent loss of muscle fiber and collagen accumulation in 
mdx mice (Stedman, et al., 1991). Similarly the closest dog model to DMD is the golden retriever 
(the GRMD dog) (Cooper, et al., 1988) also characterized by necrosis, fibrosis, regeneration 
(Valentine, Cooper, Cummings, & de Lahunta, 1990) and reduced life span (Valentine, et al., 
1992).  This canine model was first described in the golden retriever (Kornegay, Tuler, Miller, & 
Levesque, 1988) before identifying dystrophin mutations in other breeds. Genetically GRMD is 
due to a point mutation in the consensus splice acceptor site in intron 6 of the dystrophin gene 
which leads to skipping of exon 7 leading to the premature termination of translation due to 
disruption of the open reading frame (Howell, et al., 1997; Sharp, et al., 1992). 
Although there is also a feline model of DMD (Carpenter, et al., 1989; Gaschen, et al., 
1992; Winand, Edwards, Pradhan, Berian, & Cooper, 1994), which is believed to have the 
closest similarity to DMD patients (Carpenter, et al., 1989), the mdx murine model is easier to 
handle with its shorter gestation and lower cost of maintenance. 
The canine models start showing clinical symptoms around 6-8 weeks of age and become 
pronounced by 6 months. They usually survive only up to 2 to 4 years after birth and die mostly 
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due to respiratory or cardiac complications (Howell, et al., 1997; Valentine, Cooper, Cummings, 
& deLahunta, 1986; Valentine, et al., 1992). 
1.2 GENE THERAPY 
Gene therapy is described as the transfer of genetic material, such as DNA or RNA, to cells in 
order to manipulate the endogenous genetic information with the aim to treat or prevent inherited 
or acquired disease (Crystal, 1995; A. D. Miller, 1992; Mulligan, 1993). The discovery of DNA 
technology in the early 1970s (Friedmann & Roblin, 1972) paved the way for the concepts of 
gene therapy.  
1.2.1 Types of gene therapy: non-viral and viral 
Gene transfer approaches use either non-viral and viral gene delivery vehicles. Although non-
viral vectors have gained significant importance in recent times, approximately 70% of the 
clinical trials are based on the use of viral vectors. Viruses have evolved as good gene delivery 
vectors because they have the natural ability to deliver genetic material to specific cells while 
escaping the host immunosurveillance (Robbins & Ghivizzani, 1998; Smith & Enquist, 2002; 
Walther & Stein, 2000). While non-viral gene vectors have the advantage of greater DNA 
packaging capacities and lesser chance of immunologic or mutagenic side effects (Eliyahu, 
Barenholz, & Domb, 2005; Walther & Stein, 2000) they are associated with low and variable 
levels of transfection efficiency. 
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1.2.1.1 Non-viral gene therapy 
 
There are various non-viral gene therapy methods such as delivery of naked DNA using gene 
gun (Albertini, et al., 1996), DNA conjugation to different proteins such as polycations and 
antibodies which can be directed to specific cell surface proteins (Feero, et al., 1997; Shimizu, 
Chen, Gamou, & Takayanagi, 1996) and liposomes. Currently cationonic liposomes are 
frequently used in several human gene therapy studies. Although liposomes have less 
pathogenicity, the transfection efficiency is low. Hence several techniques are being attempted to 
transport the DNA into the nucleus by conjugating it with proteins or peptides (Nguyen, Wiehle, 
Roth, & Cristiano, 1997; Robbins & Ghivizzani, 1998).  
Although amphiphilic block co-polymers accentuate the uptake of plasmid DNA into 
skeletal muscle (Lu, Bou-Gharios, & Partridge, 2003; Pitard, et al., 2002) the high volumes 
needed to achieve enough gene delivery precludes their use. Studies involving in vivo 
electroporation have been tested to deliver antisense oligonucleotides to induce exon 23 skipping 
and thereby removing the premature stop codon from the murine dystrophin mRNA (Wells, 
Fletcher, Mann, Wilton, & Wells, 2003). Although, in vivo electroporation studies have shown 
enhanced distribution of corrective nucleic acids resulting in a small increase in dystrophin 
positive fibers and a preferential targeting of mature fibers compared to satellite cells (Wong, et 
al., 2005), correction levels sufficient to achieve functional benefit have not been reached. 
Furthermore, studies have shown instances of muscle damage with in vivo electroporation 
(Durieux, Bonnefoy, Busso, & Freyssenet, 2004; McMahon, Signori, Wells, Fazio, & Wells, 
2001). Various forms of ultrasound methods such as microbubbles, which are commercially 
available ultrasound contrast agents, produce membrane disruption and cause less muscle 
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disruption while achieving gene transfer compared to in vivo electroporation (T. Li, Tachibana, 
Kuroki, & Kuroki, 2003; Lu, Liang, Partridge, & Blomley, 2003; X. Wang, Liang, Dong, Lu, & 
Blomley, 2005). However with very low levels of gene transfer, they have yet to achieve 
efficiency comparable to other methods. Alternatively femtosecond infrared lasers have been 
shown to provide safe plasmid gene transfer in vivo (Zeira, et al., 2003). However this method is 
very expensive and carries bulky systems and further studies are being conducted to determine 
how to remove unwanted side effects such as formation of long lasting bubbles. Hagstrom et. al. 
have shown intravenous hydrodynamic delivery of plasmids to several muscle tissues (Hagstrom, 
et al., 2004). This is based on the principle that under high pressure and rapid injection into the 
systemic circulation the therapeutic solution is forced out of the microcirculation necessary for 
gene delivery. However, some studies in pigs have shown excess pressure beyond threshold with 
the potential to inhibit the transfection of muscle fibers (Danialou, et al., 2005). While studies 
have shown that the damage caused by edema resolved within 24 hrs in mice, with only minimal 
muscle damage (Toumi, et al., 2006), further studies need to be conducted in order to test the 
efficacy in higher animals. In conclusion, the low, variable, transient transfection efficiency and 
the frequent need for readministration have been limiting factors in most non-viral gene therapy 
studies.  
1.2.1.2 Viral gene therapy 
 
The success of gene therapy depends on the ability of vectors to deliver genes without being 
pathogenic. Viral vectors have been an integral part of the development of gene therapy 
approaches. Technological developments in viral vectors have led to larger scale production, 
improved purification and decreased pathogenicity. The commonly employed viral vectors in 
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gene therapy studies are lentivirus, retrovirus, adenovirus, adeno-associated virus, herpes 
simplex virus (HSV) and pox virus among others. Each vector has its own advantages and 
disadvantages. The various viral vectors used in gene therapy are summarized in the Table 1. 
In relation to muscle gene therapy each of these vectors plays an important role. Lentiviruses 
belong to the genera retroviridae which also includes MLV-based retrovirus. Lentivirus has a 
double-stranded RNA genome and a viral envelope. Lentiviral vectors carry up to 8 kb of 
transgene and randomly integrate into the host genome. The commonly employed lentiviral 
vectors in gene therapy are immunodeficiency viruses such as human immunodeficiency virus -1 
(HIV-1) and feline immunodeficiency virus (FIV) and equine infectious anemia virus (EIAV). 
Hybrid vectors are generated with heterologous envelope glycoproteins such as G glycoprotein 
of the vesicular stomatitis virus (VSV-G) which provides broad tropism (J. Johnston & Power, 
1999; J. C. Johnston, et al., 1999; Kim, Mitrophanous, Kingsman, & Kingsman, 1998; Naldini, 
Blomer, Gage, Trono, & Verma, 1996; Naldini, Blomer, Gallay, et al., 1996; Poeschla, Wong-
Staal, & Looney, 1998; Srinivasakumar, et al., 1997; Zufferey, Nagy, Mandel, Naldini, & Trono, 
1997). 
However lentiviruses were associated with oncogenesis limiting their use (Themis, et al., 
2005). Another member of the genera retroviridae commonly studied in gene therapy is the 
amphotropic MLV-based retrovirus (Romano, Pacilio, & Giordano, 1999; Shinnick, Lerner, & 
Sutcliffe, 1981; Weiss, 1998; Weiss & Wrangham, 1999). MLV-based retroviral vectors contain 
a single-stranded, linear, positive-sense RNA molecule of approximately 8000 nucleotides. 
MLV-based retroviral vectors infect dividing cells and integrate into the host cell genome. (D. G. 
Miller, Adam, & Miller, 1990). While studies have shown short term expression in canine 
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mucopolysaccharidosis Type I animal models, they have not demonstrated long term gene 
expression and transgene integration into the germ line (Meertens, et al., 2002). 
The low transduction efficiency, the requirement of dividing cells and instability in the 
presence of body fluids are significant limitations of the MLV-based retroviral vector for in vivo 
muscle gene transfer.  Furthermore, in recent years a study demonstrated premalignant 
proliferation and lymphoproliferative disease in an X-SCID trial in which study participants 
received transplantation of retroviral vector-transduced, autologous bone marrow-derived CD34+ 
cells (Hacein-Bey-Abina, et al., 2003). 
Adenoviruses have a non-enveloped capsid and a 36 kb double-stranded DNA genome 
that remains as an episome in an infected cell. Adenoviral vectors for gene replacement therapy 
have been developed from adenovirus through genetic modification to make them replication-
deficient (Haecker, et al., 1996; Kochanek, et al., 1996; C. M. Lai, Lai, & Rakoczy, 2002). First- 
and second-generation adenoviral vectors have deletions of one or more adenoviral early genes. 
Helper-dependent, high-capacity adenoviral vectors have been developed to circumvent the 
unfavorable immune response associated with earlier generation vectors (Haecker, et al., 1996; 
Kochanek, et al., 1996; C. M. Lai, et al., 2002). The reduced immunogenicity of the high-
capacity adenoviral vector and its large insert size capacity for carrying the 14kb dystrophin 
cDNA were significant advances for muscle-directed, adenoviral vector-mediated gene transfer 
(Clemens, et al., 1996; Kochanek, et al., 1996).  
HSV holds a 50kB double stranded DNA genome (Walther & Stein, 2000) which can 
remain latent in neuronal cells for years and therefore has been used in the treatment of 
neurological diseases such as Parkinson`s and Alzheimer’s diseases (Robbins & Ghivizzani, 
1998). However immune response (Wu, Watkins, Schaffer, & DeLuca, 1996) and wide tropism 
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into muscle and liver has limited the use of HSV (Robbins & Ghivizzani, 1998). Pox viruses 
which belong to the poxviridae family holds a 25kB genome and can hold several foreign genes 
(Walther and Stein 2000). Although these viruses have shown promise in clinical trials for the 
treatment of human papillomavirus, HIV-1, and other cancers (McAneny et al 1996, Kaufman et 
al 2002, Emery 2005), the host immune response triggered by pox viruses limits its use. 
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Table 1. Gene therapy viral vectors. (Adapted from (Nixon, et al., 2007; Walther & Stein, 2000)) 
Viral vector Advantages Disadvantages 
Adenovirus Large insert size capacity 
(37 kb), episomal 
High gene expression,  
infects dividing and 
quiescent cells, broad cell 
tropism 
Short duration of 
expression, cytotoxic, 
immunogenic 
AAV infect dividing and 
quiescent cells, broad 
cell tropism, various 
serotypes having tissue 
specific tropism, minimal 
immune response, 
nonpathogenic, episomal 
limited insert size capacity 
(4kb), 
neutralizing antibodies, 
possible cellular immune 
response,  difficulty in 
propagation 
Herpes simplex virus Infects wide variety of cell 
types, large 
packaging capacity (50kb), 
natural 
tropism for neuronal cells, 
ability to infect 
quiescent cells 
 
No integration into host 
genome, 
possible toxicity, 
recombination 
risk, very short expression 
except in 
neuronal cells 
Lenti virus Infect dividing and 
quiescent cells, stable 
gene expression, large 
packaging capacity 
(10kb) 
 
Presence of viral protein 
sequences in the 
constructs, potential 
insertional mutagenesis,  
HIV related safety issues 
Retro virus Large packaging capacity 
(7-8kb), integrates into 
host DNA, broad cell 
tropism, ease of viral 
genome manipulation 
 
Random insertion into host 
genome, vector instability, 
nonspecific cell targeting, 
infects dividing cells only 
 
 
Pox virus Large packaging capacity 
(25kB), high 
cytoplasmic expression, 
ability to produce 
humoral response makes it 
promising for 
vaccines, wide cell tropism 
 
Produces humoral and 
cytotoxic 
immune responses, no 
integration 
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1.2.2 Adeno-associated viral vectors 
Recently, AAV vectors have been utilized most extensively in preclinical and clinical muscle 
gene therapy studies. AAV is a nonenveloped, single-stranded DNA virus with a gene insert size 
capacity of about 4.7 kb for AAV serotype 2 (Srivastava, Lusby, & Berns, 1983). The discovery 
of different AAV serotypes has led to AAV vectors that have differing tissue tropisms and 
transduction efficiencies. AAV infect dividing and non-dividing cells and appear to have lower 
tendency to induce immunity compared to many other vectors. 
AAV have developed as excellent gene delivery vehicles to various tissues. AAVs are 
nonpathogenic and replication defective vectors that have broad tissue tropism and long-term 
gene expression in vivo. However, a limitation of AAV is its small size with a small carrying 
capacity for DNA. AAV has two open reading frames (ORF) and palindromic inverted terminal 
repeat elements (ITR) on either side of the gene. These ITRs play an important role in the 
integration, replication and packaging of the viral genome into the capsid shell. The wild type 
AAV has two genes, the rep gene which codes for proteins responsible for DNA replication and 
the cap gene which codes for structural proteins Vp1, Vp2, and Vp3. Although the infective 
pathway of AAV is not fully elucidated, it is believed that the pathway involves AAV binding to 
the cell surface, viral uptake, intracellular trafficking, nuclear localization, uncoating and second-
strand DNA synthesis (Ding, Zhang, Yan, & Engelhardt, 2005; Ding, Zhang, Yeaman, & 
Engelhardt, 2006; Greber, 2002; Harbison, Chiorini, & Parrish, 2008; Vihinen-Ranta, Suikkanen, 
& Parrish, 2004) Figure 4 shows the surface topology of an AAV particle. 
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Figure 4.Surface topology of AAV. 
AAV is a parvo virus icosahedral in shape with a three fold rotational axis (Xie, et al., 2002). 
 
Of the multiple different serotypes of AAV that have been discovered so far, AAV2 has 
been most extensively used in gene transfer experiments. However with the discovery of newer 
serotypes with broadened tissue tropism and better transduction efficiency, alternative serotypes 
have gained interest: AAV1 in central nervous system, pancreas, heart, vascular endothelium, 
muscle, heart; AAV3 in ear hair cells; AAV4 in brain; AAV5 in brain, lung, liver; AAV6 in 
heart, muscle and respiratory epithelium; AAV7 in muscle; AAV8 in heart, liver and muscle 
(Apparailly, et al., 2005; Auricchio, et al., 2002; Blankinship, et al., 2004; Burger, et al., 2004; 
Chen, et al., 2005; Conlon, et al., 2005; Cressant, et al., 2004; De, et al., 2004; Du, et al., 2004; 
G. P. Gao, et al., 2002; Ghosh, et al., 2006; Halbert, Allen, & Miller, 2001; Kawamoto, Shi, 
Nitta, Miyazaki, & Allen, 2005; Liu, Martins, Wemmie, Chiorini, & Davidson, 2005; Y. Liu, et 
al., 2005; Loiler, et al., 2003; Lotery, et al., 2003; Louboutin, Wang, & Wilson, 2005; Mingozzi, 
et al., 2002; Passini, et al., 2003; Reich, et al., 2003; Sandalon, et al., 2004; Sarkar, et al., 2004; 
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Sun, Zhang, Franco, Brown, et al., 2005; Sun, Zhang, Franco, Young, et al., 2005; A. Y. Wang, 
Peng, Ehrhardt, Storm, & Kay, 2004; L. Wang, et al., 2005; Z. Wang, et al., 2005). 
Recently studies in post-natal mice demonstrate efficient transduction of skeletal muscle 
and heart after systemic delivery of AAV8. The transduced muscles showed persistent gene 
expression up to 2 months after intraperitoneal injection (Z. Wang, et al., 2005). AAV9 
demonstrated robust protein transduction into skeletal muscles and heart in postnatal mice by 
various routes of delivery (Inagaki, et al., 2006; Vandendriessche, et al., 2007; Zincarelli, Soltys, 
Rengo, & Rabinowitz, 2008). Recently newer AAV vectors, such as AAV10 and AAV11 also 
demonstrated muscle transduction 6 weeks post treatment in postnatal BALB/c mice treated by 
tail vein injection (Mori, Wang, Takeuchi, & Kanda, 2004). With newer serotypes being 
discovered, the challenge for testing these vectors for muscle gene therapy becomes increasingly 
important. 
1.2.2.1 Adeno-associated viral serotype 8 
 
AAV vectors provide efficient gene delivery to striated muscle tissues (Xiao, Li, & Samulski, 
1996). Recently identified AAV serotypes have varied tissue tropism and transduction 
efficiency. Among the currently known serotypes, AAV8 demonstrates superior potential to 
deliver transgenes to muscle tissues (Inagaki, et al., 2006; Louboutin, et al., 2005; Qiao, et al., 
2008; Rodino-Klapac, et al., 2007; Sun, Zhang, Franco, Young, et al., 2005; Z. Wang, et al., 
2005; Ziegler, et al., 2008a; Zincarelli, et al., 2008). Using systemic delivery of AAV8 vectors, 
reporter gene and therapeutic gene transfer studies in postnatal mice and hamsters demonstrated 
efficient transduction of skeletal muscle and heart in neonates and adults (Inagaki, et al., 2006; Z. 
Wang, et al., 2005). Similarly Inagaki et al. demonstrated the ability of AAV8 vector to deliver a 
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transgene to skeletal muscle by systemic gene delivery in adult mice (Inagaki, et al., 2006). 
Other studies also showed AAV8 vector effectively transduced nonhuman primate skeletal 
muscles (Rodino-Klapac, et al., 2007).  
In a study of AAV vector serotypes 1, 2, 5, 6, 7 and 8, Wang et al. showed that AAV8 
efficiently crossed the blood vessel barrier after systemic delivery in neonatal and adult mice (Z. 
Wang, et al., 2005). Similarly Inagaki et al. showed robust transduction of muscle tissue 
following systemic delivery of various doses of AAV8 vector in adult mice (Inagaki, et al., 
2006). Zincarelli et al. observed that tail vein injection of an AAV8-luciferase vector into 6-8 
week old mice not only showed persistent transgene expression for at least 100 days, but also 
demonstrated uniform expression of luciferase in hindlimb, abdominal and thoracic regions 
(Zincarelli, et al., 2008). However, there are very few studies testing gene delivery and 
functional efficacy of therapeutic transgenes carried by AAV8 vectors in dystrophic animal 
models (Rodino-Klapac, et al., 2007). In a study involving AAV8 carrying microdystrophin 
delivered systemically into the femoral artery in 3 - 4 week old mdx mice and non human 
primates, significant improvement in tetanic force and protection against eccentric contraction in 
the EDL muscle was shown (Rodino-Klapac, et al., 2007). Since dystrophic patients usually die 
due to respiratory and cardiac failure (A. E. H. Emery & Muntoni, 2003), restoring dystrophin 
expression to the diaphragm, which plays a critical role in respiration and survival, will be highly 
important to DMD patients. 
AAV8 has successfully provided therapeutic benefit to skeletal muscle in two disease 
models in prior postnatal studies. Ziegler et al. showed that systemic administration of an AAV8 
vector carrying the human acid α-glucosidase (GAA) gene to 2 month old presymptomatic GAA-
deficient mice that model Pompe disease resulted in nearly complete correction of the lysosomal 
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storage of glycogen in all affected muscles (Ziegler, et al., 2008a). Another study also 
demonstrated correction of GAA deficiency in muscle tissue of immunodeficient GSD-II mice 
by treatment with an AAV8 vector (Sun, Zhang, Franco, Young, et al., 2005). In another muscle 
disease model, systemic delivery of an AAV8 vector carrying a myostatin inhibitor in adult mdx 
mice enhanced muscle growth and also ameliorated the dystrophic phenotype (Qiao, et al., 
2008). 
Furthermore, the AAV8 vector appeared to be less immunogenic (Vandenberghe, et al., 
2006) and demonstrated more rapid uncoating post-internalization (C. E. Thomas, Storm, Huang, 
& Kay, 2004) compared to the AAV2 vector. In addition, the AAV8 vector also demonstrated 
good potential to deliver transgenes in various animal models such as mouse, rat and non-human 
primates (Davidoff, et al., 2005; Nathwani, et al., 2007; Nathwani, et al., 2006; Z. Wang, et al., 
2005). The AAV8 vector also showed high level transduction in various tissues such as 
pancreatic cells (Cheng, et al., 2007), neuronal cells (Foust, Poirier, Pacak, Mandel, & Flotte, 
2008; Nakai, et al., 2005), liver cells (Graham, McIntosh, Work, Nathwani, & Baker, 2008), and 
smooth muscle cells (Nakai, et al., 2005). 
1.2.2.2 Adeno-associated viral serotype 9 
 
AAV9 was first isolated from human tissues and demonstrated to have serological characteristics 
which were different from other AAV vectors (G. Gao, et al., 2004). In a study involving tail 
vein injection of AAV1 through AAV9 carrying a CMV-luciferase transgene in mice, AAV9 
demonstrated robust viral distribution and protein expression in most tissues including muscle 
(Zincarelli, et al., 2008). This could be due to the ability of AAV9 to pass through the blood 
vessel barrier easily (Manfredsson, Rising, & Mandel, 2009). Furthermore, studies have shown 
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AAV9 to have robust tropism towards heart (Inagaki, et al., 2006; Miyagi, et al., 2008; Pacak, et 
al., 2006; Vandendriessche, et al., 2007). Studies have also demonstrated AAV8 and AAV9 to 
show minimal proinflammatory cytokine induction compared to other vectors such as lentivirus 
(Vandendriessche, et al., 2007). Interestingly it has been observed that AAV8 and AAV9 
transduced liver tissues efficiently when delivered to postnatal mice (Vandendriessche, et al., 
2007). Although AAV8 has been shown to have a good ability to cross the blood vessel barrier, 
studies have demonstrated AAV6 and AAV8 to have low penetration into the CNS following 
vascular gene delivery in neonates and adults (Foust, et al., 2008; Towne, Raoul, Schneider, & 
Aebischer, 2008). However, AAV9 has demonstrated good transduction into brain tissue through 
the blood brain barrier (Foust, et al., 2009). In addition, AAV9 has also demonstrated efficient 
vector genome transport to distal neuronal cell bodies via known axonal pathways (Cearley & 
Wolfe, 2006). Also little to no cross-reaction is observed with neutralizing antibodies towards 
AAV9 from the ones generated against AAV1-8 (G. Gao, et al., 2004; G. Gao, Vandenberghe, & 
Wilson, 2005). Although AAV9 uses the laminin receptor for cell attachment similar to AAV2 
and AAV8, it is believed that AAV9 could be using some unknown receptors for cell 
internalization (Akache, et al., 2006).  
1.3 IN UTERO GENE THERAPY 
While some genetic disorders can be lethal to the embryo or fetus, many genetic disorders are 
survived in utero, but subsequent to birth, lead to debilitating, lifespan-limiting conditions. 
Through early diagnosis and intervention during the fetal period, in utero gene delivery is 
uniquely positioned to intercede at the earliest possible stage of disease development. DMD is an 
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example of a disorder that can be identified by prenatal diagnosis, providing a window of 
opportunity to treat the disease before the signs and symptoms are clinically evident after birth. 
While in utero gene therapy is still in its infancy, numerous studies have been conducted in 
preclinical models of various genetic disorders to demonstrate the feasibility of the concept. 
Examples include cystic fibrosis (Larson, Morrow, Happel, Sharp, & Cohen, 1997; Rich, et al., 
1993), UDPglucuronyltransferase deficiency (Seppen, et al., 2003), congenital blindness 
(Dejneka, et al., 2004), α-thalassemia (Han, Lin, Chang, Sadelain, & Kan, 2007), α-1-antitrypsin 
deficiency (Rosenfeld, et al., 1991), and DMD (Reay, et al., 2008). 
 
The body mass of an organism increases dramatically from fetus to adult. Thus, gene 
delivery to the fetus provides an opportunity to target a higher percentage of cells than gene 
delivery later in life. In addition to the smaller target tissue of the fetus compared to the adult 
organism, the fetus also has less well-developed tissue barriers. Therefore, it is possible to 
accomplish gene delivery to the fetus with a lower dose and lower vector-to-tissue ratio, thereby 
lowering potential vector toxicities and decreasing vector production requirements. One study 
demonstrated that the degree of maturity of the muscle fiber basal lamina played an important 
role in the transduction efficiency of gene transfer by herpes simplex viral vectors when 
comparing neonatal and adult muscle target tissues (Huard, et al., 1996). By extension, 
immaturity of the basal lamina in the fetus enhances widespread gene delivery to fetal muscle. A 
single intramuscular adenoviral vector injection in utero led to the transduction of multiple 
muscles, supporting the concept that muscle tissue barriers that impede vector spread in mature 
tissue are less of a barrier in the fetus (Reay, et al., 2008).  
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While an immunological response that interferes with efficient gene delivery has been a 
significant concern in most postnatal gene therapy studies, immunity in the fetus is immature. 
Components of immunological immaturity during the fetal stage include a smaller number of 
immune cells, embryological immaturity of participating immune cells, variations in the early 
immune response compared to the adult, and a lack of memory cells (Adkins, Williamson, 
Guevara, & Bu, 2003). Studies have shown that human fetal T lymphocytes secrete minimal 
levels of interleukin (IL)-2, IL-4 and interferon-gamma (IFN) when stimulated by 
phytohaemagglutinin or allogeneic stimulator cells (Y. Zhao, Dai, Lv, & Gao, 2002). 
 
The development of immune tolerance either to the vector or the transgene has been 
addressed in several in utero gene therapy studies. In some preclinical experiments the fetal 
environment provided immune tolerance or ignorance to the transgene (Waddington, et al., 
2004). Delivery of a lentiviral vector  carrying the human factor IX (hFIX) cDNA and secreting 
hFIX protein into the fetal circulation elicited no humoral or celluar immune response against the 
protein (Waddington, et al., 2004). Similarly another prenatal study using systemic delivery of an 
adenoviral vector carrying hFIX showed evidence of immune tolerance to the transgene protein 
(Waddington, et al., 2003). Furthermore, this study demonstrated that 5 of 9 mice did not 
develop anti-hFIX antibodies in response to a postnatal administration of an hFIX adenoviral 
vector if the mice were given a prior prenatal administration of the vector. In contrast, mice 
treated solely with the postnatal administration of vector developed higher levels of anti-hFIX 
antibodies and experienced rapid loss of hFIX (Waddington, et al., 2003). Similarly Sabatino et 
al. demonstrated that in utero delivery of AAV 1 carrying hFIX achieved persistent expression of 
the transgene without humoral or cellular response to hFIX (Sabatino, et al., 2007). These studies 
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suggested that the induction of postnatal tolerance to an exogenous transgene was a uniquely 
advantageous immunological aspect of fetal gene therapy as compared to postnatal gene therapy. 
However, not all studies have suggested the development of immunological tolerance by 
in utero gene delivery. Although not to the degree observed with the humoral response seen in 
adult animals treated with AAV vectors (Brockstedt, et al., 1999; Chao, Mao, Bruce, & Walsh, 
2000; Halbert, Rutledge, Allen, Russell, & Miller, 2000), some fetal studies have shown a low 
level humoral immune response when treated with adenoviral or AAV delivery vectors 
(Lipshutz, et al., 2001; Schneider, et al., 2002; Vincent, et al., 1995; Yang, et al., 1999). 
Jerebtsova et al. demonstrated neutralizing antibody production in the setting of fetal gene 
delivery, but the antibody level was low and did not preclude re-administration of the vector 
postnatal (Jerebtsova, Batshaw, & Ye, 2002). Follow-up postnatal delivery of the vector not only 
triggered an adaptive immune response but also blocked transgene expression from a third vector 
administration indicating that the fetal administration did not result in immune tolerance to the 
vector or the transgene in this study (Jerebtsova, et al., 2002). Taken together, these studies 
suggest that prenatal gene delivery offers immunological ignorance at a minimum, and may offer 
immunological tolerance in some settings. 
One could postulate that the large number of proliferating progenitor and stem cells in 
embryonic and fetal tissue could provide an ideal environment for efficient gene transfer. If 
vectors that integrate in the genome transduce progenitor cells, then there is the potential of gene 
correction of all future progeny cells. Of the gene delivery vectors in common use, only MLV-
based retrovirus and lentiviral vectors integrate into the host cell genome (Fischer, Abina, 
Thrasher, von Kalle, & Cavazzana-Calvo, 2004; Lewis, Hensel, & Emerman, 1992; Naldini, 
Blomer, Gallay, et al., 1996). Very few muscle gene transfer studies demonstrate use of MLV-
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based retroviral vectors in utero (Tarantal, et al., 2001). Lentiviral vectors were used for muscle 
gene transfer studies in utero, but ultimately resulted in tumor formation and studies were halted 
(Themis, et al., 2005).   
A unique aspect of differentiated muscle is that each muscle fiber postnatal and each 
myotube in the embryo and fetus is a syncytial cell containing multiple nuclei (Emerson & 
Hauschka, 2004; Ontell & Kozeka, 1984a). Therefore, an episomal transgene or its expression 
product can diffuse a certain distance along the length of the fiber or myotube, an effect that 
could be further enhanced in utero due to tissue barriers that are not fully developed. 
1.3.1 Fetal muscle development in relation to in utero gene therapy 
Muscle gene delivery in utero must consider the unique environment of developing muscle in the 
embryo and fetus. The highly regulated processes of myogenic determination, differentiation and 
development are precisely timed (Christ & Ordahl, 1995; Rudnicki, et al., 1993; Tajbakhsh, 
Rocancourt, & Buckingham, 1996; Tajbakhsh, Rocancourt, Cossu, & Buckingham, 1997); this 
developmental program has important ramifications for muscle gene delivery in utero. Muscle 
tissue is derived from the paraxial mesoderm. Cells of the paraxial mesoderm form somites that 
give rise to the dermomyotome. The cells of the myotome, derived from the dermomyotome, 
further proliferate and migrate forming a mass of premuscle cells called myoblasts (Figure 5). 
Upon induction by extracellular signals, myogenic regulatory factors including myoD, myf5, 
myogenin and mrf4 are expressed in a regulated sequence. These signaling pathways ultimately 
result in the fusion of myoblasts to form myotubes (Christ & Ordahl, 1995; Rudnicki, et al., 
1993; Tajbakhsh, et al., 1996; Tajbakhsh, et al., 1997). 
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Figure 5.Muscle embryonic development in mammals. 
(a) Skeletal muscle is derived from embryonic structures called somites, which are blocks of mesodermal cells. (b) 
Each somite forms dermomyotome which gives rise to skin and muscle (c) The dermotome gives rise to skin 
elements (dermis), and the myotome to axial muscle. (Buckingham, 1992)) 
 
In humans, limb buds first appear at gestation day 28. By gestation day 38, the limb buds 
develop a central cartilaginous matrix segregating the dorsal and ventral premuscle masses. The 
myoblasts lining the future bone from the cartilaginous matrix arrange themselves in parallel 
arrays and by gestation day 45 myotubes begin to develop (Emerson & Hauschka, 2004). A rapid 
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increase in myotube formation is observed between gestation weeks 7 and 14. By week 20, 
muscle fibers are arranged in discrete bundles and cross striated with very few single cells 
persisting (Emerson & Hauschka, 2004).  Similarly in the mouse, embryonic myoblasts migrate 
from the dermatomytome to the future limb area and differentiate into multinucleated primary 
myotubes at approximately embryonic day 11 (E11) (Biressi, Molinaro, & Cossu, 2007; 
Buckingham, et al., 2003). From E14 to E17, secondary myotubes begin to form on the scaffold 
of the primary myotubes (Biressi, et al., 2007; Buckingham, et al., 2003; Duxson & Usson, 1989; 
Ontell, Bourke, & Hughes, 1988; Ontell & Kozeka, 1984a, 1984b; Ontell, et al., 1993). 
Therefore, most preclinical murine in utero muscle gene delivery studies have been performed at 
E15 or E16 when secondary myotubes are forming, but while many tissue barriers such as basal 
lamina and immunity are still quite rudimentary. 
1.3.2 Candidate diseases for in utero gene therapy 
Although, ideally all genetic diseases are targets for in utero gene therapy, those that manifest 
signs and symptoms shortly after birth and are associated with early mortality have the greatest 
potential to benefit from fetal gene transfer. Treatment of DMD is the principal in utero muscle 
gene transfer application in preclinical disease models (Reay, et al., 2008). DMD is an example 
of a lethal, degenerative genetic muscle disease where patients generally succumb to respiratory 
or cardiac complications in the second or third decade of life. The dystrophin gene, whose 
mutation causes DMD, encodes the protein dystrophin. The dystrophin protein is expressed in all 
striated muscles and plays an important role in muscle structure and integrity. Although a 
proportion of DMD cases are caused by new mutations and would not be suspected during the 
fetal stage without specific screening, the majority of cases are inherited in an X-linked recessive 
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pattern (Blake, et al., 2002; A.E.H. Emery, 1993a). Therefore, future pregnancies carrying male 
fetuses are tested because of prior affected family members. Dystrophin gene mutations can be 
determined prenatally from chorionic villus or amniotic fluid samples (Prior & Bridgeman, 
2005). Similar to DMD, the allelic disorder Becker muscular dystrophy could also be treated in 
utero.   
Autosomal dominant muscular dystrophies could be considered for in utero gene transfer 
as DNA diagnostics and gene transfer vectors for these rare disorders are developed. Autosomal 
recessive muscular dystrophies and metabolic muscle diseases are also candidates for in utero 
muscle gene transfer although the absence of extensive family pedigrees for autosomal recessive 
disorders makes detection of these disorders in utero more challenging. In utero diagnostic 
screening studies must be developed in parallel with in utero treatment strategies. Among the 
metabolic muscle diseases, Pompe disease is particularly attractive as a disease target because 
DNA and protein diagnostic studies are readily available, and a lethal, infantile onset of the 
disease heightens the need for in utero treatment. Gene replacement studies have been 
extensively pursued in animal models of Pompe disease, but not for in utero treatment in 
preclinical models (Sun, Zhang, Franco, Young, et al., 2005; Ziegler, et al., 2008b). 
1.3.3 Animal models and vectors 
Preclinical studies of in utero vector-mediated gene transfer have been pursued utilizing 
numerous animal models, including mice, rats, rabbits, guinea pigs, sheep, and non human 
primates (Baldwin, Mickanin, & Buck, 1997; Bilbao, Reay, Wu, et al., 2005; Cohen, Morrow, 
Cork, Delcarpio, & Larson, 1998; Hatzoglou, et al., 1990; Holzinger, Trapnell, Weaver, 
Whitsett, & Iwamoto, 1995; Larson, et al., 1997; Lipshutz, Flebbe-Rehwaldt, & Gaensler, 1999a, 
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1999b; Lipshutz, Sarkar, Flebbe-Rehwaldt, Kazazian, & Gaensler, 1999; McCray, et al., 1995; 
Mitchell, Jerebtsova, Batshaw, Newman, & Ye, 2000a; Schachtner, Buck, Bergelson, & 
Baldwin, 1999; Sekhon & Larson, 1995; Senoo, et al., 2000; Tarantal, et al., 2001; Vincent, et 
al., 1995; G. Wang, et al., 1998; Yang, et al., 1999).  
The success of gene therapy depends on the ability of vectors to deliver genes without 
being pathogenic. Viral vectors have been an integral part of the development of gene therapy 
approaches. Technological developments in viral vectors have led to larger scale production, 
improved purification and decreased pathogenicity. Ever growing efforts have successfully 
improved the performance of gene transfer in utero. For preclinical in utero gene therapy studies, 
the vectors employed have included the retroviridae family of viral vectors (example: lentivirus, 
MLV-based retrovirus) adenovirus, AAV and several others. Each vector has specific advantages 
and disadvantages which has been discussed earlier for the application of muscle gene transfer in 
utero.  
1.3.4 Challenges and future direction of in utero gene therapy 
Preclinical studies have demonstrated the feasibility of introducing an exogenous gene into 
muscle of the developing fetus, although the optimal timing and best mode of delivery have yet 
to be defined. In utero gene therapy is still in its infancy for clinical application. While there are 
many potential advantages, the various safety and ethical implications must also be considered. 
With advanced techniques such as fetoscopy, ultrasound and fetal surgical methods, it is possible 
to achieve in utero gene delivery while limiting the invasiveness of the procedure to both the 
fetus and the mother. While the aim of in utero gene therapy is to provide an optimal therapeutic 
benefit, every attempt must be made to minimize potential complications. Therefore, careful 
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monitoring for birth defects and any long term side effects of in utero gene transfer will be 
required.  
Important perinatal considerations of in utero gene transfer to muscle include minimizing 
any increased risk of preterm labor, infection and fetal loss. Human clinical approaches to fetal 
muscle have included fetal muscle biopsy (Heckel, et al., 1999; Kuller, Hoffman, Fries, & 
Golbus, 1992) and ultrasound guided fetal gluteal muscle injection of corticosteroid, employed to 
improve fetal lung maturation (Ljubic, et al., 1999). Therefore, the surgical approaches that 
would be required for human in utero gene transfer have precedence.  
Some of the many factors concerning optimal timing of injecting the viral vector include 
prevention of insertional mutagenesis, avoidance of integration into the germ line and avoidance 
of deleterious immunity. Insertional mutagenesis, which could possibly lead to oncogenesis, can 
be avoided by using vectors that do not integrate into the host cell genome. Germ line integration 
can be minimized by injecting the vector into fetal tissue after the process of gonadal 
compartmentalization is completed in the fetus. In mouse, primordial germ cells complete 
colonization into gonadal primordium by E13 (Hogan, 1994). Similarly in humans the primordial 
germ cells are completely compartmentalized by week 7 of gestation (Gillman.J, 1948). By 
choosing the appropriate fetal developmental stage for gene delivery, germ line integration can 
be minimized. It is clear from the variable results to date that further studies of immunity and the 
development of tolerance in the setting of muscle gene transfer in utero are required.  
One of the drawbacks of postnatal gene therapy is hepatic toxicity. Although some in 
utero studies in guinea pigs have shown liver transduction (Senoo, et al., 2000), which could be 
due to the choice of the promoter, most evidence suggests low levels of liver transduction 
following in utero muscle or systemic gene delivery (Bilbao, Reay, Li, Xiao, & Clemens, 2005; 
 35 
Bilbao, Reay, Wu, et al., 2005; Boyle, Enke, Adams, Guggino, & Zeitlin, 2001). Similar to AAV 
vector-mediated gene transduction in utero, AAV vector-mediated gene delivery in neonatal 
mice yielded significantly lower levels of liver transduction compared to gene delivery in adult 
mice (B. Wang, Li, Fu, & Xiao, 2008; Z. Wang, et al., 2005). While additional studies are 
needed to understand the mechanisms of low liver transduction in most in utero studies, the high 
proliferative state and unique properties of the fetal liver during development could play a role 
(Lansdorp, Dragowska, & Mayani, 1993; O'Donoghue & Fisk, 2004; Taylor, McElmurry, Lees, 
Harrison, & Blazar, 2002). Another consideration that impacts the ultimate safety of in utero 
gene transfer is the transplacental spread of vector from the fetus to tissues of the pregnant 
female. Studies have shown the presence of anti-adenovirus and anti-transgene antibodies in 
maternal serum (Bilbao, Reay, Wu, et al., 2005). Although these antibodies were not neutralizing 
(Bilbao, Reay, Wu, et al., 2005), immune tolerance, liver toxicity and other consequences need 
to be considered. 
Future advances will depend on continued vector development, a better understanding of 
effects on target and non-target tissues and the induction of immunity and strategies to safely 
enhance efficient gene transduction of muscle tissue for long-lasting therapeutic benefit. of 
genetic muscle diseases. 
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2.0  MUSCLE TRANSDUCTION AND BIODISTRIBUITION EFFICIENCY OF AAV8 
LACZ AFTER IN UTERO GENE THERAPY 
2.1 BACKGROUND AND SIGNIFICANCE 
DMD is a serious debilitating muscle disorder characterized by progressive muscle weakness. It 
is caused by deficiency of dystrophin protein due to a defective dystrophin gene. This deficiency 
leads to a series of pathophysiological changes as explained before leading to respiratory and 
cardiac complications and finally leading to death. 
In order to test potential gene therapies, various gene delivery vectors are being pursued. 
Recently AAVs have gained significant importance due to various advantages as explained in 
detail in the introduction. One of the vectors, AAV8, has shown significant transduction into 
various tissues and especially muscle (Z. Wang, et al., 2005). Furthermore, AAV8 has 
demonstrated widespread expression in postnatal mice, even when delivered systemically, 
suggesting that the vector can be disseminated through the blood vessels and transduce tissues 
efficiently (Z. Wang, et al., 2005). However the effectiveness of AAV8 remains unknown when 
delivered during the fetal period; a time that is often before the signs and symptoms of a disease 
are manifested. Therefore, the biodistribution and tissue transduction levels of AAV8 carrying a 
lacZ gene as a marker was tested in utero. 
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2.2 METHODS 
2.2.1 Mice  
CD1 pregnant E16 mice were purchased from Harlan Sprangue Dawley Colony 208 (Maryland). 
All studies involving animals were reviewed and approved by the University of Pittsburgh’s 
Institutional Animal Care and Use Committee.  
2.2.2 Production of AAV8lacZ vector 
AAV8 vector carrying a lacZ expression cassette driven by the human cytomegalovirus (HCMV) 
promoter (AAV8lacZ) vector stocks were generated by the triple-plasmid transfection method 
(Xiao, Li, & Samulski, 1998). Briefly, the three plasmids are the AAV-CMV-lacZ vector 
plasmid, the mini-adeno helper plasmid, and the AAV8 packaging plasmid containing the AAV2 
Rep gene and AAV8 Cap gene, which has an ATG to ACG start codon mutation to increase the 
vector yield (J. Li, Samulski, & Xiao, 1997). AAV8lacZ viral particles were purified by double 
CsCl gradient centrifugation and dialyzed three times against PBS containing 5% Sorbitol. The 
titer of vector genomes was determined by a standard DNA dot-blot assay. The vector stocks 
were provided by the laboratory of Xiao Xiao. 
2.2.3 In utero AAV8lacZ vector administration 
Timed pregnant CD1 mice were anesthetized with an intraperioneal injection of 5mg/kg of 
xylazine and 50mg/kg of ketamine. After shaving the abdominal wall and cleaning the skin with 
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betadine, a single vertical incision was made through the abdominal wall and peritoneal 
membrane to expose the uterus. Fetal injections were performed under sterile conditions and 
high magnification. A total volume of 8-10 µl of AAV8lacZ solution/fetus (dose: 6.4 x 1011 
vector genomes per fetus) was injected IP using a 33G needle (Hamilton, USA) attached to a 
PB600 syringe dispenser (Hamilton, USA).  About 1 to 2 l of a fluorescent marker (fluorescent 
beads or fluorescent dextran) was also injected as a means to identify treated mice after birth 
(Figure 6). For this study, I injected 14 pups from 9 pregnant CD1 mothers to achieve 8 positive 
pups. A total of 8 treated and 8 untreated littermate pups were studied. The schematic 
arrangement of the pups in a pregnant mouse is shown in Figure 7. 
 
 
 
 
 
a b c
Figure 6.Identification of the injected pup using fluorescent beads. 
Five days following delivery, the treated pups injected intramuscularly (a), (b), and intraperitoneally (c),
were examined under a fluorescent microscope for fluorescent markers orange fluorescent beads (540/560
emission/excitiation) to identify the injected pup. 
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Between 2 and 5 days following injection, the naturally delivered pups were examined 
using a fluorescence microscope to identify those pups that were injected by the presence of the 
fluorescent marker. The surgical procedure is briefly demonstrated in Figure 8. At 9 weeks 
following injection, different tissues from the mother, the injected pups and uninjected 
littermates were analyzed for biodistribution of -galactosidase (-gal) expression and vector 
content. 
 
 
 
 
ovary 
uterine horns 
maternal circulation 
Single  
embryo 
Figure 7.Schematic arrangement of pups in a pregnant mouse. 
Each pregnant mother holds approximately 5-15 pups depending on the strain and several other factors.
Each of the uterine horn is vascularized by maternal blood supply and each horn holds a single pup
[Adapted from(Itah, Gitelman, Tal, & Davis, 2004)]. 
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2.2.4 Whole tissue staining 
Tissues including forelimb muscle, hindlimb muscle, heart, diaphragm, intercostal muscle and 
abdominal muscles, were isolated from mice, washed in 1x PBS for 5 minutes and stained for -
gal expression. Whole muscle tissues were fixed with 0.5% glutaraldehyde and immersed in 5-
bromo-4-chloro-3-indole-β-D-galactopyranoside (X-gal) staining solution (5 mM K3Fe(CN)6, 5 
mM K4Fe(CN)6, 1 mg/ml X-gal and 1 mM MgCl2) for 1- 2 hours at 37°C. Stained tissues were 
imaged using a Fujipix 5400 camera. 
a b
c d
Figure 8. In utero gene therapy in mice. 
The surgical procedure first involves exposing the skin and peritoneum (a), and the uterine horns (b) and
(c). Under bright light and high magnification the pups are visible through the uterine horns. Viral vector is
injected, into the pups of E-16 pregnant mice. The peritoneum is sutured (d) and the skin clipped to close. 
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2.2.5 Cryosections 
The tissues that were analyzed were tibialis anterior, quadriceps, gastrocnemius, forelimb 
muscle, abdominal muscle, intercostal muscle, diaphragm, heart, liver, lung, spleen, and kidney. 
Tissue samples were snap-frozen in 2-methylbutane cooled with dry ice. Half of the sample was 
used for preparing cryo-sections using a cryostat (HM 550, Richard-Allan Scientific) and the 
other half was used to extract protein and DNA. The cryosections taken on glass slides were 
stained for -gal expression. Sections were fixed with 0.5% glutaraldehyde, stained in X-gal 
staining solution (5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 1 mg/ml X-gal and 1 mM MgCl2) for 2- 
3 hours at 37°C, mounted and viewed with a Zeiss Axiophot microscope.  
2.2.6 Immunohistochemistry 
Tibialis anterior muscle sections were pretreated with a blocking solution (Mouse-on Mouse 
[M.O.M.]; Vector, Burlingame, CA) in order to prevent nonspecific antibody binding. Sections 
were then incubated with polyclonal rabbit anti--galactosidase (5' Prime 3' Prime, Inc., 
Boulder,CO, USA) diluted at 1:2000 and monoclonal anti-myosin (skeletal, slow) (Sigma, USA) 
diluted at 1:2000 for 2 hrs. After a 20 min wash in 1X phosphate buffered saline (PBS), the 
sections were incubated with a Cy3 AffiniPure Donkey Anti-Rabbit IgG (Jackson 
ImmunoResearch Inc., USA) diluted 1:300 with M.O.M. and an Alexa Fluor® 488 goat anti-
mouse IgG (Invitrogen, USA) diluted 1:100 with M.O.M. for 30 min at room temperature.Cell 
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nuclei were stained with Hoechst. Muscle sections were visualized using fluorescence 
microscopy. 
2.2.7 Ortho-nitro-phenyl galactopyranoside (ONPG) -gal expression assay 
To quantitate -gal expression, the ONPG assay was performed on extracted protein from tissue 
samples as previously described (Bilbao, et al., 2003). Briefly, snap frozen tissue samples were 
treated with TEES buffer (25 mM Tris-HCl pH 8.0, 2.5 mM ethylenediaminetetraacetic acid 
[EDTA] pH 8.0, 2.5 mM ethyleneglycoltetraacetic acid [EGTA] pH 7.4, 5% sodium dodecyl 
sulfate [SDS]) on ice. Samples were then centrifuged at 14,000 rpm for 30 min and protein 
extracts were collected and stored at -80°C until analysis. Subsequently, the protein extracts were 
used for ONPG assay and bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL). For the 
ONPG assay, serial dilutions of the protein extract were incubated at 37°C for 30 min in a 96-
well plate with a buffer containing the enzyme substrate for the reaction. The optical density of 
the reaction was then read at wavelength 420 nm. The quantified samples were presented as units 
of -gal activity/ng of protein. 
2.2.8 Real time PCR assay 
Total DNA was isolated from the muscle tissue by ethanol precipitation (Wizard genomic DNA 
purification kit, Promega, USA). Viral genomes were quantified in DNA from tissue samples 
using real-time PCR as previously described (Bilbao, et al., 2003). Briefly, a 50 µl PCR volume 
contained 10 µl of DNA, 200 nM of each primer, 200 nM probe and 25 µl of TaqMan Universal 
Master Mix (PE Applied Biosystem, Foster City, CA) containing 8% glycerol, 1X TaqMan 
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buffer A, 5 mM MgCl2, 400µM dUTP, 200µM dATP, dCTP, dGTP (each), AmpliTaq Gold 
(0.025 U/ µl) and AmpErase UNG (0.01 U/ µl). The vector genomes were calculated by 
amplifying lacZ and normalized to endogenous mouse apolipoprotein B (Apo-B) (a single copy 
gene used as an internal control) used to calculate the amount of DNA (and thus the number of 
nuclei) in each sample. The primers and probes for the lacZ (Senoo, et al., 2000) and Apo B 
(Pan, et al., 2002) genes have been previously described. The amount of DNA for each sample 
was calculated from the number of nuclei in each sample using the approximation that a murine 
diploid nucleus contains 6 pg of DNA. All real-time PCR assays were performed in MicroAmp 
optical 96-well reaction plates (PE Applied Biosystem, USA). Amplification conditions of 2 min 
at 50°C and 10 min at 95°C for the first cycle, followed by 40 cycles of 95°C for 15 s and 60°C 
for 1 min were used. The results were presented as copies of vector particles per 1000 nuclei. 
2.3 RESULTS  
2.3.1 Identification of the injected pup 
In utero gene delivery involves administration of vector into the pup(s) a few days before birth. 
In the literature, several strategies have been used to identify the injected pup. Some researchers 
performed a cesarean section to deliver and identify the injected pup (Waddington, et al., 2004). 
Furthermore, a cesarean section usually involves delivery of premature pups and requires the use 
of a foster mother. 
Some researchers also inject all of the fetuses along the uterine horns (Figure 7) (Garrett, 
Larson, Dunn, Marrero, & Cohen, 2003). However, this could result in a higher rate of 
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pregnancy loss. Another strategy commonly employed is to analyze all the pups that are 
delivered naturally and look for the marker in the viral vector such as GFP or LacZ gene. 
However, these strategies not only involve laborious work but also are not a conclusive way to 
identify the injected pups. One way to address this problem is to identify markers that can be 
used to visualize the injected pup. In this study various fluorescent and non-fluorescent markers 
were injected into pups of E-16 pregnant mice and examined visually or under fluorescence 
microscopy to identify the injected pup. Fetal injections were performed as discussed below. 
During these experiments the markers were diluted with Ringer lactate buffer in the ratio of (1:4) 
and 10 µl were injected intraperitoneally and 4 µl injected intramuscularly into E-16 pregnant 
mice. Approximately 3-7 days following delivery, pups were examined visually for non-
fluorescent markers and by fluorescent microscopy for fluorescent markers to identify the 
injected pup. I observed that orange fluorescent beads (540/560 emission/excitiation) and 
Dextran Alexa Fluor were good markers to identify injected pups for up to 9 days post treatment 
(Figure 6).  
 
 
 
 
ITR ITRCMV lacZ PolyA
Figure 9. Schematic diagram of AAV8lacZ vector used in this study. 
The AAV8 vector contains a lacZ gene driven by a CMV promoter. The vector is flanked by inverted
terminal repeats and carries a 3’ PolyA site. ITR, terminal repeats; CMV, Cytomegalovirus promoter, lacZ,
lacZ gene; PolyA, polyadenylation site. 
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Figure 10. -galactosidase (-gal) expression in skeletal and cardiac muscle tissues. 
Tissues were collected 9 weeks after an intraperitoneal injection of 6.4 x 1011 vector genomes of AAV8lacZ into E-
16 pups of pregnant CD1 mice and stained for -gal expression using X-gal. X-gal staining was observed in 
hindlimb (a), forelimb (b), heart (c), abdominal muscles (d), diaphragm (e), and intercostal muscles (f). 
 
 
 
 
 46 
2.3.2 Gross biodistribution of lacZ expression  
To determine the biodistribution and gene transfer efficiency of systemically delivered AAV8 in 
utero, 6.4 x 1011 vector genomes of AAV8lacZ were injected IP per fetus at E16. The schematic 
diagram of the AAVlacZ used is shown in Figure 9.  Post birth at 9 weeks of age, tissues were 
collected from injected pups, uninjected littermates and mothers that carried the treated pups. To 
assess the results of gene delivery, all tissues were analyzed for the expression of -gal by X-gal 
staining. By whole tissue staining, diaphragm, intercostal muscles and abdominal muscles from 
the injected pups had the highest levels of -gal expression (Figure 10). Moderate levels of 
expression were seen in hindlimb muscles, forelimb muscles and heart. Although considerable 
AAV8 gene therapy studies have been done in adult and neonatal mice, the biodistribution of the 
AAV8 vector after in utero gene delivery has not been reported. Here, I provide the first report of 
the widespread gene expression in various muscles, including forelimb, diaphragm, intercostal, 
heart, tibialis anterior, quadriceps, and gastrocnemius muscles after AAV8 lacZ in utero 
injection. Minimal to undetectable levels of expression were observed in liver, lung, spleen and 
kidney (Figure 11).  
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Figure 11. -galactosidase (-gal) expression in non-skeletal muscles. 
Tissues were collected 9 weeks after an intraperitoneal injection of 6.4 x 1011 vector genomes of AAV8lacZ into E-
16 pups of pregnant CD1 mice and stained for -gal expression using X-gal. Tissues shown are: observed in liver 
(a), lung (b), kidney (c), and spleen (d). 
2.3.3 Histology of lacZ expression 
Cryosections of diaphragm, quadriceps, gastrocnemius, tibialis anterior, forelimb muscle and 
heart collected from injected pups at 9 weeks of age were stained for -gal expression.  
Diaphragm exhibited -gal expression in nearly all muscle fibers (Figure 12). A mosaic pattern 
of muscle fibers expressing -gal was observed in forelimb, tibialis anterior, quadriceps and 
gastrocnemius muscles (Figure 12). A mosaic pattern of -gal expressing cells was observed in 
cross-sections of heart with most transgene-expressing cells in close proximity to the ventricles. 
Low to undetectable levels of expression were observed in liver, lung, spleen and kidney (Figure 
13). The untreated pups had no detectable levels of expression (not shown). 
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Figure 12. -galactosidase (-gal) expression in cryosections of muscle and heart.  
Tissues were sectioned and stained for -gal 9 weeks following an intraperitoneal injection of 6.4 x 1011 vector 
genomes of AAV8lacZ into E-16 pups of pregnant CD1 mice. -gal expression was observed in cryo-sections of 
forelimb (a), diaphragm (b), heart (c), tibialis anterior (d), quadriceps (e), and gastrocnemius (f) muscles. Scale bar = 
200 µm. 
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Figure 13. -galactosidase (-gal) expression in cryosections of non-muscle tissues. 
Tissues were sectioned and stained for -gal 9 weeks following an intraperitoneal injection of 6.4 x 1011 vector 
genomes of AAV8lacZ into E-16 pups of pregnant CD1 mice. Tissue sections shown are liver (a), lung (b), kidney 
(c), and spleen (d). 
2.3.4 Quantification of -gal expression  
In order to quantify the expression of protein I performed the ONPG assay on protein extracts 
from all tissues. Diaphragm and intercostal muscles exhibited high levels of expression of 7.73 ± 
1.63 and 6.48 ± 0.94 units of -gal per ng of protein respectively (Figure 14a). Quadriceps, 
tibialis anterior, gastrocnemius and forelimb muscle, and heart had moderate levels of expression 
of 2.2 ± 0.46, 1.40 ± 0.28, 1.91 ± 0.41, 2.47 ± 0.43, and 1.39 ± 0.29 units of -gal per ng of 
protein respectively (Figure 14b).   
 
a b
c d
 50 
 
 
Figure 14. Biodistribution of vector particles of AAV8lacZ and expression of -galactosidase -gal). 
Tissues were collected 9 weeks after an intraperitoneal injection of 6.4 x 1011 vector genomes of AAV8lacZ into E-
16 pups of pregnant CD1 mice. Viral particles and -gal expression were quantified by real-time PCR and ONPG 
assay, respectively, in diaphragm and intercostal muscles (a) and quadriceps, tibialis anterior, gastrocnemius, 
forelimb muscle, heart, liver, lung, kidney and spleen (b). Quantification of viral particles is expressed as mean viral 
particles per 1000 nuclei. Quantification of -gal expression is shown as units of -gal per ng of protein. Error bars 
represent standard error; number of mice analyzed (n) = 8. Viral particles per 1000 nuclei ■; Units of -gal per ng 
protein ■. 
2.3.5 Quantification of AAV vector genomes  
In order to quantify the expression of vector genomes I performed the ONPG assay on protein 
extracts from all tissues. Diaphragm and intercostal muscles exhibited high levels of expression 
of 7.73 ± 1.63 and 6.48 ± 0.94 units of -gal per ng of protein respectively (Figure 14a). 
Quadriceps, tibialis anterior, gastrocnemius and forelimb muscle, and heart had moderate levels 
of expression of 2.2 ± 0.46, 1.40 ± 0.28, 1.91 ± 0.41, 2.47 ± 0.43, and 1.39 ± 0.29 units of -gal 
per ng of protein respectively (Figure 14b).  There were no detectable levels of -gal expression 
in diaphragm, intercostal muscles, quadriceps, gastrocnemius, tibialis anterior, forelimb, heart, 
liver, lung, spleen and kidney tissues collected from the mothers that carried the treated mice in 
utero (data not shown). Liver, lung, kidney, and spleen had 3.79 ± 1.28, 3.76 ± 1.28, 3.76 ± 1.35, 
and 1.32 ± 0.49 viral particles per 1000 nuclei respectively (Figure 14b). There were no 
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detectable levels of vector genomes in diaphragm, intercostal muscles, quadriceps, 
gastrocnemius, tibialis anterior, forelimb, heart, liver, lung, spleen and kidney tissues collected 
from the mothers that carried the treated mice in utero (data not shown). 
2.3.6 Preferential transduction of fast-twitch muscle fibers 
To better understand the distribution of muscle fibers transduced by AAV8lacZ in utero, I 
correlated transduction efficiency with muscle fiber type. Myofibers can be classified as fast-
twitch or slow-twitch based on the isoform of myosin heavy chain (MyHC) expressed (Barany, 
1967; Reiser, Greaser, & Moss, 1988). Previous studies have shown that AAV2 preferentially 
transduced slow-twitch fibers and AAV6 transduced both fiber types in mice (Blankinship, et al., 
2004; Y. Lai, et al., 2005; Pruchnic, et al., 2000). Similarly another study showed AAV9 
preferentially transduced fast-twitch fibers in mice;(Bostick, Ghosh, Yue, Long, & Duan, 2007) 
however AAV9 did not show any fiber type transduction preference in dogs (Yue, et al., 2008). 
To determine if the transduction by AAV8lacZ in utero correlated with fiber type I performed 
double immunostaining with antibodies raised against -gal and slow-twitch MyHC. 
Interestingly, I observed that the majority of -gal-expressing muscle fibers did not express 
slow-twitch MyHC. However, rare slow-twitch fibers were transduced (Figure 15). However 
both fast and slow fibers were transduced in the diaphragm which exhibited extensive vector 
transduction (Figure 16).  
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Figure 15. Expression of  -galactosidase (-gal) in slow- and fast-twitch muscle fibers. 
Section of tibialis anterior muscle from a 9-week-old CD1 mouse treated in utero at E-16 with intraperitoneal 
administration of 6.4 x 1011 vector genomes of AAV8lacZ was immunostained for -gal (red, -gal) and slow-
twitch myosin heavy chain (green, Slow). The merge image shows that most transduced fibers were fast-twitch 
fibers (examples labeled with #). Rare slow-twitch fibers were also transduced by AAV8lacZ (examples labeled 
with *). Nuclei are stained with Hoechst. Scale bar = 200 µm. 
2.4 DISCUSSION AND CONCLUSIONS 
In utero gene delivery involves administration of vector into the pup(s) a few days before 
delivery. In our in utero studies all the pups in the pregnant mother are not treated to minimize 
stress and pregnancy loss. In order to identify the pup which was treated with the vector, several 
markers were tested. In this study it was shown for the first time that fluorescent markers can be 
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used to effectively and efficiently identify the injected pups. In this study orange fluorescent 
beads (540/560 emission/excitiation) and Dextran Alexa Fluor were found to be good markers to 
identify the injected pups, and have been used in all of my subsequent in utero gene transfer 
studies.     
 
 
 
 
To characterize the biodistributuion of the AAV8 vector when delivered in utero, 
AAV8lacZ was systemically delivered to E-16 mice. The distribution of transgene expression 
and vector genomes were analyzed in treated mice at 9 weeks of age. While considerable AAV8 
gene therapy studies have been done in adult and neonatal mice, the biodistribution of AAV8 
vector after in utero gene delivery has not been reported. I here provide the first report of 
widespread gene expression in various muscles, including forelimb, diaphragm, intercostal, 
heart, tibialis anterior, quadriceps, and gastrocnemius muscles after AAV8 lacZ in utero 
injection. In addition to demonstrating lacZ gene expression by X-gal staining, I quantified gene 
expression by ONPG assay, and quantified the number of gene copies by real time PCR.  I 
b
Figure 16. Expression of -galactosidase (-gal) in slow- and fast-twitch muscle fibers in diaphragm. 
Section of diaphragm muscle from a 9-week-old CD1 mouse treated in utero at E-16 with intraperitoneal
administration of 6.4 x 1011 vector genomes of AAV8lacZ was stained for -gal (a), and slow-twitch myosin heavy
chain (green, Slow) (b). The images show that AAV8 transduced both fast-twitch and slow-twitch muscle fibers. 
 
a 
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observed a good correlation between the level of transgene protein expression and vector 
genome copy numbers in individual tissues. In particular, I observed highest levels of expression 
in diaphragm and intercostal muscles followed by other skeletal muscles.  
Previous studies have shown the potential of AAV8 vectors to deliver transgenes to 
muscle tissue of postnatal mice (Inagaki, et al., 2006; Louboutin, et al., 2005; Qiao, et al., 2008; 
Rodino-Klapac, et al., 2007; Sun, Zhang, Franco, Young, et al., 2005; Z. Wang, et al., 2005; 
Ziegler, et al., 2008a; Zincarelli, et al., 2008). With systemic administration, AAV8 vector 
exhibited better transduction in neonates than adults in mice suggesting systemic barriers to gene 
delivery that develop with maturation of adult tissues (Z. Wang, et al., 2005). This suggested that 
in utero gene delivery of AAV8 would offer even more efficient gene delivery with potential 
benefit for the treatment of genetic diseases in particular. Consistent with previous postnatal 
AAV8 vector studies I observed high gene transduction in skeletal muscles with in utero AAV8 
vector gene transfer. In this respect, I noted a widespread and mosaic pattern of gene expression 
throughout various muscle groups both in the upper and lower limbs. Importantly, a high level of 
gene transduction was observed in diaphragm and intercostal muscles when gene delivery of 
AAV8 vector was accomplished in utero. 
Some parallels can be drawn between gene delivery in utero and to neonatal mice by 
comparing our results with a prior AAV8 systemic delivery study in neonatal mice published by 
Wang et al (Z. Wang, et al., 2005). In this study 1-day-old mouse pups treated with IP 
administration of AAV8 showed high transduction efficiency in various muscle tissues for up to 
2 months. The dose and period of analysis of the neonatal study were comparable to my in utero 
study. Similar to the neonatal study, I observed expression in various muscle tissues, heart and 
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diaphragm. Furthermore, similar to the neonatal study, our study also showed minimal to 
undetectable expression in non-muscle tissues such as liver, lung, kidney and spleen.  
Previous studies of viral vectors injected in utero have exhibited promising, but varying 
abilities to deliver transgenes to different tissues (Bilbao, Reay, Li, et al., 2005; Bilbao, Reay, 
Wu, et al., 2005; Boyle, et al., 2001; Mitchell, Jerebtsova, Batshaw, Newman, & Ye, 2000b). 
Prior in utero viral vector-mediated gene delivery studies have been done with AAV1 and 
AAV2,(Bilbao, Reay, Li, et al., 2005; Bouchard, et al., 2003; Mitchell, et al., 2000b; Sabatino, et 
al., 2007) AAV5,(Bouchard, et al., 2003) adenoviral vectors,(Bilbao, Reay, Wu, et al., 2005; 
Bouchard, et al., 2003; Reay, et al., 2008) and lentiviral vectors (MacKenzie, et al., 2005). While 
some of the previous in utero studies using viral vectors such as AAV1, (Bilbao, Reay, Li, et al., 
2005) AAV2 (Bilbao, Reay, Li, et al., 2005) and AAV5 (Bouchard, et al., 2003) demonstrated 
minimal skeletal muscle expression, my study using AAV8 in utero systemic gene delivery 
demonstrated significant levels of widespread gene delivery to skeletal muscles including 
forelimbs and hindlimbs. Furthermore, the high level of gene transduction in respiratory muscles 
was accomplished with a relatively low dose of AAV8 vector. 
 Different patterns of association of gene transduction to muscle fiber type have been 
observed for different AAV serotypes. While studies have shown AAV6 transduces both fast- 
and slow-twitch fibers in young adult mice (5-6 week old C57BL/6) in extensor digitorum 
longus (EDL) and soleus muscles (Blankinship, et al., 2004) but with a trend towards preferential 
transduction of fast-twitch fibers treated in 3-day-old mdx hind limb muscle, (Y. Lai, et al., 2005) 
it has also been shown that AAV2 preferentially transduces slow-twitch fibers in hindlimb 
muscle of both newborn and adult mice (Pruchnic, et al., 2000). Moreover, studies with AAV9 
demonstrated that both fiber types were transduced in gastocnemius muscle of newborn dogs and 
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that AAV9 transduction was independent of laminin receptor (LamR) expression, (Yue, et al., 
2008) a known receptor of AAV9 (Akache, et al., 2006). In contrast, studies in soleus and TA 
muscles of newborn and young adult (7 week old) C57BL/10 mice demonstrated that AAV9 
preferentially transduced fast-twitch fibers (Bostick, et al., 2007). Hence to further understand 
the transduction profile of AAV8 in utero I studied the fiber type transduction in TA muscle. I 
observed preferential transduction of fast-twitch fibers. However, I also noted transduction of 
rare slow-twitch fibers. Interestingly, at very high levels of transduction, such as in the 
diaphragm preferential transduction of one fiber type was not observed. Further studies will be 
required to understand the reasons for fiber type preference in transduction that appears to 
depend upon vector serotype and level of transduction and host factors such as species and age. 
One of the challenges of vector muscle gene therapy is to achieve specific expression in 
targeted tissues (i.e the muscles) and to achieve minimal expression in non-muscle tissues. I 
noted minimal vector transduction in non-muscle tissues such as the liver, lung, spleen and 
kidney. Importantly, I observed no detectable levels of -gal expression (by ONPG) or vector 
genomes (by Taqman real time PCR) in tissues collected from the mothers that carried the 
experimental mice in utero. Maternal tissues studied included diaphragm, intercostal muscles, 
quadriceps, gastrocnemius, tibialis anterior, forelimb, heart, liver, lung, spleen and kidney. 
Studies have shown that many viral vectors injected systemically into adult mice 
preferentially transduce the liver (Z. Wang, et al., 2005; Zincarelli, et al., 2008). However, our in 
utero gene delivery data, consistent with other in utero studies,(Bilbao, Reay, Li, et al., 2005; 
Bilbao, Reay, Wu, et al., 2005; Boyle, et al., 2001) demonstrated minimal transduction of viral 
vectors into liver. It is interesting to note that even when delivered by the intrahepatic route, in 
utero injection of AAV2 provided minimal liver transduction (<1%) at days 21 and 70 post 
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treatment in mice (Mitchell, et al., 2000b). Similarly intra-amniotic injection of AAV2 to 
transduce rabbit fetuses demonstrated no transduction into liver tissue (Boyle, et al., 2001). 
These and other studies (Bilbao, Reay, Li, et al., 2005; Bilbao, Reay, Wu, et al., 2005) 
demonstrated very low transduction of the liver by in utero gene transfer. This possibly is due to 
high cell turn over and unique properties in the fetal liver compared to the adult liver (Lansdorp, 
et al., 1993; O'Donoghue & Fisk, 2004; Taylor, et al., 2002). From the standpoint of safety this is 
significant since liver transduction often leads to toxicity and has been an important limitation of 
clinical viral vector gene transfer studies (Marshall, 1999). Furthermore, liver transduction is 
generally not desired as a component of muscle gene transfer strategies. 
Studies have shown that IP injections of vectors such as AAV1 and AAV2 have varying 
abilities to transduce the murine heart in utero (Bilbao, Reay, Li, et al., 2005; Lipshutz, et al., 
2001). Lipshutz et al. showed that while the gene expression of AAV2 in the peritoneum of CD1 
mice continued to persist up to 18 months post in utero transuterine IP injection, the expression 
in heart declined (Lipshutz, et al., 2001). Similarly, it has been shown that while the diaphragm 
showed high transgene expression for up to 4 weeks after intraperitoneal in utero treatment of 
AAV1, the heart demonstrated minimal expression in C57BL/6 mice (Bilbao, Reay, Li, et al., 
2005). Hence in order to understand the transduction ability of AAV8 vector in heart after in 
utero gene delivery, I performed X-gal staining and quantitative assessment of -gal expression. 
I observed that although the transgene expression levels in heart did not reach as high as most 
limb muscles I did observe -gal-expressing cells in close proximity to the ventricles with levels 
approaching that of the limb muscle tissues. In this chapter I demonstrated the potential of 
systemic delivery of AAV8 vector in utero to achieve widespread muscle transduction with 
especially high levels in respiratory muscles. The findings suggest the therapeutic potential for 
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delivering genes systemically to muscle cells of disease models by in utero gene delivery of 
AAV8 vectors. 
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3.0  MUSCLE TRANSDUCTIONAL AND FUNCTIONAL EFFICIENCY OF AAV8 
MINIDYSTROPHIN AFTER IN UTERO GENE THERAPY 
3.1 BACKGROUND AND SIGNIFICANCE 
A crucial challenge of DMD therapeutic research is to develop approaches with functional 
benefit to widespread muscle tissues. Preclinical gene replacement therapy has shown promising 
results in postnatal dystrophic mice (Gregorevic, et al., 2006; Gregorevic, et al., 2004; M. Liu, et 
al., 2005; Yoshimura, et al., 2004) and dogs (Cerletti, et al., 2003; McClorey, Moulton, Iversen, 
Fletcher, & Wilton, 2006). 
As described before, AAV serotype 8 vectors demonstrate robust muscle transduction 
after systemic delivery to postnatal mice and hamsters (Z. Wang, et al., 2005; Zincarelli, et al., 
2008). However, there are very few studies testing gene delivery and functional efficacy of 
therapeutic transgenes carried by AAV8 vectors in dystrophic animal models (Rodino-Klapac, et 
al., 2007). 
Since most primary muscle disorders affect multiple muscle groups including the 
diaphragm, an important challenge for muscle gene therapy is to achieve transgene expression in 
widespread muscle tissues. In order to test the efficiency of AAV8 gene delivery as treatment for 
a muscle disease in utero, I injected AAV8 carrying a minidystrophin gene into a murine model 
of muscular dystrophy, the mouse. In the current section below, the muscle transduction 
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efficiency, muscle functional benefit and muscle pathology are tested using AAV8 carrying a 
minidystrophin gene. 
 
3.2 METHODS 
3.2.1 Mouse colony breeding 
In order to generate pregnant mdx mice male and female mdx mice where caged together on 
Mondays and the mating pairs were separated on Tuesdays to obtain timed pregnancies for 
treating them at E16. All studies involving animals were reviewed and approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee. 
3.2.2 Production of AAV8 minidystrophin vector 
The cloning and construction of the canine minidystrophin cDNA has been previously described 
(B. Wang, Li, Qiao, et al., 2008). Briefly, stocks of an AAV8 vector carrying a canine 
minidystrophin expression cassette driven by the HCMV promoter (AAV8 minidystrophin) were 
generated by the triple-plasmid transfection method (Xiao, et al., 1998) using the three plasmids, 
the AAV-CMV-minidystrophin vector plasmid, the mini-adeno helper plasmid, and the AAV8 
packaging plasmid containing the AAV2 Rep gene and AAV8 Cap gene, as described previously 
(J. Li, et al., 1997). AAV8 minidystrophin viral particles were purified by double CsCl gradient 
centrifugation and dialyzed three times against PBS containing 5% Sorbitol. The titer of vector 
 62 
genomes was determined by a standard DNA dot-blot assay. The schematic of the AAV8 
minidystrophin used is shown in Figure 17. The vector stocks were provided by the laboratory of 
Xiao Xiao. 
 
 
 
 
 
 
3.2.3 In utero administration of AAV8 minidystrophin vector 
AAV8 minidystrophin was administered intraperitoneally in utero into E16 pups of timed 
pregnant mdx female mice as described previously (Koppanati, Li, Xiao, & Clemens, 2009b) 
according to a protocol approved by the University of Pittsburgh Institutional Animal Care and 
Use Committee. The vector was injected at a dose of 6.4 x 1011 vg/pup. In order to identify the 
injected pup, a fluorescent marker, 2% orange fluorescent FluoSpheres (Invitrogen, Carlsbad, 
CA, USA), was injected into one of the limbs permitting identification of injected pups several 
days after birth by observation under a fluorescent microscope. The vector-treated mice were 
analyzed at 9 weeks of age in parallel with age-matched untreated mdx littermate and C57BL/10 
controls. 
3.2.4 In vitro functional analysis of diaphragm  
In vitro functional analysis was performed on diaphragm 9 weeks after birth following in utero 
treatment with AAV8 minidystrophin vector. Diaphragm specific force (peak isometric tetanic 
ITR ITRCMV Mini-dys PolyA
Figure 17. Schematic diagram of AAV8 minidystrophin vector used in this study. 
The AAV8 vector contains a minidystrophin  gene driven by a CMV promoter. The vector is flanked by ITR and
carries a 3’ PolyA site. ITR, inverted terminal repeats; CMV, Cytomegalovirus promoter, PolyA, polyadenylation
site; Mini-dys, minidystrophin. 
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force normalized for muscle cross-sectional area) and force generation during repetitive 
isovelocity lengthening activations were performed as previously described (Watchko, Johnson, 
Gosselin, Prakash, & Sieck, 1994). Analysis of variance with Tukey`s post hoc test for multiple 
comparisons was used to identify statistical differences between groups with respect to specific 
force and residual force following lengthening activations (P<0.05). The in vitro functional 
analysis was performed by Dr. Jon Watchko and Molly Daood. 
3.2.5 Immunohistochemistry 
Muscle samples were snap frozen and sectioned using a cryostat. Immunostaining for -
sarcoglycan and -dystroglycan was performed as described previously (Bilbao, Reay, Wu, et 
al., 2005; Lu & Partridge, 1998). For dystrophin staining, sections were incubated with a rabbit 
anti-dystrophin antibody (Invitrogen, Eugene, OR, USA) at a dilution of 1:800, followed by 
AffiniPure Donkey Anti-Rabbit IgG (Jackson ImmunoResearch Inc., West Grove, PA, USA) at a 
dilution of 1:1000. Cell nuclei were stained with Hoechst dye. The sections were blocked with 
2% bovine serum albumin and washed with 1x phosphate-buffered saline 3X after each step. 
Uninjected mdx littermates and C57BL/10 normal muscles were used as negative and positive 
controls, respectively, for immunostaining. 
3.2.6 Quantification of fibers with centrally-placed nuclei 
Muscle sections stained for dystrophin and Hoechst dye were counted to score the number of 
fibers with centrally-placed nuclei in dystrophin positive and dystrophin negative fibers in 
muscle sections from treated mice. A similar analysis of uninjected mdx littermates and 
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C57BL/10 mice was performed for disease and normal controls, respectively. The percentage of 
fibers with centrally-placed nuclei was than calculated from analysis of approximately 300 
muscle fibers in randomly selected fields. Analysis of variance with Tukey`s post hoc test for 
multiple comparisons was used to identify statistical differences between groups (P<0.05). 
3.2.7 Analysis of vector genomes by real time PCR 
Total DNA was isolated from the muscle tissues of treated and untreated mdx and C57BL/10 
muscles by ethanol precipitation (Wizard genomic DNA purification kit, Promega, Madison, WI, 
USA) and the vector genomes calculated as described previously (Koppanati, et al., 2009b). PCR 
primers for the minidystrophin gene had the following sequence: forward primer: 
CACCCATAAGGAAAGGCTTCTAGAA and reverse primer: 
GAGATCTTGCCATTGTTTCATCAG. The TaqMan probe sequence was: 
ATTCCAAGGGAGTAAGAGA. The results were presented as copies of vector particles per 
1000 nuclei. 
3.3 RESULTS  
3.3.1 Expression of recombinant dystrophin and improvement in muscle 
morphology  
A dose of 6.4 x 1011 vector genomes of an AAV8 vector carrying a canine mini-dystrophin 
cDNA driven by the HCMV promoter was injected intraperitoneally per fetus on E-16. Pups 
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were delivered naturally at full term. At 9 weeks of age, experimental mice were sacrificed and 
diaphragm, upper limb, and lower limb muscles were collected from the injected pups and the 
uninjected littermates. To assess the gene transfer efficiency, cryosections of these tissues were 
analyzed for expression of dystrophin (Figure 18). The treated diaphragm exhibited the highest 
level of transgene expression compared to limb muscles, while in the control mdx muscles only 
rare revertant dystrophin positive fibers were observed. The dystrophic change of mdx muscle 
tissue at 9 weeks of age is characterized by necrotic and regenerating muscle fibers, a 
mononuclear cell infiltrate and increased fibrous connective tissue. To evaluate the histology of 
muscle tissues, cryosections of diaphragm, upper limb and lower limb muscles collected from 
the injected pups at 9 weeks of age were stained with hematoxylin and eosin (H & E). The 
treated muscles showed decreased fiber size variability, less mononuclear cellular infiltration, 
and reduced fibrosis compared to untreated mdx controls (Figure 18). Together, the 
morphological findings suggest skeletal muscle benefit from expression of recombinant 
dystrophin delivered by an AAV8 vector in utero to mdx mice. 
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Figure 18. Restoration of dystrophin and amelioration of dystrophic pathology in AAV8 minidystrophin treated 
mdx diaphragm, upper limb and lower limb muscles. 
Tissues were collected at 9 weeks after an intraperitoneal injection of AAV8 minidystrophin into E-16 pups of 
pregnant mdx mice and analyzed for dystrophin expression and morphology. Dystrophin immunohistochemistry 
(upper panels) and H & E staining (lower panels) were evaluated in (a) diaphragm, (b) upper limb, and (c) lower 
limb muscles. Uninjected mdx littermates and C57BL/10 tissues were used as negative and positive controls, 
respectively, for immunohistochemistry and histology. Dys, dystrophin; H&E, Hematoxylin & Eosin. Bar = 100 
µm. 
3.3.2 Restoration of dystrophin-associated glycoprotein complex in muscle  
The absence of dystrophin expression in mdx muscle disrupts the structural link between 
cytoplasmic actin filaments and the sarcolemmal DAG complex leading to the dysfunction 
and/or loss of the DAG complex from the sarcolemma. Dystrophin protein functions in 
conjunction with the DAG complex [reviewed in (Blake, et al., 2002; Rando, 2001)]. Hence, I 
studied whether in utero gene transfer of an AAV8 vector carrying minidystrophin can restore 
the DAG complex. At 9 weeks of age the diaphragm, the upper limb, and the lower limb muscles 
from the injected pups, and the uninjected littermates were analyzed for α-sarcoglycan and -
dystroglycan expression. Expression of α-sarcoglycan and -dystroglycan was restored in fibers 
expressing recombinant dystrophin (Figure 19) suggesting functional benefit of AAV8 vector-
mediated minidystrophin gene delivery in utero to mdx mice. 
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Figure 19. Restoration of dystrophin associated glycoprotein (DAG) complex proteins in lower limb muscle 
sections after in utero gene transfer of AAV8 minidystrophin. 
Cross-sections of lower limb muscles treated with AAV8 minidystrophin at E16 in utero at a dose of 6.4 x 1011 
vector genomes per fetus show localization of dystrophin to the muscle membrane and the reassembly of the DAG 
complex (-SG and -DG) in the treated muscle fibers. Untreated mdx and C57BL/10 lower limb muscles were 
used as negative and positive controls respectively for immunohistochemistry. Dys, dystrophin; -SG, -
sarcoglycan; -DG, -dystroglycan. Bar = 100 µm. 
3.3.3 Decreased percentage of fibers harboring centrally-placed nuclei in muscle  
Cycles of degeneration and regeneration of muscle fibers result in the accumulation of muscle 
fibers harboring centrally-placed nuclei (Bockhold, Rosenblatt, & Partridge, 1998; Torres & 
Duchen, 1987). To characterize the degree of this pathological process I calculated the 
percentage of muscle fibers with centrally-placed nuclei in mdx untreated fibers, AAV8 
minidystrophin treated, dystrophin-positive fibers, AAV8 minidystrophin-treated, dystrophin-
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negative fibers, and C57BL/10 fibers in diaphragm and hindlimb muscles of 9-week-old mice 
(Figure 20). I observed a high percentage of fibers with centrally-placed nuclei in untreated mdx 
diaphragm (62.6% ± 4.7) and hindlimb muscle (71.8% ± 4.6), while C57BL/10 muscle showed 
very few fibers with centrally-placed nuclei in the diaphragm and hindlimb (1.1% ± 0.7 and 
1.3% ± 0.5 respectively). Figure 21 shows the restoration of peripheral nuclei in dystrophin 
positive fibers. The percentage of fibers with centrally placed nuclei in dystrophin-expressing 
fibers of AAV8 minidystrophin treated mdx mice was significantly less (P < 0.05) in diaphragm 
and hindlimb (21.7% ± 2.4 and 26.7% ± 2.7 respectively) compared to untreated control mdx 
mice. The improvements in mdx muscle pathology observed after AAV8 minidystrophin 
treatment in utero suggest the potential of clinical benefit in a muscular dystrophy animal model. 
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Figure 20. Decreased percentage of fibers with centrally placed nuclei associated with recombinant minidystrophin 
expression in muscle tissues after intraperitoneal administration of AAV8 minidystrophin vector in utero. 
The percentage of fibers with centrally-placed nuclei was calculated from cross-sections of (a) diaphragm and (b) 
lower limb muscles treated by systemic in utero delivery of an AAV8 minidystrophin vector at E16 at a dose of 6.4 
x 1011 vector genomes per fetus. Dystrophin-expressing fibers and dystrophin-non-expressing fibers in treated mdx, 
untreated mdx and C57BL/10 control mice were analyzed. The data is shown as mean  SE. Significant differences 
from untreated mdx mice are shown (*P<0.05). 
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3.3.4 Improvement of in vitro functional force generation properties of costal 
diaphragm  
To test whether widespread expression of minidystrophin in costal diaphragm could provide 
functional improvement, the force properties of treated mdx diaphragm, untreated mdx 
diaphragm and C57BL/10 control diaphragm were tested and compared. Nine weeks after birth, 
costal diaphragm was collected for in vitro force measurements. Diaphragm specific force (peak 
isometric tetanic force normalized for muscle cross-sectional area) and force generation during 
repetitive isovelocity lengthening activations were performed as previously described (Watchko, 
et al., 1994). AAV8 minidystrophin-treated diaphragm exhibited a statistically significant (P < 
0.05) 32.6% increase in specific force compared to paired littermate untreated mdx diaphragm 
[mdx untreated (n=11): 14.7  3.0 N/cm2, mdx treated (n=6): 19.5    1.5 N/cm2, C57BL/10 
control (n=5) 21.1    2.7] (Figure 22a). Specific force of AAV8 minidystrophin-treated 
diaphragm approximated (statistically insignificant difference) that seen in age-matched 
C57BL/10 wild-type controls. After determining peak tetanic force the diaphragm was subjected 
to repetitive lengthening activations, a paradigm of mechanical stress (Watchko, O'Day, & 
Hoffman, 2002). Residual diaphragm force following 10 repetitive lengthening activations, 
expressed as a percent of initial, was significantly greater in AAV8 minidystrophin-treated 
diaphragm than untreated littermate paired mdx diaphragm [mdx untreated (n=11): 84.5    5, 
mdx treated (n=6): 99    7.6, C57BL10 control (n=5): 101    7.1] (Figure 22b). These data 
demonstrate that AAV8 minidystrophin delivered systemically in utero provides significant 
functional improvements in the dystrophic mdx diaphragm as demonstrated by specific force 
generation and the ability to withstand eccentric muscle contraction.   
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3.3.5 Quantification of AAV vector genomes in muscle tissues  
To determine viral vector gene transfer efficiency and compare with the previous marker gene 
study in normal mice, I quantified the number of viral particles in individual tissues by real time 
PCR. The highest levels of viral vector particles were observed in diaphragm. Diaphragm had 
227.77 ± 85.07 viral particles per 1000 nuclei respectively. Upper and lower limbs had 38.70 ± 
22.59 and 33.90.72 ± 13.82 viral particles per 1000 nuclei respectively. These findings are 
similar to and confirm our previous study in normal mice in whom a similar dose of AAV8 
carrying a lacZ gene was delivered by the same route in utero (Koppanati, et al., 2009b). The 
results thus demonstrate the efficacy of AAV8 minidystrophin to successfully deliver the 
Figure 21. Restoration of peripherally placed nuclei associated with recombinant minidystrophin expression in 
muscle tissues after intraperitoneal administration of AAV8 minidystrophin vector in utero. 
Dystrophin-expressing fibers and dystrophin-non-expressing fibers in treated mdx mice were associated with 
peripherally placed nuclei and centrally placed nuclei respectively. An example of a muscle cryosection prepared
for analysis of a centrally placed nuclei from a mouse treated with the AAV8 minidystrophin vector IP in utero. 
The section was immunostained for dystrophin (green) and stained for nuclei (blue). 
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therapeutic gene into dystrophic muscle tissues that was comparable to gene delivery to normal 
muscle tissue. 
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Figure 22. Improvement in force generation properties in diaphragm after intraperitoneal administration of AAV8 
minidystrophin vector in utero. 
The diaphragm muscles were collected at 9 weeks of age from mice treated in utero and were analyzed in vitro. 
Diaphragms of control C57BL/10 (n=5), AAV8 minidystrophin vector-treated mdx (n=6) and untreated mdx (n=11) 
mice were analyzed for (a) specific force (N/cm2) and (b) residual force following 10 repetitive lengthening 
activations divided by initial force and expressed as a percentage. The data is shown as mean  SE. Significant 
differences from untreated mdx mice are shown (*P<0.05). 
3.4 DISCUSSION AND CONCLUSIONS 
This study demonstrates the potential of fetal gene therapy to correct a genetic defect that is 
lethal in humans, in a preclinical model. Other disorders where preclinical fetal gene transfer 
studies have shown partial correction of a genetic defect include mucopolysaccharidosis type VII 
(Karolewski & Wolfe, 2006; Shen, Meng, Maeda, Ohashi, & Eto, 2004) Crigler-Najjar 
Syndrome Type 1, (Seppen, et al., 2003), -thalassemia (Han, et al., 2007), hemophilia B 
(Waddington, et al., 2004), cystic fibrosis (Larson, et al., 1997), and Pompe disease (Rucker, et 
al., 2004). In this study, the improvements in muscle pathology, which are also reflected in 
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functional benefit in the diaphragm, suggest that dystrophin gene transfer in utero for the 
treatment of dystrophin deficiency has the potential to preserve muscle regenerative capacity by 
gene replacement at this very early stage. 
This study demonstrates the ability of AAV8 to systemically transduce widespread 
muscles, including the diaphragm and therapeutic benefit in a DMD model in utero. Although in 
utero dystrophin gene delivery in mdx mice was also achieved with an adenoviral vector (Reay, 
et al., 2008), the AAV8 vector provides markedly more evidence of morphological and 
functional benefit. One limitation of the AAV8 vector for the treatment of DMD in utero, 
however, is a low level of cardiac transduction (Koppanati, et al., 2009b). Another serotype of 
AAV, AAV9, offers higher levels of cardiac transduction when delivered postnatal, (Inagaki, et 
al., 2006) but had not been tested for in utero gene delivery. 
Most previous muscle gene transfer studies with AAV8 have been performed in postnatal 
animals and showed that the AAV8 vector efficiently transduces muscle tissues of neonatal and 
adult animals. In a study of multiple AAV vector serotypes, Wang et al. showed that AAV8 was 
systemically delivered efficiently to muscle in neonatal and adult mice (Z. Wang, et al., 2005). 
Similarly, Inagaki et al. showed robust transduction of muscle tissue following systemic delivery 
of various doses of AAV8 vector in adult mice (Inagaki, et al., 2006). Zincarelli et al. observed 
that tail vein injection of an AAV8-luciferase vector into 6-8 week old mice not only showed 
persistent transgene expression for at least 100 days, but also demonstrated uniform expression 
of luciferase in hindlimb, abdominal and thoracic regions (Zincarelli, et al., 2008). 
The biodistribution of AAV8 when delivered in utero was shown in my previous study of 
AAV8 gene delivery in utero. Intraperitoneal delivery of an AAV8 vector carrying a lacZ gene 
to fetal mice in utero resulted in widespread postnatal gene expression in multiple muscle 
 74 
tissues, including diaphragm, intercostal muscles, forelimb and hindlimb muscles with the 
highest expression seen in the diaphragm and intercostal muscles (Koppanati, et al., 2009b).  
Encouraged by these results with gene delivery of a marker gene in utero using an AAV8 
vector, I performed the present in utero gene transfer study in a muscular dystrophy model with a 
therapeutic transgene and demonstrated for the first time that an AAV8 vector carrying a 
minidystrophin gene injected systemically in utero could restore muscle structure and function. 
The AAV8 vector carrying a mindystrophin gene was injected intraperitoneally into E16 mdx 
pups and muscle was analyzed 9 weeks after birth. I observed efficient transduction and 
restoration of dystrophin in diaphragm, forelimb and hindlimb muscles. In addition, 
immunostaining of the transduced muscles demonstrated restoration of the DAG complex, 
evidenced by expression of -sarcoglycan and -dystroglycan at the sarcolemma of those fibers 
expressing recombinant dystrophin.  
Mdx muscle tissues undergo degeneration evidenced pathologically by necrosis and 
regeneration. The degree of regeneration is proportional to the percentage of fibers harboring 
centrally-placed nuclei. In this study I observed that the dystrophin-expressing fibers in treated 
muscle had significantly fewer centrally-placed nuclei compared to muscle fibers of untreated 
mdx mice. This finding suggested that recombinant dystrophin provided by systemic gene 
delivery in utero partially protected transduced muscle fibers from cycles of degeneration and 
regeneration. Furthermore, in treated mdx muscle, even among the fibers where recombinant 
dystrophin was not detected, there was a non-significant decrease in the number of fibers with 
centrally-placed nuclei compared to muscle of untreated mdx mice. It is possible that despite 
absence of immunohistochemical detection of dystrophin expressed by these fibers, dystrophin 
expression may have been present at a level below the detection threshold and may have 
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provided functional benefit. Alternatively, there may be a ‘bystander’ benefit to non-transduced 
fibers or non-transduced regions of fibers from being in a treated muscle in close proximity to 
fibers and fiber segments that express recombinant dystrophin. Therefore, a significant potential 
benefit of in utero muscle gene transfer for DMD may be to reduce the degree of exhaustion of 
the satellite cell pool by achieving gene transfer early.  
To date, AAV8 has successfully provided therapeutic benefit to skeletal muscle in two 
disease models in prior postnatal studies. Ziegler et al. showed that systemic administration of an 
AAV8 vector carrying the GAA gene to 2 month old presymptomatic GAA-deficient mice that 
model Pompe disease resulted in nearly complete correction of the lysosomal storage of 
glycogen in all the affected muscles (Ziegler, et al., 2008a). Another study also demonstrated 
correction of GAA deficiency in muscle tissue of immunodeficient GSD-II mice by treatment 
with an AAV8 vector (Sun, Zhang, Franco, Young, et al., 2005). In another muscle disease 
model, systemic delivery of an AAV8 vector carrying a myostatin inhibitor in adult mdx mice 
enhanced muscle growth and also ameliorated the dystrophic phenotype (Qiao, et al., 2008). 
Only one previous study reported on AAV gene transfer in utero for treatment of a 
muscle disease. In a mouse model of Pompe disease, an AAV2 vector carrying the α-glucosidase 
gene was delivered intraperitoneally in utero and resulted in improvement in diaphragmatic in 
vitro isometric force-frequency studies 6 months after birth (Rucker, et al., 2004). However, 
AAV8 has not been previously reported in therapeutic gene delivery studies in utero in a 
preclinical model of a muscle disease. 
In postnatal gene delivery studies, restoration of dystrophin expression has been 
correlated with muscle functional benefit after AAV8 gene delivery. In a study involving AAV8 
carrying microdystrophin delivered systemically into the femoral artery in 3 - 4 week old mdx 
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mice and non-human primates, significant improvement in tetanic force and protection against 
eccentric contraction in the EDL muscle was shown (Rodino-Klapac, et al., 2007). Since 
dystrophic patients usually die due to respiratory and cardiac failure, (A. E. H. Emery & 
Muntoni, 2003) restoring dystrophin expression to the diaphragm, which plays a critical role in 
respiration and survival, will be highly important to DMD patients. In the study reported here, 
the diaphragm was collected 9 weeks following birth for ex vivo force measurements. AAV8 
minidystrophin treated diaphragm exhibited a 32% improvement in specific force compared to 
diaphragms from untreated mdx littermates. In normal muscle, dystrophin provides resistance 
against contraction induced injury. I observed that the residual force generated following 10 
repetitive lengthening activations was significantly improved by AAV8 minidystrophin gene 
delivery in utero compared to untreated mdx diaphragm.  
In summary, systemic delivery of minidystrophin with an AAV8 vector in utero provides 
efficient transduction of diaphragm and limb muscles of the mdx mouse when studied after birth. 
The functional benefit demonstrated in transduced diaphragm muscle encourages further studies 
to test the persistence of vector expression and in utero gene delivery in large animal models of 
DMD. 
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4.0  TRANSDUCTION EFFICIENCY OF AAV9MINIDYSTROPHIN AFTER IN 
UTERO GENE THERAPY 
4.1 BACKGROUND AND SIGNIFICANCE  
DMD patients suffer from debilitating muscle weakness and usually die from respiratory and 
cardiac complications (A. E. H. Emery & Muntoni, 2003). In order to test for potential therapies 
for muscular dystrophies, strategies targeting respiratory and heart muscles are important. AAV9 
has shown significant transduction into various muscle tissues including skeletal muscle, heart 
and diaphragm in postnatal mice (Inagaki, et al., 2006; Zincarelli, et al., 2008). Furthermore, 
previous studies using AAV9 have shown that this vector transduces blood vessels efficiently 
(Manfredsson, et al., 2009). In addition there are several studies suggesting AAV9 shows robust 
transduction into the heart (Inagaki, et al., 2006; Miyagi, et al., 2008; Pacak, et al., 2006; 
Vandendriessche, et al., 2007).  
Studies have shown that immaturity of the basal lamina plays an important role in vector 
transduction. Moreover AAV9 has been shown to effectively transverse the endothelium even 
through the blood brain barrier, suggesting that it could be an even better vector to transduce 
muscle tissue. Sun et al. demonstrated that use of AAV9 vectors for gene delivery to postnatal 
mice resulted in enhancement of therapeutic efficiency in the mouse model of Pompe disease 
(Sun, et al., 2008). However the effectiveness of AAV9 when delivered in the fetus remains 
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unknown. Furthermore, the efficiency of an AAV9 carrying a minidystrophin gene in treating a 
murine model would be beneficial. It has been shown that dys3978 which is constructed by 
removing exon 79 (12bp) from dys 3990 (B. Wang, et al., 2000), can provide high levels of 
dystrophin expression. This codon-optimized minidystrophin contains 3 hinges and 5 spectrin-
like repeat regions. Thus, I hypothesized that truncation of the dystrophin cDNA and performing 
codon optimization of the expression cassette in an AAV9 vector would optimize potential 
therapeutic benefit. Therefore, I tested the transduction and muscle biodistribution of AAV9 
carrying a minidystrophin gene. 
4.2 METHODS 
4.2.1 Mouse colony breeding 
In order to generate pregnant mdx mice, male and female mdx mice where caged together on 
Mondays and the mating pairs were separated on Tuesdays to obtain timed pregnancies for 
treating them at E16. All studies involving animals were reviewed and approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee. 
 
 
 
 
 
 
 
 
ITR ITRCMV Opti-dys PolyA
Figure 23. Schematic diagram of AAV9 opti-minidystrophin vector used in this study. 
Twelve base-pairs comprising exon 79 were removed from dysΔ3990 to generate the dysΔ3978 which has a
complement of 3 hinges and 5 spectrin-like repeats. This codon optimized AAV9 mini-dystrophin gene is driven by a
CMV promoter. The vector is flanked by ITR and carries a  3’ PolyA site. ITR, inverted terminal repeats; CMV,
Cytomegalovirus promoter, PolyA, polyadenylation site; Opti-dys, codon-optimized minidystrophin. 
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4.2.2 Production of AAV9 minidystrophin vector 
The construct of the AAV9 minidystrophin used in this study is shown in Figure 23. Twelve 
base-pairs comprising exon 79 were removed from dysΔ3990 forming the dysΔ3978 which has a 
complement of 3 hinges and 5 spectrin-like repeats. This codon optimized mini-dystrophin 
cDNA is driven by HCMV and cloned into an AAV shuttle plasmid (Figure 24) and rescued by 
triple plasmid transfection in 293HEK cells as an AAV9 vector. A dose of 5 x 1010 vector 
genomes was delivered systemically to E16 mice in utero. Production of the AAV vector was 
carried out as previously described in Methods Section 2.2.2 and was done in the Xiao Xiao 
laboratory. 
                         
 
 
pAAV-cmv-opti-dys3978
9009 bp
opti-dys3978
5' - ITR
3' - ITR
Xho I
Xho I
Amp
small polyA
CMV promoter
Xho I (2046)
Xho I (6109)
Figure 24. Plasmid map of pAAV-cmv-opti-dys3978. 
The codon optimized mini-dystrophin cDNA is driven by HCMV and cloned into an AAV shuttle plasmid and
rescued by triple plasmid transfection in 293HEK cells as an AAV9 vector. 
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4.2.3 Mice and in utero AAV9 minidystrophin vector administration 
In utero gene delivery of AAV9 minidystrophin vector was administered as described in 
Methods Section 2.2.3 
4.2.4 Cryosections and Immunostaining 
Muscle tissues, diaphragm and heart were isolated from mice and were analyzed by cryosections 
and immunostaining as previously described in Methods Section 2.2.4, 2.2.5, and 2.2.6. For 
immunohistochemistry, the sections were blocked with 2% bovine serum albumin and washed 
with phosphate-buffered saline 3 times after each step. Immunostaining for -sarcoglycan and -
dystroglycan was performed as described previously (Bilbao, Reay, Wu, et al., 2005; Lu & 
Partridge, 1998). For dystrophin staining, sections were incubated with a human specific anti-
dystrophin antibody (Vector Laboratories, Inc. Burlingame. CA, USA) at a dilution of 1:800, 
followed by AffiniPure Donkey Anti-Rabbit IgG (Jackson ImmunoResearch Inc., West Grove, 
PA, USA) at a dilution of 1:1000. Cell nuclei were stained with Hoechst dye. Uninjected mdx 
littermate and C57BL/10 normal muscles were used as negative and positive controls, 
respectively, for immunostaining. 
4.2.5 Western blot analysis 
In order to quantify the protein expression western blot analysis was performed as described 
before (J. Watchko, et al., 2002) using polyclonal antibody directed against the regions of human 
dystrophin and α-sarcoglycan (1:5000). The membranes were incubated with 1:25 and 1:50 
 81 
dilution of primary antibody for detecting human specific dystrophin (Vector Laboratories, Inc. 
Burlingame. CA, USA) and α-sarcoglycan (NCL-L-b-SARC, Vector Laboratories, Inc. 
Burlingame. CA, USA ) respectively. Positive and negative controls were muscles from 
C57/BL10 and mdx respectively. 
 
 
a b 
d 
c 
e f 
 
Figure 25. Dystrophin expression in skeletal and cardiac muscles of mdx mice treated IP at E16 in utero with  
AAV9 opti-dys. 
Mdx mice at E-16 fetuses were given 5 x 1010 vector genomes of AAV9 carrying codon optimized minidystrophin 
by intraperitoneal injection. At 4 weeks of age, the injected mice were sacrificed for dystrophin expression analysis 
in (a) tibialis anterior, (b) gastrocnemius (c) quadriceps, (d) upper limb (e) diaphragm, and (f) heart. 
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4.3 RESULTS  
4.3.1 Expression of recombinant dystrophin expression 
I investigated the efficacy of AAV9 minidystrophin for the treatment of mdx mice in utero. In 
order to test this I administered 5x1010 vg/ fetus of an AAV9 vector carrying a minidystrophin 
gene driven by CMV promoter by intraperitoneal injection into mdx fetuses at E16. I analyzed 
dystrophin expression at 4 weeks and 3 months post treatment. At 4 weeks post birth, I observed 
widespread recombinant human minidystrophin expression in various muscle tissues such as 
quadriceps, gastrocnemius, tibialis anterior, diaphragm, heart and forelimb muscles (Figure 25) 
in several mice (n=3 out of 6) treated with gene delivery at E16. At 3 months, robust mosaic 
pattern of expression in the heart especially surrounding the ventricles of the heart. However the 
muscle samples showed moderate expression in the muscles. The highest expression was 
observed in the diaphragm at 4 weeks.  
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Figure 26. Restoration of dystrophin associated glycoprotein (DAG) complex proteins and improvement in muscle 
pathology in lower limb muscle sections after in utero gene transfer of AAV9 minidystrophin. 
Cross-sections of lower limb muscles treated with AAV9 codon optimized minidystrophin at E16 in utero at a dose 
of 5 x 1010 vector genomes per fetus show colocalization of dystrophin (a), the reassembly of the DAG complex [-
SG (b)and -DG (c)] and H&E staining (d) to demonstrate morphology in the treated muscle fibers.  
4.3.2 Restoration of dystrophin associated glycoprotein (DAG) complex and 
histopathological improvement in muscle  
Dystrophin functioning in conjunction with several proteins such as α-SG and -DG forms a 
structural complex called the DAG complex. Studies have shown that the absence of dystrophin 
dissociates the complex and debilitates the structural and functional properties of other DAG 
complex proteins as well [reviewed in (Blake, et al., 2002; Rando, 2001). Hence in order to test 
if AAV9 minidystrophin delivered intraperitoneally in utero restores the DAG complex, I 
performed immunostaining for -SG and -DG, in addition to H&E staining. I observed co-
localization of recombinant human dystrophin, -SG, -DG suggesting restoration of the DAG 
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complex (Figure 26). Furthermore, by H&E staining, I observed AAV9 treated muscle also 
demonstrated improvement in muscle pathology, as evidenced by decreased fiber size variability, 
mononuclear cellular infiltration, and fibrosis compared to untreated mdx controls (Figure 27). 
 
 
 
 
4.3.3 Western blot analysis of minidystrophin expression in muscle tissues  
In order to determine minidystrophin derived expression, the treated muscles were analyzed by 
western blot analysis. Dystrophin expression was observed at 4 weeks by western blot in various 
muscles including diaphragm, heart, forelimb, quadriceps, gastrocnemius and tibialis anterior 
muscles of mdx mice treated intraperitonealy at E16 in utero with AAV9 minidystrophin (Figure 
28).  Diaphragm showed robust expression of dystrophin expression compared to other muscles. 
Since a human-specific human dystrophin was used and I do not have a normal mouse positive 
control counterpart, a western blot for restoration of -SG expression was performed (Figure 
29). Each of the muscle tissues, including TA, gastrocnemius, quadriceps, forelimb, and 
diaphragm, showed -SG protein expression. 
H&E 
mdx treated 
a H&E
mdx untreated
b
Figure 27. Amelioration of dystrophic pathology in AAV9 minidystrophin treated mdx lower limb muscles. 
Tissues were collected at 4 weeks after an intraperitoneal injection of AAV9 codon optimized minidystrophin into
E-16 pups of pregnant mdx mice and analyzed for H & E staining Treated mdx section (a) exhibited uniform muscle
fibers with peripherally placed nuclei compared to the uninjected mdx littermates exhibited areas of irregular muscle
fibers. 
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4.3.4 Persistent dystrophin expression in heart  
Our studies demonstrate persistent long term expression of human-specific minidystrophin at 4 
weeks (n = 3) and interestingly even higher expression levels widespread throughout the 
ventricular wall at 3 months post treatment in cardiac tissue (n = 3) (Figure 30).  
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Figure 28. Western blotting to analyze dystrophin in AAV9 in utero injected mdx muscles. 
Dystrophin expression was observed at 4 weeks by westernblot in muscles of mdx mice treated
intraperitoneally at E16 in utero with AAV9 codon optimized minidystrophin. Lane 1, untreated mdx muscle;
lanes 2–7, AAV9 vector-injected mdx muscles; Dystrophin (lanes 2–7) and GAPDH (lane 1) were detected at
the predicted sizes (160 and 37 kDa, respectively). 
Figure 29. Western blotting to analyze α-sarcoglycan in AAV9 in utero injected mdx muscles. 
α-sarcoglycan expression was observed at 4 weeks by western blot in muscles of mdx mice treated intraperitoneally
at E16 in utero with AAV9 codon optimized minidystrophin. Lane 1, C57BL/10, Lane 2, untreated mdx muscle;
lanes 3–7, AAV9 vector-injected mdx muscles; α-sarcoglycan (-SG) (lanes 3–7, row 1) and GAPDH (all lanes,
row 2) were detected at the predicted size (50 and 37 kDa, respectively). 
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4.4 DISCUSSION AND CONCLUSIONS 
In this study, in utero gene delivery of codon-optmized AAV9 minidystrophin to a mouse model 
of DMD was analyzed.  The goal was to determine the transduction efficiency of AAV9 in 
muscle tissues in utero. Previous studies have shown that AAV9 provides robust expression in 
muscle and heart tissues in postnatal mice (Inagaki, et al., 2006). Although studies have shown 
AAV9 to effectively transduce cardiac tissue, no studies have studied the efficiency of AAV9 
gene delivery in utero. In order to test the efficacy and persistence of expression in utero, I 
injected 5x1010 vg/ fetus of an AAV9 vector carrying a minidystrophin gene driven by the CMV 
promoter into the peritoneum of mdx fetuses at E16.  The AAV9 minidystrophin used is a novel 
human mini-dystrophin cDNA synthesized using codon optimization. In this study the codon 
optimized minidystrophin vector was employed to improve the efficiency of the transgene 
expression. Widespread robust expression was observed by immunostaining TA, quadriceps, 
gastrocnemius, forelimb and diaphragm at 4 weeks post treatment in utero. The treated muscle 
also demonstrated improvement in muscle pathology, decreased fiber size variability, less 
mononuclear cellular infiltration, and reduced fibrosis compared to untreated mdx controls as 
seen on H&E staining. More importantly, AAV9 demonstrated persistence of expression in heart 
up to 3 months post treatment. 
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Results from several other in utero AAV transduction studies consistently showed high 
expression in the diaphragm by systemic delivery (Bilbao, Reay, Li, et al., 2005; Koppanati, Li, 
Xiao, & Clemens, 2009a). As expected in this study too, we observed robust expression in the 
diaphragm by systemic delivery at 4 weeks post birth. In addition this study demonstrated 
dystrophin expression into the heart of the mdx mice. These findings in the heart and the 
diaphragm significantly support AAV9 as a therapeutic vector as DMD patients usually die due 
to respiratory and cardiac complications. The effects of dystrophin deficiency on the heart in the 
mdx mouse share several similarities with DMD cardiomyopathy. Usually before the age of 6 
years cardiac function is normal in DMD patients (Nigro, et al., 1983; Nigro, et al., 1990), 
similar to the normal cardiac function in younger mdx mice (Quinlan, et al., 2004). Studies have 
been conducted to study the evolution of cardiac dysfunction in mdx mice. Morphometric 
analysis has revealed widespread and patchy ventricular fibrosis in very old mdx mice (Quinlan, 
et al., 2004). Although younger mice had normal cardiac function studies using murine serial 
Figure 30. Persistent expression of dystrophin in heart sections up to 3 months after in utero gene transfer of 
AAV9 minidystrophin. 
Cross-section of heart muscle treated with AAV9 codon optimized minidystrophin at E16 in utero at a dose of 5
x 1010 vector genomes per fetus and collected 3 months after birth. 
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echocardiograms, catheterization studies showed older mdx mice exhibited dilated 
cardiomyopathy (Quinlan, et al., 2004). Hence restoring dystrophin to heart also plays an 
important role as part of murine muscle gene therapy studies. Delivering the deficient dystrophin 
gene at an early stage can potentially delay this dystrophin deficiency-induced cardiac pathology.  
At 3 months of age persistent expression was seen in the heart tissue. Interestingly we 
noted more robust dystrophin expression in cardiac myocytes at 3 months compared to 4 weeks. 
One hypothesis for this increase in expression could possibly be due to the presence of vector 
genomes dispersed within the completely differentiated target cardiac cells. The cardiac fibers 
being multinucleated and the lasting vector genomes could possibly provide an exponential 
protein expression due to the codon optimization characteristic of the vector, while in the muscle 
the vector could have possibly gone through dilution due to exponential muscle proliferation in 
the growing muscle and fusion of myotubes. Another hypothesis that needs to be considered is 
the possibility of vector integration. Although recombinant AAV vectors have not known to 
integrate in the genome to any significant degree, studies did show the potential to integrate into 
the  genome. Nakai et al showed although most of the recombinant AAV vector remained 
extrachromosomal, 10% host cell genome integration was observed (Nakai, et al., 2001). 
Furthermore, Fisher et al showed 9 weeks post transduction host genome integrated recombinant 
AAV appeard in the form of head-to-tail concatomers (Fisher, et al., 1997). So although minute, 
the potential of vector integration cannot be completely ruled out without testing. It will be 
important to perform analysis of vector DNA levels in transduced cardiac tissue at the different 
time points.  
In order to further confirm the efficacy of restoration of dystrophin in the limb muscle 
fibers at 4 weeks of age, immunostaining was performed using -SG and -DG. Serial 
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cryosections of transduced muscle demonstrated restoration of the DAG complex proteins in 
those fibers expressing recombinant dystrophin  
Western blot dystophin experiments, used to quantify protein transduction using 
dystrophin antibody, revealed high expression in the diaphragm at 4 weeks of age and moderate 
expression in limb muscles. Since it is a human dystrophin we did not have a positive human 
control, hence we performed western blot using SG. The western blot study shows the restoration 
of the DAG as indicated by the restoration of the SG band. With the widespread skeletal gene 
transfer demonstrated by AAV9 and the potential benefits of in utero gene delivery, testing of 
such AAV vectors in canine DMD models should lead to better treatment strategies for DMD. 
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5.0  DISCUSSION 
This dissertation focused upon evaluation of in utero gene therapy using viral vectors for DMD. 
Among the currently used vectors, multiple serotypes of AAV are commonly used. This is due to 
the smaller size, lesser immunogenicity and good transduction ability of AAV vectors. To ensure 
the success of gene therapy as a therapeutic modality for muscular dystrophy, widespread muscle 
gene transfer and functional benefit are essential. In this study, I investigated the approach of 
systemic in utero gene delivery using AAV serotype 8 and 9 and applied this technology to 
dystrophin gene delivery in a murine model of DMD. 
Single gene disorders are genetic diseases caused by mutations of a specific gene.  These 
disorders can be heritable or spontaneous. Some of the examples include cystic fibrosis, sickle 
cell anemia, myotonic dystrophy, Duchenne and Becker muscular dystrophy.  Most of these 
diseases can be diagnosed by testing the DNA at a prenatal stage.  While many of these diseases 
start exhibiting disease symptoms, some diseases such as DMD usually can be clinically 
observed at later stages of childhood or adult life. The single gene muscle disorders include 
autosomal-dominant Emery-Drefuss muscular dystrophy, fascioscapulohumeral muscular 
dystrophy, spinal muscular atrophy, DMD and BMD among many others. Pompe disease is 
another genetic muscle disorder which is due to the absence of a gene that codes for acid alpha-
glucosidase. However, DMD is the most common primary muscle disorder, affecting 1 in 3600 
male births (Drousiotou, et al., 1998; A. E. Emery, 1991). Currently there is no treatment for 
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DMD. However with improvements in the medical multidisciplinary clinical approach, patients 
are able to survive as long as the fourth decade of life. Several of these approaches include 
physical therapy, routine vaccinations such as flu and pneumococcus, use of antibiotics, 
improved oxygenation methods (Eagle, et al., 2002). In addition, corticosteroids play an 
important role in improving muscle strength and function in DMD patients (Mendell, et al., 
1989). While the multidsicplinary care approaches provide benefit, the underlying cause of the 
disease is not fundamentally addressed by the measures.  
With the advancement of science the commonly employed research strategies for the 
treatment of DMD are utrophin upregulation, myoblast transplantation, stem-cell transplantation, 
modification of dystrophin mRNA splicing (exon skipping), readthrough of stop codon 
mutations and viral and nonviral vector gene delivery.  
Most of the single gene disorders can be diagnosed at early stages in life, as early as 
prenatally. Hence it would make sense to intervene as early as possible much before the disease 
reaches its terminal stages. Furthermore there are several advantages of fetal intervention as a 
therapeutic benefit. Gene delivery can be accomplished when the tissue mass is small. The tissue 
barriers such as basal lamina surrounding the muscle are not completely developed yet. The 
immune system is still immature. Higher amounts of proliferating and undifferentiated cells are 
present and more importantly the disease is not completely developed. Based on these ideas 
several gene delivery studies have been conducted in various disease models. During this fetal 
developmental stage, skeletal muscle undergoes several proliferative phases. For example, at 
embryonic day 11 the myoblasts proliferate and begin forming myotubes and by embryonic day 
17 the secondary myotubes have already begun forming. Thus delivering the vector during this 
stage allows the vector to potentially deliver a transgene more efficiently and more widely. 
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 AAV8 and AAV9 have consistently demonstrated widespread skeletal muscle 
transduction by several studies (Inagaki, et al., 2006; Z. Wang, et al., 2005; Zincarelli, et al., 
2008). Based on the advantages of in utero studies and the potential of AAV8 and AAV9 
vectors, I approached this study by first testing the biodistribution and tissue transduction ability 
of an AAV8 vector carrying a lacZ gene to different tissues in normal CD1 mice. In this study I 
observed widespread expression in various muscle tissues and diaphragm with moderate 
expression in the heart. In order to take advantage of the efficient muscle transduction ability of 
AAV8 in mouse tissues, I tested an AAV8 vector carrying a minidystrophin gene which showed 
good expression in various muscle tissues and robust expression in heart. With high expression 
in diaphragm tissues muscle functional studies were conducted. The high diaphragmatic 
expression correlated with a significant increase in specific force and residual force following 
lengthening activation. Thus the in utero delivery of an AAV8 vector provided good transduction 
and functional benefit to the mouse model of DMD. In order to further test other AAV vectors by 
the in utero route, I selected AAV9 carrying a minidystrophin gene, since this vector is known to 
provide robust transduction in both heart and skeletal muscle. This AAV9 vector carried a 
human minidystrophin gene that was providing enhanced levels of dystrophin expression. 
Consistent with previous studies I observed robust transduction in various muscle tissues and 
heart. Furthermore, I observed persistant expression up to as long as 3 months post birth. My 
studies support the therapeutic potential of in utero gene delivery. 
However with this approach I came across several limitations. The mouse model of DMD 
does not provide large litters and maternal cannibalism of mouse pups is common despite 
optimization of environmental conditions. In addition another limitation is surgical stress 
induced by injecting all the pups in a pregnant mouse. This not only increases cannibalism, but 
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also increases the likelihood of spontaneous abortion. While it still remains unknown, the 
surgical stress has the potential to be significant in larger animals, including humans, in future 
studies. 
Another important lesson in these studies was the need to continually optimize the in utero 
surgical procedures. This provided the potential to greatly enhance not only survival of the pups, 
but also to minimize injury to the pups. In this study I tested several techniques such as syringe 
dispensers, tubing connected to a syringe and a timer, syringes with micro needles etc to 
optimize the gene delivery procedure.  
As a future direction, building on the results in this study, in utero gene delivery has the 
potential to be tested in larger mammals such as the dog model of DMD, which has a dystrophic 
phenotype that is closer to human DMD. Furthermore with the identification of additional AAV 
serotypes, even more effective vectors may be discovered for muscle gene delivery. With the 
advantages of in utero gene delivery to muscle, other rare but debilitating single gene muscle 
diseases may also be treated in the future. 
 
 
 
 
 
 94 
6.0  REFERENCES 
Acsadi, G., Dickson, G., Love, D. R., Jani, A., Walsh, F. S., Gurusinghe, A., et al. (1991). 
Human dystrophin expression in mdx mice after intramuscular injection of DNA 
constructs. Nature, 352(6338), 815-818. 
Adkins, B., Williamson, T., Guevara, P., & Bu, Y. (2003). Murine neonatal lymphocytes show 
rapid early cell cycle entry and cell division. J Immunol, 170(9), 4548-4556. 
Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006). The 37/67-
kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 
9. J Virol, 80(19), 9831-9836. 
Albertini, M. R., Emler, C. A., Schell, K., Tans, K. J., King, D. M., & Sheehy, M. J. (1996). Dual 
expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule 
(CD80) on human melanoma cells after particle-mediated gene transfer. Cancer Gene 
Ther, 3(3), 192-201. 
Alexander, B. L., Ali, R. R., Alton, E. W., Bainbridge, J. W., Braun, S., Cheng, S. H., et al. 
(2007). Progress and prospects: gene therapy clinical trials (part 1). Gene Ther, 14(20), 
1439-1447. 
Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., et al. (2006). Systemic 
delivery of morpholino oligonucleotide restores dystrophin expression bodywide and 
improves dystrophic pathology. Nat Med, 12(2), 175-177. 
Amalfitano, A., Rafael, J. A., & Chamberalin, J. S. (1997). Structure and mutation of the 
dystrophin gene. In B. S. a. L. JA (Ed.), Dystrophin: Gene, Protein and Cell Biology (pp. 
1-26). Cambridge, UK: Cambridge Univ. Press. 
Apparailly, F., Khoury, M., Vervoordeldonk, M. J., Adriaansen, J., Gicquel, E., Perez, N., et al. 
(2005). Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic 
joints. Hum Gene Ther, 16(4), 426-434. 
Arahata, K., & Engel, A. G. (1984). Monoclonal antibody analysis of mononuclear cells in 
myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation 
and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol, 16(2), 
193-208. 
 95 
Auricchio, A., O'Connor, E., Weiner, D., Gao, G. P., Hildinger, M., Wang, L., et al. (2002). 
Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin 
Invest, 110(4), 499-504. 
Balaban, B., Matthews, D. J., Clayton, G. H., & Carry, T. (2005). Corticosteroid treatment and 
functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys 
Med Rehabil, 84(11), 843-850. 
Baldwin, H. S., Mickanin, C., & Buck, C. (1997). Adenovirus-mediated gene transfer during 
initial organogenesis in the mammalian embryo is promoter-dependent and tissue-
specific. Gene Ther, 4(11), 1142-1149. 
Barany, M. (1967). ATPase activity of myosin correlated with speed of muscle shortening. J Gen 
Physiol, 50(6), Suppl:197-218. 
Barton-Davis, E. R., Cordier, L., Shoturma, D. I., Leland, S. E., & Sweeney, H. L. (1999). 
Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. 
J Clin Invest, 104(4), 375-381. 
Bassett, D. I., Bryson-Richardson, R. J., Daggett, D. F., Gautier, P., Keenan, D. G., & Currie, P. 
D. (2003). Dystrophin is required for the formation of stable muscle attachments in the 
zebrafish embryo. Development, 130(23), 5851-5860. 
Becker, P. E., & Kiener, F. (1955). [A new x-chromosomal muscular dystrophy.]. Arch Psychiatr 
Nervenkr Z Gesamte Neurol Psychiatr, 193(4), 427-448. 
Beggs, A. H., Koenig, M., Boyce, F. M., & Kunkel, L. M. (1990). Detection of 98% of 
DMD/BMD gene deletions by polymerase chain reaction. Hum Genet, 86(1), 45-48. 
Bell, C. D., & Conen, P. E. (1968). Histopathological changes in Duchenne muscular dystrophy. 
J Neurol Sci, 7(3), 529-544. 
Bertoni, C., Morris, G. E., & Rando, T. A. (2005). Strand bias in oligonucleotide-mediated 
dystrophin gene editing. Hum Mol Genet, 14(2), 221-233. 
Bertoni, C., & Rando, T. A. (2002). Dystrophin gene repair in mdx muscle precursor cells in 
vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. Hum Gene Ther, 
13(6), 707-718. 
Bessou, C., Giugia, J. B., Franks, C. J., Holden-Dye, L., & Segalat, L. (1998). Mutations in the 
Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a 
link with cholinergic transmission. Neurogenetics, 2(1), 61-72. 
Bies, R. D., Caskey, C. T., & Fenwick, R. (1992). An intact cysteine-rich domain is required for 
dystrophin function. J Clin Invest, 90(2), 666-672. 
 96 
Bilbao, R., Reay, D. P., Hughes, T., Biermann, V., Volpers, C., Goldberg, L., et al. (2003). Fetal 
muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity 
adenoviral vectors. Gene Ther, 10(21), 1821-1829. 
Bilbao, R., Reay, D. P., Li, J., Xiao, X., & Clemens, P. R. (2005). Patterns of gene expression 
from in utero delivery of adenoviral-associated vector serotype 1. Hum Gene Ther, 16(6), 
678-684. 
Bilbao, R., Reay, D. P., Wu, E., Zheng, H., Biermann, V., Kochanek, S., et al. (2005). 
Comparison of high-capacity and first-generation adenoviral vector gene delivery to 
murine muscle in utero. Gene Ther, 12(1), 39-47. 
Biressi, S., Molinaro, M., & Cossu, G. (2007). Cellular heterogeneity during vertebrate skeletal 
muscle development. Dev Biol, 308(2), 281-293. 
Blake, D. J., & Kroger, S. (2000). The neurobiology of duchenne muscular dystrophy: learning 
lessons from muscle? Trends Neurosci, 23(3), 92-99. 
Blake, D. J., Tinsley, J. M., Davies, K. E., Knight, A. E., Winder, S. J., & Kendrick-Jones, J. 
(1995). Coiled-coil regions in the carboxy-terminal domains of dystrophin and related 
proteins: potentials for protein-protein interactions. Trends Biochem Sci, 20(4), 133-135. 
Blake, D. J., Weir, A., Newey, S. E., & Davies, K. E. (2002). Function and genetics of 
dystrophin and dystrophin-related proteins in muscle. Physiol Rev, 82(2), 291-329. 
Blankinship, M. J., Gregorevic, P., Allen, J. M., Harper, S. Q., Harper, H., Halbert, C. L., et al. 
(2004). Efficient transduction of skeletal muscle using vectors based on adeno-associated 
virus serotype 6. Mol Ther, 10(4), 671-678. 
Bockhold, K. J., Rosenblatt, J. D., & Partridge, T. A. (1998). Aging normal and dystrophic 
mouse muscle: analysis of myogenicity in cultures of living single fibers. Muscle Nerve, 
21(2), 173-183. 
Bork, P., & Sudol, M. (1994). The WW domain: a signalling site in dystrophin? Trends Biochem 
Sci, 19(12), 531-533. 
Bostick, B., Ghosh, A., Yue, Y., Long, C., & Duan, D. (2007). Systemic AAV-9 transduction in 
mice is influenced by animal age but not by the route of administration. Gene Ther, 
14(22), 1605-1609. 
Bouchard, S., MacKenzie, T. C., Radu, A. P., Hayashi, S., Peranteau, W. H., Chirmule, N., et al. 
(2003). Long-term transgene expression in cardiac and skeletal muscle following fetal 
administration of adenoviral or adeno-associated viral vectors in mice. J Gene Med, 
5(11), 941-950. 
Boyd, Y., & Buckle, V. J. (1986). Cytogenetic heterogeneity of translocations associated with 
Duchenne muscular dystrophy. Clin Genet, 29(2), 108-115. 
 97 
Boyle, M. P., Enke, R. A., Adams, R. J., Guggino, W. B., & Zeitlin, P. L. (2001). In utero AAV-
mediated gene transfer to rabbit pulmonary epithelium. Mol Ther, 4(2), 115-121. 
Bradley, W. G., Hudgson, P., Larson, P. F., Papapetropoulos, T. A., & Jenkison, M. (1972). 
Structural changes in the early stages of Duchenne muscular dystrophy. J Neurol 
Neurosurg Psychiatry, 35(4), 451-455. 
Brockstedt, D. G., Podsakoff, G. M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., & 
Engleman, E. G. (1999). Induction of immunity to antigens expressed by recombinant 
adeno-associated virus depends on the route of administration. Clin Immunol, 92(1), 67-
75. 
Buckingham, M. (1992). Making muscle in mammals. Trends Genet, 8(4), 144-148. 
Buckingham, M., Bajard, L., Chang, T., Daubas, P., Hadchouel, J., Meilhac, S., et al. (2003). 
The formation of skeletal muscle: from somite to limb. J Anat, 202(1), 59-68. 
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984). X chromosome-linked muscular 
dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A, 81(4), 1189-1192. 
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., et al. 
(2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 
2, and 5 display differential efficiency and cell tropism after delivery to different regions 
of the central nervous system. Mol Ther, 10(2), 302-317. 
Carlson, C. G., & Makiejus, R. V. (1990). A noninvasive procedure to detect muscle weakness in 
the mdx mouse. Muscle Nerve, 13(6), 480-484. 
Carpenter, J. L., Hoffman, E. P., Romanul, F. C., Kunkel, L. M., Rosales, R. K., Ma, N. S., et al. 
(1989). Feline muscular dystrophy with dystrophin deficiency. Am J Pathol, 135(5), 909-
919. 
Cearley, C. N., & Wolfe, J. H. (2006). Transduction characteristics of adeno-associated virus 
vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther, 13(3), 
528-537. 
Cerletti, M., Negri, T., Cozzi, F., Colpo, R., Andreetta, F., Croci, D., et al. (2003). Dystrophic 
phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated 
utrophin gene transfer. Gene Ther, 10(9), 750-757. 
Chamberlain, J. S., Metzger, J., Reyes, M., Townsend, D., & Faulkner, J. A. (2007). Dystrophin-
deficient mdx mice display a reduced life span and are susceptible to spontaneous 
rhabdomyosarcoma. Faseb J, 21(9), 2195-2204. 
Chao, H., Mao, L., Bruce, A. T., & Walsh, C. E. (2000). Sustained expression of human factor 
VIII in mice using a parvovirus-based vector. Blood, 95(5), 1594-1599. 
 98 
Chelly, J., Kaplan, J. C., Maire, P., Gautron, S., & Kahn, A. (1988). Transcription of the 
dystrophin gene in human muscle and non-muscle tissue. Nature, 333(6176), 858-860. 
Chen, S., Kapturczak, M., Loiler, S. A., Zolotukhin, S., Glushakova, O. Y., Madsen, K. M., et al. 
(2005). Efficient transduction of vascular endothelial cells with recombinant adeno-
associated virus serotype 1 and 5 vectors. Hum Gene Ther, 16(2), 235-247. 
Cheng, H., Wolfe, S. H., Valencia, V., Qian, K., Shen, L., Phillips, M. I., et al. (2007). Efficient 
and persistent transduction of exocrine and endocrine pancreas by adeno-associated virus 
type 8. J Biomed Sci, 14(5), 585-594. 
Christ, B., & Ordahl, C. P. (1995). Early stages of chick somite development. Anat Embryol 
(Berl), 191(5), 381-396. 
Clemens, P. R., Kochanek, S., Sunada, Y., Chan, S., Chen, H. H., Campbell, K. P., et al. (1996). 
In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks 
all viral genes. Gene Ther, 3(11), 965-972. 
Coffey, A. J., Roberts, R. G., Green, E. D., Cole, C. G., Butler, R., Anand, R., et al. (1992). 
Construction of a 2.6-Mb contig in yeast artificial chromosomes spanning the human 
dystrophin gene using an STS-based approach. Genomics, 12(3), 474-484. 
Cohen, J. C., Morrow, S. L., Cork, R. J., Delcarpio, J. B., & Larson, J. E. (1998). Molecular 
pathophysiology of cystic fibrosis based on the rescued knockout mouse model. Mol 
Genet Metab, 64(2), 108-118. 
Conlon, T. J., Cossette, T., Erger, K., Choi, Y. K., Clarke, T., Scott-Jorgensen, M., et al. (2005). 
Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 
pseudotyped alpha1-antitrypsin vector. Mol Ther, 12(5), 867-875. 
Cooper, B. J., Winand, N. J., Stedman, H., Valentine, B. A., Hoffman, E. P., Kunkel, L. M., et al. 
(1988). The homologue of the Duchenne locus is defective in X-linked muscular 
dystrophy of dogs. Nature, 334(6178), 154-156. 
Coulton, G. R., Morgan, J. E., Partridge, T. A., & Sloper, J. C. (1988). The mdx mouse skeletal 
muscle myopathy: I. A histological, morphometric and biochemical investigation. 
Neuropathol Appl Neurobiol, 14(1), 53-70. 
Cressant, A., Desmaris, N., Verot, L., Brejot, T., Froissart, R., Vanier, M. T., et al. (2004). 
Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB 
disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci, 
24(45), 10229-10239. 
Crystal, R. G. (1995). Transfer of genes to humans: early lessons and obstacles to success. 
Science, 270(5235), 404-410. 
 99 
Danialou, G., Comtois, A. S., Matecki, S., Nalbantoglu, J., Karpati, G., Gilbert, R., et al. (2005). 
Optimization of regional intraarterial naked DNA-mediated transgene delivery to skeletal 
muscles in a large animal model. Mol Ther, 11(2), 257-266. 
Davidoff, A. M., Gray, J. T., Ng, C. Y., Zhang, Y., Zhou, J., Spence, Y., et al. (2005). 
Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 
5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and 
nonhuman primate models. Mol Ther, 11(6), 875-888. 
Davies, K. E., Pearson, P. L., Harper, P. S., Murray, J. M., O'Brien, T., Sarfarazi, M., et al. 
(1983). Linkage analysis of two cloned DNA sequences flanking the Duchenne muscular 
dystrophy locus on the short arm of the human X chromosome. Nucleic Acids Res, 11(8), 
2303-2312. 
De, B., Heguy, A., Leopold, P. L., Wasif, N., Korst, R. J., Hackett, N. R., et al. (2004). 
Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-
antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin. Mol 
Ther, 10(6), 1003-1010. 
Dejneka, N. S., Surace, E. M., Aleman, T. S., Cideciyan, A. V., Lyubarsky, A., Savchenko, A., et 
al. (2004). In utero gene therapy rescues vision in a murine model of congenital 
blindness. Mol Ther, 9(2), 182-188. 
DiMario, J. X., Uzman, A., & Strohman, R. C. (1991). Fiber regeneration is not persistent in 
dystrophic (MDX) mouse skeletal muscle. Dev Biol, 148(1), 314-321. 
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005). Intracellular trafficking of adeno-
associated viral vectors. Gene Ther, 12(11), 873-880. 
Ding, W., Zhang, L. N., Yeaman, C., & Engelhardt, J. F. (2006). rAAV2 traffics through both 
the late and the recycling endosomes in a dose-dependent fashion. Mol Ther, 13(4), 671-
682. 
Drousiotou, A., Ioannou, P., Georgiou, T., Mavrikiou, E., Christopoulos, G., Kyriakides, T., et 
al. (1998). Neonatal screening for Duchenne muscular dystrophy: a novel 
semiquantitative application of the bioluminescence test for creatine kinase in a pilot 
national program in Cyprus. Genet Test, 2(1), 55-60. 
Du, L., Kido, M., Lee, D. V., Rabinowitz, J. E., Samulski, R. J., Jamieson, S. W., et al. (2004). 
Differential myocardial gene delivery by recombinant serotype-specific adeno-associated 
viral vectors. Mol Ther, 10(3), 604-608. 
Dubowitz, V. (1978). Muscle disorders in childhood. Major Probl Clin Pediatr, 16, iii-xiii, 1-
282. 
Dunckley, M. G., Wells, D. J., Walsh, F. S., & Dickson, G. (1993). Direct retroviral-mediated 
transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Genet, 2(6), 
717-723. 
 100 
Durieux, A. C., Bonnefoy, R., Busso, T., & Freyssenet, D. (2004). In vivo gene electrotransfer 
into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle 
damage. J Gene Med, 6(7), 809-816. 
Duxson, M. J., & Usson, Y. (1989). Cellular insertion of primary and secondary myotubes in 
embryonic rat muscles. Development, 107(2), 243-251. 
Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., & Bushby, K. (2002). 
Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 
and the impact of home nocturnal ventilation. Neuromuscul Disord, 12(10), 926-929. 
Eliyahu, H., Barenholz, Y., & Domb, A. J. (2005). Polymers for DNA delivery. Molecules, 
10(1), 34-64. 
Emerson, C. P., & Hauschka, S. D. (2004). Embryonic Origins of Skeletal Muscles. In A. G. 
Engel & C. Franzini-Armstrong (Eds.), Myology (pp. 3-44). NewYork, USA: McGraw-
Hill. 
Emery, A. E. (1991). Population frequencies of inherited neuromuscular diseases--a world 
survey. Neuromuscul Disord, 1(1), 19-29. 
Emery, A. E. H. (1993a). Duchenne Muscular Dystrophy. Oxford Monographs on Medical 
Genetics (2 ed., Vol. xv, pp. 392): Oxford, UK: Oxford Univ. Press,. 
Emery, A. E. H. (1993b). Duchenne Muscular Dystrophy. Oxford Monographs on Medical 
Genetics. xv 392. 
Emery, A. E. H., & Muntoni, F. (2003). Duchenne Muscular Dystrophy (3 ed.). Oxford, New 
York: Oxford Univ. Press. 
Feero, W. G., Li, S., Rosenblatt, J. D., Sirianni, N., Morgan, J. E., Partridge, T. A., et al. (1997). 
Selection and use of ligands for receptor-mediated gene delivery to myogenic cells. Gene 
Ther, 4(7), 664-674. 
Finder, J. D., Birnkrant, D., Carl, J., Farber, H. J., Gozal, D., Iannaccone, S. T., et al. (2004). 
Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus 
statement. Am J Respir Crit Care Med, 170(4), 456-465. 
Fischer, A., Abina, S. H., Thrasher, A., von Kalle, C., & Cavazzana-Calvo, M. (2004). LMO2 
and gene therapy for severe combined immunodeficiency. N Engl J Med, 350(24), 2526-
2527; author reply 2526-2527. 
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., et al. (1997). Recombinant 
adeno-associated virus for muscle directed gene therapy. Nat Med, 3(3), 306-312. 
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. 
(2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. 
Nat Biotechnol, 27(1), 59-65. 
 101 
Foust, K. D., Poirier, A., Pacak, C. A., Mandel, R. J., & Flotte, T. R. (2008). Neonatal 
intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 
transduce dorsal root ganglia and lower motor neurons. Hum Gene Ther, 19(1), 61-70. 
Francke, U., Ochs, H. D., de Martinville, B., Giacalone, J., Lindgren, V., Disteche, C., et al. 
(1985). Minor Xp21 chromosome deletion in a male associated with expression of 
Duchenne muscular dystrophy, chronic granulomatous disease, retinitis pigmentosa, and 
McLeod syndrome. Am J Hum Genet, 37(2), 250-267. 
Friedmann, T., & Roblin, R. (1972). Gene therapy for human genetic disease? Science, 178(61), 
648-649. 
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., et al. (2004). Clades 
of Adeno-associated viruses are widely disseminated in human tissues. J Virol, 78(12), 
6381-6388. 
Gao, G., Vandenberghe, L. H., & Wilson, J. M. (2005). New recombinant serotypes of AAV 
vectors. Curr Gene Ther, 5(3), 285-297. 
Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002). Novel 
adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc 
Natl Acad Sci U S A, 99(18), 11854-11859. 
Gardner, R. J., Bobrow, M., & Roberts, R. G. (1995). The identification of point mutations in 
Duchenne muscular dystrophy patients by using reverse-transcription PCR and the 
protein truncation test. Am J Hum Genet, 57(2), 311-320. 
Garrett, D. J., Larson, J. E., Dunn, D., Marrero, L., & Cohen, J. C. (2003). In utero recombinant 
adeno-associated virus gene transfer in mice, rats, and primates. BMC Biotechnol, 3, 16. 
Gaschen, F. P., Hoffman, E. P., Gorospe, J. R., Uhl, E. W., Senior, D. F., Cardinet, G. H., 3rd, et 
al. (1992). Dystrophin deficiency causes lethal muscle hypertrophy in cats. J Neurol Sci, 
110(1-2), 149-159. 
Ghosh, A., Allamarvdasht, M., Pan, C. J., Sun, M. S., Mansfield, B. C., Byrne, B. J., et al. 
(2006). Long-term correction of murine glycogen storage disease type Ia by recombinant 
adeno-associated virus-1-mediated gene transfer. Gene Ther, 13(4), 321-329. 
Gillman.J. (1948). The development of the gonads in man, with a consideration of the role of the 
fetal endocrines and the histogenesis of ovarian tumours. Contrib. Embryol., 32, 81-132. 
Gorospe, J. R. M., Nishikawa, B. K., & Hoffman, E. P. (1997). Pathophysiology of dystrophin 
deficiency: a clinical and biological enigma. In S. C. Brown & J. A. Lucy (Eds.), 
Dystrophin: Gene, Protein, and Cell Biology (pp. 201–232). Cambridge, UK: Cambridge 
Univ. Press. 
Gowers, W. (1879). Clinical lecture on pseudo-hypertrophic muscular paralysis Lancet (Vol. 2, 
pp. 1–2, 37–39, 73–35, 113–116). 
 102 
Graham, T., McIntosh, J., Work, L. M., Nathwani, A., & Baker, A. H. (2008). Performance of 
AAV8 vectors expressing human factor IX from a hepatic-selective promoter following 
intravenous injection into rats. Genet Vaccines Ther, 6, 9. 
Greber, U. F. (2002). Signalling in viral entry. Cell Mol Life Sci, 59(4), 608-626. 
Gregorevic, P., Allen, J. M., Minami, E., Blankinship, M. J., Haraguchi, M., Meuse, L., et al. 
(2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in 
severely dystrophic mice. Nat Med, 12(7), 787-789. 
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., et al. 
(2004). Systemic delivery of genes to striated muscles using adeno-associated viral 
vectors. Nat Med, 10(8), 828-834. 
Griggs, R. C., Moxley, R. T., 3rd, Mendell, J. R., Fenichel, G. M., Brooke, M. H., Pestronk, A., 
et al. (1991). Prednisone in Duchenne dystrophy. A randomized, controlled trial defining 
the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. 
Arch Neurol, 48(4), 383-388. 
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, 
P., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene 
therapy for SCID-X1. Science, 302(5644), 415-419. 
Haecker, S. E., Stedman, H. H., Balice-Gordon, R. J., Smith, D. B., Greelish, J. P., Mitchell, M. 
A., et al. (1996). In vivo expression of full-length human dystrophin from adenoviral 
vectors deleted of all viral genes. Hum Gene Ther, 7(15), 1907-1914. 
Hagstrom, J. E., Hegge, J., Zhang, G., Noble, M., Budker, V., Lewis, D. L., et al. (2004). A 
facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian 
limbs. Mol Ther, 10(2), 386-398. 
Halbert, C. L., Allen, J. M., & Miller, A. D. (2001). Adeno-associated virus type 6 (AAV6) 
vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared 
to that of AAV2 vectors. J Virol, 75(14), 6615-6624. 
Halbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W., & Miller, A. D. (2000). Repeat 
transduction in the mouse lung by using adeno-associated virus vectors with different 
serotypes. J Virol, 74(3), 1524-1532. 
Hall-Craggs, E. C., & Seyan, H. S. (1975). Histochemical changes in innervated and denervated 
skeletal muscle fibers following treatment with bupivacaine (marcain). Exp Neurol, 
46(2), 345-354. 
Han, X. D., Lin, C., Chang, J., Sadelain, M., & Kan, Y. W. (2007). Fetal gene therapy of alpha-
thalassemia in a mouse model. Proc Natl Acad Sci U S A, 104(21), 9007-9011. 
Harbison, C. E., Chiorini, J. A., & Parrish, C. R. (2008). The parvovirus capsid odyssey: from 
the cell surface to the nucleus. Trends Microbiol, 16(5), 208-214. 
 103 
Hatzoglou, M., Lamers, W., Bosch, F., Wynshaw-Boris, A., Clapp, D. W., & Hanson, R. W. 
(1990). Hepatic gene transfer in animals using retroviruses containing the promoter from 
the gene for phosphoenolpyruvate carboxykinase. J Biol Chem, 265(28), 17285-17293. 
Heckel, S., Favre, R., Flori, J., Koenig, M., Mandel, J., Gasser, B., et al. (1999). In utero fetal 
muscle biopsy: a precious aid for the prenatal diagnosis of Duchenne muscular 
dystrophy. Fetal Diagn Ther, 14(3), 127-132. 
Hillier, B. J., Christopherson, K. S., Prehoda, K. E., Bredt, D. S., & Lim, W. A. (1999). 
Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin 
complex. Science, 284(5415), 812-815. 
Hoffman, E. P., Brown, R. H., Jr., & Kunkel, L. M. (1987). Dystrophin: the protein product of 
the Duchenne muscular dystrophy locus. Cell, 51(6), 919-928. 
Hoffman, E. P., Garcia, C. A., Chamberlain, J. S., Angelini, C., Lupski, J. R., & Fenwick, R. 
(1991). Is the carboxyl-terminus of dystrophin required for membrane association? A 
novel, severe case of Duchenne muscular dystrophy. Ann Neurol, 30(4), 605-610. 
Hogan, B., Beddington, R., Constantini, F. and Lacy, E. (1994). Summary of mouse development. 
In Manipulating the Mouse Embryo a laboratory manual (2nd Edn. ed.): Cold Spring 
Harbor Laboratory Press, Cold Spring Harbor. 
Holzinger, A., Trapnell, B. C., Weaver, T. E., Whitsett, J. A., & Iwamoto, H. S. (1995). 
Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and 
mouse tissues. Pediatr Res, 38(6), 844-850. 
Howell, J. M., Fletcher, S., Kakulas, B. A., O'Hara, M., Lochmuller, H., & Karpati, G. (1997). 
Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. 
Neuromuscul Disord, 7(5), 325-328. 
Huard, J., Feero, W. G., Watkins, S. C., Hoffman, E. P., Rosenblatt, D. J., & Glorioso, J. C. 
(1996). The basal lamina is a physical barrier to herpes simplex virus-mediated gene 
delivery to mature muscle fibers. J Virol, 70(11), 8117-8123. 
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., McTiernan, C. F., Kay, M. A., et al. (2006). 
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene 
transfer superior to that of AAV8. Mol Ther, 14(1), 45-53. 
Itah, R., Gitelman, I., Tal, J., & Davis, C. (2004). Viral inoculation of mouse embryos in utero. J 
Virol Methods, 120(1), 1-8. 
Jennekens, F. G., ten Kate, L. P., de Visser, M., & Wintzen, A. R. (1991). Diagnostic criteria for 
Duchenne and Becker muscular dystrophy and myotonic dystrophy. Neuromuscul 
Disord, 1(6), 389-391. 
 104 
Jerebtsova, M., Batshaw, M. L., & Ye, X. (2002). Humoral immune response to recombinant 
adenovirus and adeno-associated virus after in utero administration of viral vectors in 
mice. Pediatr Res, 52(1), 95-104. 
Johnston, J., & Power, C. (1999). Productive infection of human peripheral blood mononuclear 
cells by feline immunodeficiency virus: implications for vector development. J Virol, 
73(3), 2491-2498. 
Johnston, J. C., Gasmi, M., Lim, L. E., Elder, J. H., Yee, J. K., Jolly, D. J., et al. (1999). 
Minimum requirements for efficient transduction of dividing and nondividing cells by 
feline immunodeficiency virus vectors. J Virol, 73(6), 4991-5000. 
Karolewski, B. A., & Wolfe, J. H. (2006). Genetic correction of the fetal brain increases the 
lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. 
Mol Ther, 14(1), 14-24. 
Kawamoto, S., Shi, Q., Nitta, Y., Miyazaki, J., & Allen, M. D. (2005). Widespread and early 
myocardial gene expression by adeno-associated virus vector type 6 with a beta-actin 
hybrid promoter. Mol Ther, 11(6), 980-985. 
Kim, V. N., Mitrophanous, K., Kingsman, S. M., & Kingsman, A. J. (1998). Minimal 
requirement for a lentivirus vector based on human immunodeficiency virus type 1. J 
Virol, 72(1), 811-816. 
Kochanek, S., Clemens, P. R., Mitani, K., Chen, H. H., Chan, S., & Caskey, C. T. (1996). A new 
adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA 
independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl 
Acad Sci U S A, 93(12), 5731-5736. 
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., et al. (1989). 
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of 
severity with type of deletion. Am J Hum Genet, 45(4), 498-506. 
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. 
(1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and 
preliminary genomic organization of the DMD gene in normal and affected individuals. 
Cell, 50(3), 509-517. 
Koenig, M., & Kunkel, L. M. (1990). Detailed analysis of the repeat domain of dystrophin 
reveals four potential hinge segments that may confer flexibility. J Biol Chem, 265(8), 
4560-4566. 
Koppanati, B. M., Li, J., Xiao, X., & Clemens, P. R. (2009a). Systemic delivery of AAV8 in 
utero results in gene expression in diaphragm and limb muscle: treatment implications for 
muscle disorders. Gene Ther, 16(9), 1130-1137. 
 105 
Koppanati, B. M., Li, J., Xiao, X., & Clemens, P. R. (2009b). Systemic delivery of AAV8 in 
utero results in gene expression in diaphragm and limb muscle: treatment implications for 
muscle disorders. Gene Ther. 
Kornegay, J. N., Tuler, S. M., Miller, D. M., & Levesque, D. C. (1988). Muscular dystrophy in a 
litter of golden retriever dogs. Muscle Nerve, 11(10), 1056-1064. 
Kuller, J. A., Hoffman, E. P., Fries, M. H., & Golbus, M. S. (1992). Prenatal diagnosis of 
Duchenne muscular dystrophy by fetal muscle biopsy. Hum Genet, 90(1-2), 34-40. 
Lai, C. M., Lai, Y. K., & Rakoczy, P. E. (2002). Adenovirus and adeno-associated virus vectors. 
DNA Cell Biol, 21(12), 895-913. 
Lai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., et al. (2009). Dystrophins 
carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance 
exercise performance in a mouse model of muscular dystrophy. J Clin Invest, 119(3), 
624-635. 
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., et al. (2005). Efficient 
in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol, 
23(11), 1435-1439. 
Lansdorp, P. M., Dragowska, W., & Mayani, H. (1993). Ontogeny-related changes in 
proliferative potential of human hematopoietic cells. J Exp Med, 178(3), 787-791. 
Larson, J. E., Morrow, S. L., Happel, L., Sharp, J. F., & Cohen, J. C. (1997). Reversal of cystic 
fibrosis phenotype in mice by gene therapy in utero. Lancet, 349(9052), 619-620. 
Lenk, U., Hanke, R., Thiele, H., & Speer, A. (1993). Point mutations at the carboxy terminus of 
the human dystrophin gene: implications for an association with mental retardation in 
DMD patients. Hum Mol Genet, 2(11), 1877-1881. 
Lenk, U., Oexle, K., Voit, T., Ancker, U., Hellner, K. A., Speer, A., et al. (1996). A cysteine 
3340 substitution in the dystroglycan-binding domain of dystrophin associated with 
Duchenne muscular dystrophy, mental retardation and absence of the ERG b-wave. Hum 
Mol Genet, 5(7), 973-975. 
Lewis, P., Hensel, M., & Emerman, M. (1992). Human immunodeficiency virus infection of 
cells arrested in the cell cycle. Embo J, 11(8), 3053-3058. 
Li, J., Samulski, R. J., & Xiao, X. (1997). Role for highly regulated rep gene expression in 
adeno-associated virus vector production. J Virol, 71(7), 5236-5243. 
Li, T., Tachibana, K., Kuroki, M., & Kuroki, M. (2003). Gene transfer with echo-enhanced 
contrast agents: comparison between Albunex, Optison, and Levovist in mice--initial 
results. Radiology, 229(2), 423-428. 
 106 
Lidov, H. G., Byers, T. J., Watkins, S. C., & Kunkel, L. M. (1990). Localization of dystrophin to 
postsynaptic regions of central nervous system cortical neurons. Nature, 348(6303), 725-
728. 
Liechti-Gallati, S., Koenig, M., Kunkel, L. M., Frey, D., Boltshauser, E., Schneider, V., et al. 
(1989). Molecular deletion patterns in Duchenne and Becker type muscular dystrophy. 
Hum Genet, 81(4), 343-348. 
Lipshutz, G. S., Flebbe-Rehwaldt, L., & Gaensler, K. M. (1999a). Adenovirus-mediated gene 
transfer in the midgestation fetal mouse. J Surg Res, 84(2), 150-156. 
Lipshutz, G. S., Flebbe-Rehwaldt, L., & Gaensler, K. M. (1999b). Adenovirus-mediated gene 
transfer to the peritoneum and hepatic parenchyma of fetal mice in utero. Surgery, 
126(2), 171-177. 
Lipshutz, G. S., Gruber, C. A., Cao, Y., Hardy, J., Contag, C. H., & Gaensler, K. M. (2001). In 
utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces 
long-term expression. Mol Ther, 3(3), 284-292. 
Lipshutz, G. S., Sarkar, R., Flebbe-Rehwaldt, L., Kazazian, H., & Gaensler, K. M. (1999). Short-
term correction of factor VIII deficiency in a murine model of hemophilia A after 
delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci U S A, 96(23), 
13324-13329. 
Liu, G., Martins, I., Wemmie, J. A., Chiorini, J. A., & Davidson, B. L. (2005). Functional 
correction of CNS phenotypes in a lysosomal storage disease model using adeno-
associated virus type 4 vectors. J Neurosci, 25(41), 9321-9327. 
Liu, M., Yue, Y., Harper, S. Q., Grange, R. W., Chamberlain, J. S., & Duan, D. (2005). Adeno-
associated virus-mediated microdystrophin expression protects young mdx muscle from 
contraction-induced injury. Mol Ther, 11(2), 245-256. 
Liu, Y., Okada, T., Sheykholeslami, K., Shimazaki, K., Nomoto, T., Muramatsu, S., et al. (2005). 
Specific and efficient transduction of Cochlear inner hair cells with recombinant adeno-
associated virus type 3 vector. Mol Ther, 12(4), 725-733. 
Ljubic, A., Cvetkovic, M., Sulovic, V., Radunovic, N., Antonovic, O., Vukolic, D., et al. (1999). 
New technique for artificial lung maturation. Direct intramuscular fetal corticosteroid 
therapy. Clin Exp Obstet Gynecol, 26(1), 16-19. 
Loiler, S. A., Conlon, T. J., Song, S., Tang, Q., Warrington, K. H., Agarwal, A., et al. (2003). 
Targeting recombinant adeno-associated virus vectors to enhance gene transfer to 
pancreatic islets and liver. Gene Ther, 10(18), 1551-1558. 
Lotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., et al. (2003). 
Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the 
primate retina. Hum Gene Ther, 14(17), 1663-1671. 
 107 
Louboutin, J. P., Wang, L., & Wilson, J. M. (2005). Gene transfer into skeletal muscle using 
novel AAV serotypes. J Gene Med, 7(4), 442-451. 
Love, D. R., Flint, T. J., Genet, S. A., Middleton-Price, H. R., & Davies, K. E. (1991). Becker 
muscular dystrophy patient with a large intragenic dystrophin deletion: implications for 
functional minigenes and gene therapy. J Med Genet, 28(12), 860-864. 
Lu, Q. L., Bou-Gharios, G., & Partridge, T. A. (2003). Non-viral gene delivery in skeletal 
muscle: a protein factory. Gene Ther, 10(2), 131-142. 
Lu, Q. L., Liang, H. D., Partridge, T., & Blomley, M. J. (2003). Microbubble ultrasound 
improves the efficiency of gene transduction in skeletal muscle in vivo with reduced 
tissue damage. Gene Ther, 10(5), 396-405. 
Lu, Q. L., & Partridge, T. A. (1998). A new blocking method for application of murine 
monoclonal antibody to mouse tissue sections. J Histochem Cytochem, 46(8), 977-984. 
Lynch, G. S., Hinkle, R. T., Chamberlain, J. S., Brooks, S. V., & Faulkner, J. A. (2001). Force 
and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J 
Physiol, 535(Pt 2), 591-600. 
MacKenzie, T. C., Kobinger, G. P., Louboutin, J. P., Radu, A., Javazon, E. H., Sena-Esteves, M., 
et al. (2005). Transduction of satellite cells after prenatal intramuscular administration of 
lentiviral vectors. J Gene Med, 7(1), 50-58. 
Manfredsson, F. P., Rising, A. C., & Mandel, R. J. (2009). AAV9: a potential blood-brain barrier 
buster. Mol Ther, 17(3), 403-405. 
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., et al. (2001). Antisense-
induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci 
U S A, 98(1), 42-47. 
Marshall, E. (1999). Gene therapy death prompts review of adenovirus vector. Science, 
286(5448), 2244-2245. 
McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006). Antisense 
oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine 
model of DMD. Gene Ther, 13(19), 1373-1381. 
McCray, P. B., Jr., Armstrong, K., Zabner, J., Miller, D. W., Koretzky, G. A., Couture, L., et al. 
(1995). Adenoviral-mediated gene transfer to fetal pulmonary epithelia in vitro and in 
vivo. J Clin Invest, 95(6), 2620-2632. 
McDouall, R. M., Dunn, M. J., & Dubowitz, V. (1990). Nature of the mononuclear infiltrate and 
the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular 
dystrophy. J Neurol Sci, 99(2-3), 199-217. 
 108 
McMahon, J. M., Signori, E., Wells, K. E., Fazio, V. M., & Wells, D. J. (2001). Optimisation of 
electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase -- 
increased expression with reduced muscle damage. Gene Ther, 8(16), 1264-1270. 
Meertens, L., Zhao, Y., Rosic-Kablar, S., Li, L., Chan, K., Dobson, H., et al. (2002). In utero 
injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis 
type I: infection of multiple tissues and neonatal gene expression. Hum Gene Ther, 
13(15), 1809-1820. 
Mehler, M. F. (2000). Brain dystrophin, neurogenetics and mental retardation. Brain Res Brain 
Res Rev, 32(1), 277-307. 
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., et al. 
(1989). Randomized, double-blind six-month trial of prednisone in Duchenne's muscular 
dystrophy. N Engl J Med, 320(24), 1592-1597. 
Miller, A. D. (1992). Human gene therapy comes of age. Nature, 357(6378), 455-460. 
Miller, D. G., Adam, M. A., & Miller, A. D. (1990). Gene transfer by retrovirus vectors occurs 
only in cells that are actively replicating at the time of infection. Mol Cell Biol, 10(8), 
4239-4242. 
Mingozzi, F., Schuttrumpf, J., Arruda, V. R., Liu, Y., Liu, Y. L., High, K. A., et al. (2002). 
Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J 
Virol, 76(20), 10497-10502. 
Mitchell, M., Jerebtsova, M., Batshaw, M. L., Newman, K., & Ye, X. (2000a). Long-term gene 
transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) 
vectors. Gene Therapy, 7(23), 1986-1992. 
Mitchell, M., Jerebtsova, M., Batshaw, M. L., Newman, K., & Ye, X. (2000b). Long-term gene 
transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) 
vectors. Gene Ther, 7(23), 1986-1992. 
Miyagi, N., Rao, V. P., Ricci, D., Du, Z., Byrne, G. W., Bailey, K. R., et al. (2008). Efficient and 
durable gene transfer to transplanted heart using adeno-associated virus 9 vector. J Heart 
Lung Transplant, 27(5), 554-560. 
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988). An 
explanation for the phenotypic differences between patients bearing partial deletions of 
the DMD locus. Genomics, 2(1), 90-95. 
Monaco, A. P., Bertelson, C. J., Middlesworth, W., Colletti, C. A., Aldridge, J., Fischbeck, K. 
H., et al. (1985). Detection of deletions spanning the Duchenne muscular dystrophy locus 
using a tightly linked DNA segment. Nature, 316(6031), 842-845. 
 109 
Monaco, A. P., Walker, A. P., Millwood, I., Larin, Z., & Lehrach, H. (1992). A yeast artificial 
chromosome contig containing the complete Duchenne muscular dystrophy gene. 
Genomics, 12(3), 465-473. 
Mori, S., Wang, L., Takeuchi, T., & Kanda, T. (2004). Two novel adeno-associated viruses from 
cynomolgus monkey: pseudotyping characterization of capsid protein. Virology, 330(2), 
375-383. 
Moxley, R. T., 3rd, Ashwal, S., Pandya, S., Connolly, A., Florence, J., Mathews, K., et al. 
(2005). Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the 
Quality Standards Subcommittee of the American Academy of Neurology and the 
Practice Committee of the Child Neurology Society. Neurology, 64(1), 13-20. 
Mulligan, R. C. (1993). The basic science of gene therapy. Science, 260(5110), 926-932. 
Nakai, H., Fuess, S., Storm, T. A., Muramatsu, S., Nara, Y., & Kay, M. A. (2005). Unrestricted 
hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol, 
79(1), 214-224. 
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001). 
Extrachromosomal recombinant adeno-associated virus vector genomes are primarily 
responsible for stable liver transduction in vivo. J Virol, 75(15), 6969-6976. 
Naldini, L., Blomer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996). Efficient transfer, 
integration, and sustained long-term expression of the transgene in adult rat brains 
injected with a lentiviral vector. Proc Natl Acad Sci U S A, 93(21), 11382-11388. 
Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., et al. (1996). In vivo gene 
delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 
272(5259), 263-267. 
Nathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y., Zhou, J., Spence, Y., et al. (2007). Safe 
and efficient transduction of the liver after peripheral vein infusion of self-
complementary AAV vector results in stable therapeutic expression of human FIX in 
nonhuman primates. Blood, 109(4), 1414-1421. 
Nathwani, A. C., Gray, J. T., Ng, C. Y., Zhou, J., Spence, Y., Waddington, S. N., et al. (2006). 
Self-complementary adeno-associated virus vectors containing a novel liver-specific 
human factor IX expression cassette enable highly efficient transduction of murine and 
nonhuman primate liver. Blood, 107(7), 2653-2661. 
Nguyen, D. M., Wiehle, S. A., Roth, J. A., & Cristiano, R. J. (1997). Gene delivery into 
malignant cells in vivo by a conjugated adenovirus/DNA complex. Cancer Gene Ther, 
4(3), 183-190. 
Nigro, G., Comi, L. I., Limongelli, F. M., Giugliano, M. A., Politano, L., Petretta, V., et al. 
(1983). Prospective study of X-linked progressive muscular dystrophy in Campania. 
Muscle Nerve, 6(4), 253-262. 
 110 
Nigro, G., Comi, L. I., Politano, L., & Bain, R. J. (1990). The incidence and evolution of 
cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol, 26(3), 271-277. 
Nixon, A. J., Goodrich, L. R., Scimeca, M. S., Witte, T. H., Schnabel, L. V., Watts, A. E., et al. 
(2007). Gene therapy in musculoskeletal repair. Ann N Y Acad Sci, 1117, 310-327. 
Nohria, A., Lewis, E., & Stevenson, L. W. (2002). Medical management of advanced heart 
failure. Jama, 287(5), 628-640. 
O'Donoghue, K., & Fisk, N. M. (2004). Fetal stem cells. Best Pract Res Clin Obstet Gynaecol, 
18(6), 853-875. 
Ontell, M., Bourke, D., & Hughes, D. (1988). Cytoarchitecture of the fetal murine soleus muscle. 
Am J Anat, 181(3), 267-278. 
Ontell, M., & Kozeka, K. (1984a). The organogenesis of murine striated muscle: a 
cytoarchitectural study. Am J Anat, 171(2), 133-148. 
Ontell, M., & Kozeka, K. (1984b). Organogenesis of the mouse extensor digitorum logus 
muscle: a quantitative study. Am J Anat, 171(2), 149-161. 
Ontell, M., Ontell, M. P., Sopper, M. M., Mallonga, R., Lyons, G., & Buckingham, M. (1993). 
Contractile protein gene expression in primary myotubes of embryonic mouse hindlimb 
muscles. Development, 117(4), 1435-1444. 
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., et al. 
(2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac 
transduction in vivo. Circ Res, 99(4), e3-9. 
Pan, D., Gunther, R., Duan, W., Wendell, S., Kaemmerer, W., Kafri, T., et al. (2002). 
Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after 
intravenous administration in mice with the observation of in vivo transduction of bone 
marrow. Mol Ther, 6(1), 19-29. 
Passini, M. A., Watson, D. J., Vite, C. H., Landsburg, D. J., Feigenbaum, A. L., & Wolfe, J. H. 
(2003). Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in 
neonatal mice results in complementary patterns of neuronal transduction to AAV2 and 
total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient 
mice. J Virol, 77(12), 7034-7040. 
Pastoret, C., & Sebille, A. (1993). Further aspects of muscular dystrophy in mdx mice. 
Neuromuscul Disord, 3(5-6), 471-475. 
Pastoret, C., & Sebille, A. (1995). mdx mice show progressive weakness and muscle 
deterioration with age. J Neurol Sci, 129(2), 97-105. 
Pfeffer, M. A., Braunwald, E., Moye, L. A., Basta, L., Brown, E. J., Jr., Cuddy, T. E., et al. 
(1992). Effect of captopril on mortality and morbidity in patients with left ventricular 
 111 
dysfunction after myocardial infarction. Results of the survival and ventricular 
enlargement trial. The SAVE Investigators. N Engl J Med, 327(10), 669-677. 
Pitard, B., Pollard, H., Agbulut, O., Lambert, O., Vilquin, J. T., Cherel, Y., et al. (2002). A 
nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac 
muscles. Hum Gene Ther, 13(14), 1767-1775. 
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., et al. 
(2000). Effect of losartan compared with captopril on mortality in patients with 
symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study 
ELITE II. Lancet, 355(9215), 1582-1587. 
Poeschla, E. M., Wong-Staal, F., & Looney, D. J. (1998). Efficient transduction of nondividing 
human cells by feline immunodeficiency virus lentiviral vectors. Nat Med, 4(3), 354-357. 
Prior, T. W., Bartolo, C., Pearl, D. K., Papp, A. C., Snyder, P. J., Sedra, M. S., et al. (1995). 
Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet, 57(1), 
22-33. 
Prior, T. W., & Bridgeman, S. J. (2005). Experience and strategy for the molecular testing of 
Duchenne muscular dystrophy. J Mol Diagn, 7(3), 317-326. 
Pruchnic, R., Cao, B., Peterson, Z. Q., Xiao, X., Li, J., Samulski, R. J., et al. (2000). The use of 
adeno-associated virus to circumvent the maturation-dependent viral transduction of 
muscle fibers. Hum Gene Ther, 11(4), 521-536. 
Qiao, C., Li, J., Jiang, J., Zhu, X., Wang, B., Li, J., et al. (2008). Myostatin propeptide gene 
delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and 
ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther, 19(3), 241-254. 
Quinlan, J. G., Hahn, H. S., Wong, B. L., Lorenz, J. N., Wenisch, A. S., & Levin, L. S. (2004). 
Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. 
Neuromuscul Disord, 14(8-9), 491-496. 
Rafael, J. A., Nitta, Y., Peters, J., & Davies, K. E. (2000). Testing of SHIRPA, a mouse 
phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient 
mice. Mamm Genome, 11(9), 725-728. 
Ragot, T., Vincent, N., Chafey, P., Vigne, E., Gilgenkrantz, H., Couton, D., et al. (1993). 
Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal 
muscle of mdx mice. Nature, 361(6413), 647-650. 
Rando, T. A. (2001). The dystrophin-glycoprotein complex, cellular signaling, and the regulation 
of cell survival in the muscular dystrophies. Muscle Nerve, 24(12), 1575-1594. 
Rando, T. A., Disatnik, M. H., & Zhou, L. Z. (2000). Rescue of dystrophin expression in mdx 
mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci U S A, 97(10), 5363-
5368. 
 112 
Reay, D. P., Bilbao, R., Koppanati, B. M., Cai, L., O'Day, T. L., Jiang, Z., et al. (2008). Full-
length dystrophin gene transfer to the mdx mouse in utero. Gene Ther, 15(7), 531-536. 
Reich, S. J., Auricchio, A., Hildinger, M., Glover, E., Maguire, A. M., Wilson, J. M., et al. 
(2003). Efficient trans-splicing in the retina expands the utility of adeno-associated virus 
as a vector for gene therapy. Hum Gene Ther, 14(1), 37-44. 
Reiser, P. J., Greaser, M. L., & Moss, R. L. (1988). Myosin heavy chain composition of single 
cells from avian slow skeletal muscle is strongly correlated with velocity of shortening 
during development. Dev Biol, 129(2), 400-407. 
Rich, D. P., Couture, L. A., Cardoza, L. M., Guiggio, V. M., Armentano, D., Espino, P. C., et al. 
(1993). Development and analysis of recombinant adenoviruses for gene therapy of cystic 
fibrosis. Hum Gene Ther, 4(4), 461-476. 
Robbins, P. D., & Ghivizzani, S. C. (1998). Viral vectors for gene therapy. Pharmacol Ther, 
80(1), 35-47. 
Roberts, R. G., Coffey, A. J., Bobrow, M., & Bentley, D. R. (1993). Exon structure of the human 
dystrophin gene. Genomics, 16(2), 536-538. 
Roberts, R. G., Gardner, R. J., & Bobrow, M. (1994). Searching for the 1 in 2,400,000: a review 
of dystrophin gene point mutations. Hum Mutat, 4(1), 1-11. 
Rodino-Klapac, L. R., Janssen, P. M., Montgomery, C. L., Coley, B. D., Chicoine, L. G., Clark, 
K. R., et al. (2007). A translational approach for limb vascular delivery of the micro-
dystrophin gene without high volume or high pressure for treatment of Duchenne 
muscular dystrophy. J Transl Med, 5, 45. 
Romano, G., Pacilio, C., & Giordano, A. (1999). Gene transfer technology in therapy: current 
applications and future goals. Stem Cells, 17(4), 191-202. 
Romero, N. B., Braun, S., Benveniste, O., Leturcq, F., Hogrel, J. Y., Morris, G. E., et al. (2004). 
Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular 
dystrophy. Hum Gene Ther, 15(11), 1065-1076. 
Rosa, G., Ceccarini, M., Cavaldesi, M., Zini, M., & Petrucci, T. C. (1996). Localization of the 
dystrophin binding site at the carboxyl terminus of beta-dystroglycan. Biochem Biophys 
Res Commun, 223(2), 272-277. 
Rosenfeld, M. A., Siegfried, W., Yoshimura, K., Yoneyama, K., Fukayama, M., Stier, L. E., et 
al. (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the 
lung epithelium in vivo. Science, 252(5004), 431-434. 
Rucker, M., Fraites, T. J., Jr., Porvasnik, S. L., Lewis, M. A., Zolotukhin, I., Cloutier, D. A., et 
al. (2004). Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of 
metabolic myopathy: Pompe disease. Development, 131(12), 3007-3019. 
 113 
Rudnicki, M. A., Schnegelsberg, P. N., Stead, R. H., Braun, T., Arnold, H. H., & Jaenisch, R. 
(1993). MyoD or Myf-5 is required for the formation of skeletal muscle. Cell, 75(7), 
1351-1359. 
Rybakova, I. N., Amann, K. J., & Ervasti, J. M. (1996). A new model for the interaction of 
dystrophin with F-actin. J Cell Biol, 135(3), 661-672. 
Sabatino, D. E., Mackenzie, T. C., Peranteau, W., Edmonson, S., Campagnoli, C., Liu, Y. L., et 
al. (2007). Persistent expression of hF.IX After tolerance induction by in utero or 
neonatal administration of AAV-1-F.IX in hemophilia B mice. Mol Ther, 15(9), 1677-
1685. 
Sadoulet-Puccio, H. M., Rajala, M., & Kunkel, L. M. (1997). Dystrobrevin and dystrophin: an 
interaction through coiled-coil motifs. Proc Natl Acad Sci U S A, 94(23), 12413-12418. 
Sandalon, Z., Bruckheimer, E. M., Lustig, K. H., Rogers, L. C., Peluso, R. W., & Burstein, H. 
(2004). Secretion of a TNFR:Fc fusion protein following pulmonary administration of 
pseudotyped adeno-associated virus vectors. J Virol, 78(22), 12355-12365. 
Sander, M., Chavoshan, B., Harris, S. A., Iannaccone, S. T., Stull, J. T., Thomas, G. D., et al. 
(2000). Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal 
muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A, 
97(25), 13818-13823. 
Sarkar, R., Tetreault, R., Gao, G., Wang, L., Bell, P., Chandler, R., et al. (2004). Total correction 
of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood, 103(4), 1253-
1260. 
Schachtner, S., Buck, C., Bergelson, J., & Baldwin, H. (1999). Temporally regulated expression 
patterns following in utero adenovirus-mediated gene transfer. Gene Ther, 6(7), 1249-
1257. 
Schmalbruch, H. (1984). Regenerated muscle fibers in Duchenne muscular dystrophy: a serial 
section study. Neurology, 34(1), 60-65. 
Schneider, H., Muhle, C., Douar, A. M., Waddington, S., Jiang, Q. J., von der Mark, K., et al. 
(2002). Sustained delivery of therapeutic concentrations of human clotting factor IX--a 
comparison of adenoviral and AAV vectors administered in utero. J Gene Med, 4(1), 46-
53. 
Sekhon, H. S., & Larson, J. E. (1995). In utero gene transfer into the pulmonary epithelium. Nat 
Med, 1(11), 1201-1203. 
Senoo, M., Matsubara, Y., Fujii, K., Nagasaki, Y., Hiratsuka, M., Kure, S., et al. (2000). 
Adenovirus-mediated in utero gene transfer in mice and guinea pigs: tissue distribution of 
recombinant adenovirus determined by quantitative TaqMan-polymerase chain reaction 
assay. Mol Genet Metab, 69(4), 269-276. 
 114 
Seppen, J., van der Rijt, R., Looije, N., van Til, N. P., Lamers, W. H., & Oude Elferink, R. P. 
(2003). Long-term correction of bilirubin UDPglucuronyltransferase deficiency in rats by 
in utero lentiviral gene transfer. Mol Ther, 8(4), 593-599. 
Sharp, N. J., Kornegay, J. N., Van Camp, S. D., Herbstreith, M. H., Secore, S. L., Kettle, S., et 
al. (1992). An error in dystrophin mRNA processing in golden retriever muscular 
dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics, 13(1), 
115-121. 
Shen, J. S., Meng, X. L., Maeda, H., Ohashi, T., & Eto, Y. (2004). Widespread gene transduction 
to the central nervous system by adenovirus in utero: implication for prenatal gene 
therapy to brain involvement of lysosomal storage disease. J Gene Med, 6(11), 1206-
1215. 
Shimizu, N., Chen, J., Gamou, S., & Takayanagi, A. (1996). Immunogene approach toward 
cancer therapy using erythrocyte growth factor receptor-mediated gene delivery. Cancer 
Gene Ther, 3(2), 113-120. 
Shinnick, T. M., Lerner, R. A., & Sutcliffe, J. G. (1981). Nucleotide sequence of Moloney 
murine leukaemia virus. Nature, 293(5833), 543-548. 
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. 
(1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. 
Science, 244(4912), 1578-1580. 
Smith, G. A., & Enquist, L. W. (2002). Break ins and break outs: viral interactions with the 
cytoskeleton of Mammalian cells. Annu Rev Cell Dev Biol, 18, 135-161. 
Srinivasakumar, N., Chazal, N., Helga-Maria, C., Prasad, S., Hammarskjold, M. L., & Rekosh, 
D. (1997). The effect of viral regulatory protein expression on gene delivery by human 
immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol, 
71(8), 5841-5848. 
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983). Nucleotide sequence and organization of the 
adeno-associated virus 2 genome. J Virol, 45(2), 555-564. 
Stedman, H. H., Sweeney, H. L., Shrager, J. B., Maguire, H. C., Panettieri, R. A., Petrof, B., et 
al. (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne 
muscular dystrophy. Nature, 352(6335), 536-539. 
Sun, B., Young, S. P., Li, P., Di, C., Brown, T., Salva, M. Z., et al. (2008). Correction of 
multiple striated muscles in murine Pompe disease through adeno-associated virus-
mediated gene therapy. Mol Ther, 16(8), 1366-1371. 
Sun, B., Zhang, H., Franco, L. M., Brown, T., Bird, A., Schneider, A., et al. (2005). Correction 
of glycogen storage disease type II by an adeno-associated virus vector containing a 
muscle-specific promoter. Mol Ther, 11(6), 889-898. 
 115 
Sun, B., Zhang, H., Franco, L. M., Young, S. P., Schneider, A., Bird, A., et al. (2005). Efficacy 
of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. 
Mol Ther, 11(1), 57-65. 
Tajbakhsh, S., Rocancourt, D., & Buckingham, M. (1996). Muscle progenitor cells failing to 
respond to positional cues adopt non-myogenic fates in myf-5 null mice. Nature, 
384(6606), 266-270. 
Tajbakhsh, S., Rocancourt, D., Cossu, G., & Buckingham, M. (1997). Redefining the genetic 
hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. 
Cell, 89(1), 127-138. 
Tanabe, Y., Esaki, K., & Nomura, T. (1986). Skeletal muscle pathology in X chromosome-linked 
muscular dystrophy (mdx) mouse. Acta Neuropathol, 69(1-2), 91-95. 
Tarantal, A. F., O'Rourke, J. P., Case, S. S., Newbound, G. C., Li, J., Lee, C. I., et al. (2001). 
Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector 
systems. Mol Ther, 3(2), 128-138. 
Taylor, P. A., McElmurry, R. T., Lees, C. J., Harrison, D. E., & Blazar, B. R. (2002). Allogenic 
fetal liver cells have a distinct competitive engraftment advantage over adult bone 
marrow cells when infused into fetal as compared with adult severe combined 
immunodeficient recipients. Blood, 99(5), 1870-1872. 
Themis, M., Waddington, S. N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., et al. 
(2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to 
fetal and neonatal mice. Mol Ther, 12(4), 763-771. 
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004). Rapid uncoating of vector 
genomes is the key to efficient liver transduction with pseudotyped adeno-associated 
virus vectors. J Virol, 78(6), 3110-3122. 
Thomas, G. D., Sander, M., Lau, K. S., Huang, P. L., Stull, J. T., & Victor, R. G. (1998). 
Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-
deficient skeletal muscle. Proc Natl Acad Sci U S A, 95(25), 15090-15095. 
Tidball, J. G., & Wehling-Henricks, M. (2004). Evolving therapeutic strategies for Duchenne 
muscular dystrophy: targeting downstream events. Pediatr Res, 56(6), 831-841. 
Tochio, H., Zhang, Q., Mandal, P., Li, M., & Zhang, M. (1999). Solution structure of the 
extended neuronal nitric oxide synthase PDZ domain complexed with an associated 
peptide. Nat Struct Biol, 6(5), 417-421. 
Torres, L. F., & Duchen, L. W. (1987). The mutant mdx: inherited myopathy in the mouse. 
Morphological studies of nerves, muscles and end-plates. Brain, 110 ( Pt 2), 269-299. 
 116 
Toumi, H., Hegge, J., Subbotin, V., Noble, M., Herweijer, H., Best, T. M., et al. (2006). Rapid 
intravascular injection into limb skeletal muscle: a damage assessment study. Mol Ther, 
13(1), 229-236. 
Towne, C., Raoul, C., Schneider, B. L., & Aebischer, P. (2008). Systemic AAV6 delivery 
mediating RNA interference against SOD1: neuromuscular transduction does not alter 
disease progression in fALS mice. Mol Ther, 16(6), 1018-1025. 
Trollet, C., Athanasopoulos, T., Popplewell, L., Malerba, A., & Dickson, G. (2009). Gene 
therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol 
Ther, 9(7), 849-866. 
Valentine, B. A., Cooper, B. J., Cummings, J. F., & de Lahunta, A. (1990). Canine X-linked 
muscular dystrophy: morphologic lesions. J Neurol Sci, 97(1), 1-23. 
Valentine, B. A., Cooper, B. J., Cummings, J. F., & deLahunta, A. (1986). Progressive muscular 
dystrophy in a golden retriever dog: light microscope and ultrastructural features at 4 and 
8 months. Acta Neuropathol, 71(3-4), 301-310. 
Valentine, B. A., Winand, N. J., Pradhan, D., Moise, N. S., de Lahunta, A., Kornegay, J. N., et 
al. (1992). Canine X-linked muscular dystrophy as an animal model of Duchenne 
muscular dystrophy: a review. Am J Med Genet, 42(3), 352-356. 
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., et al. 
(2006). Heparin binding directs activation of T cells against adeno-associated virus 
serotype 2 capsid. Nat Med, 12(8), 967-971. 
Vandendriessche, T., Thorrez, L., Acosta-Sanchez, A., Petrus, I., Wang, L., Ma, L., et al. (2007). 
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. 
lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost, 5(1), 16-24. 
Vihinen-Ranta, M., Suikkanen, S., & Parrish, C. R. (2004). Pathways of cell infection by 
parvoviruses and adeno-associated viruses. J Virol, 78(13), 6709-6714. 
Vincent, M. C., Trapnell, B. C., Baughman, R. P., Wert, S. E., Whitsett, J. A., & Iwamoto, H. S. 
(1995). Adenovirus-mediated gene transfer to the respiratory tract of fetal sheep in utero. 
Hum Gene Ther, 6(8), 1019-1028. 
Waddington, S. N., Buckley, S. M., Nivsarkar, M., Jezzard, S., Schneider, H., Dahse, T., et al. 
(2003). In utero gene transfer of human factor IX to fetal mice can induce postnatal 
tolerance of the exogenous clotting factor. Blood, 101(4), 1359-1366. 
Waddington, S. N., Nivsarkar, M. S., Mistry, A. R., Buckley, S. M., Kemball-Cook, G., Mosley, 
K. L., et al. (2004). Permanent phenotypic correction of hemophilia B in 
immunocompetent mice by prenatal gene therapy. Blood, 104(9), 2714-2721. 
Wagner, K. R., Lechtzin, N., & Judge, D. P. (2007). Current treatment of adult Duchenne 
muscular dystrophy. Biochim Biophys Acta, 1772(2), 229-237. 
 117 
Walther, W., & Stein, U. (2000). Viral vectors for gene transfer: a review of their use in the 
treatment of human diseases. Drugs, 60(2), 249-271. 
Wang, A. Y., Peng, P. D., Ehrhardt, A., Storm, T. A., & Kay, M. A. (2004). Comparison of 
adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum 
Gene Ther, 15(4), 405-413. 
Wang, B., Li, J., Fu, F. H., & Xiao, X. (2008). Systemic human minidystrophin gene transfer 
improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J 
Orthop Res. 
Wang, B., Li, J., Qiao, C., Chen, C., Hu, P., Zhu, X., et al. (2008). A canine minidystrophin is 
functional and therapeutic in mdx mice. Gene Ther, 15(15), 1099-1106. 
Wang, B., Li, J., & Xiao, X. (2000). Adeno-associated virus vector carrying human 
minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. 
Proc Natl Acad Sci U S A, 97(25), 13714-13719. 
Wang, G., Williamson, R., Mueller, G., Thomas, P., Davidson, B. L., & McCray, P. B., Jr. 
(1998). Ultrasound-guided gene transfer to hepatocytes in utero. Fetal Diagn Ther, 13(4), 
197-205. 
Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., et al. (2005). 
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: 
AAV2/8-mediated, liver-directed gene therapy. Blood, 105(8), 3079-3086. 
Wang, X., Liang, H. D., Dong, B., Lu, Q. L., & Blomley, M. J. (2005). Gene transfer with 
microbubble ultrasound and plasmid DNA into skeletal muscle of mice: comparison 
between commercially available microbubble contrast agents. Radiology, 237(1), 224-
229. 
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., et al. (2005). Adeno-associated virus 
serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol, 23(3), 321-328. 
Watchko, J., O'Day, T., Wang, B., Zhou, L., Tang, Y., Li, J., et al. (2002). Adeno-associated 
virus vector-mediated minidystrophin gene therapy improves dystrophic muscle 
contractile function in mdx mice. Hum Gene Ther, 13(12), 1451-1460. 
Watchko, J. F., Johnson, B. D., Gosselin, L. E., Prakash, Y. S., & Sieck, G. C. (1994). Age-
related differences in diaphragm muscle injury after lengthening activations. J Appl 
Physiol, 77(5), 2125-2133. 
Watchko, J. F., O'Day, T. L., & Hoffman, E. P. (2002). Functional characteristics of dystrophic 
skeletal muscle: insights from animal models. J Appl Physiol, 93(2), 407-417. 
Weiss, R. A. (1998). Retroviral zoonoses. Nat Med, 4(4), 391-392. 
Weiss, R. A., & Wrangham, R. W. (1999). From Pan to pandemic. Nature, 397(6718), 385-386. 
 118 
Wells, K. E., Fletcher, S., Mann, C. J., Wilton, S. D., & Wells, D. J. (2003). Enhanced in vivo 
delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx 
mouse muscle. FEBS Lett, 552(2-3), 145-149. 
Winand, N. J., Edwards, M., Pradhan, D., Berian, C. A., & Cooper, B. J. (1994). Deletion of the 
dystrophin muscle promoter in feline muscular dystrophy. Neuromuscul Disord, 4(5-6), 
433-445. 
Winnard, A. V., Klein, C. J., Coovert, D. D., Prior, T., Papp, A., Snyder, P., et al. (1993). 
Characterization of translational frame exception patients in Duchenne/Becker muscular 
dystrophy. Hum Mol Genet, 2(6), 737-744. 
Wong, S. H., Lowes, K. N., Quigley, A. F., Marotta, R., Kita, M., Byrne, E., et al. (2005). DNA 
electroporation in vivo targets mature fibres in dystrophic mdx muscle. Neuromuscul 
Disord, 15(9-10), 630-641. 
Wu, N., Watkins, S. C., Schaffer, P. A., & DeLuca, N. A. (1996). Prolonged gene expression and 
cell survival after infection by a herpes simplex virus mutant defective in the immediate-
early genes encoding ICP4, ICP27, and ICP22. J Virol, 70(9), 6358-6369. 
Xiao, X., Li, J., & Samulski, R. J. (1996). Efficient long-term gene transfer into muscle tissue of 
immunocompetent mice by adeno-associated virus vector. J Virol, 70(11), 8098-8108. 
Xiao, X., Li, J., & Samulski, R. J. (1998). Production of high-titer recombinant adeno-associated 
virus vectors in the absence of helper adenovirus. J Virol, 72(3), 2224-2232. 
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., et al. (2002). The atomic 
structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl 
Acad Sci U S A, 99(16), 10405-10410. 
Yang, E. Y., Kim, H. B., Shaaban, A. F., Milner, R., Adzick, N. S., & Flake, A. W. (1999). 
Persistent postnatal transgene expression in both muscle and liver after fetal injection of 
recombinant adenovirus. Journal of Pediatric Surgery, 34(5), 766-772; discussion 772-
763. 
Yoshida, M., Suzuki, A., Yamamoto, H., Noguchi, S., Mizuno, Y., & Ozawa, E. (1994). 
Dissociation of the complex of dystrophin and its associated proteins into several unique 
groups by n-octyl beta-D-glucoside. Eur J Biochem, 222(3), 1055-1061. 
Yoshimura, M., Sakamoto, M., Ikemoto, M., Mochizuki, Y., Yuasa, K., Miyagoe-Suzuki, Y., et 
al. (2004). AAV vector-mediated microdystrophin expression in a relatively small 
percentage of mdx myofibers improved the mdx phenotype. Mol Ther, 10(5), 821-828. 
Yue, Y., Ghosh, A., Long, C., Bostick, B., Smith, B. F., Kornegay, J. N., et al. (2008). A single 
intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal 
muscle transduction in dogs. Mol Ther, 16(12), 1944-1952. 
 119 
Zeira, E., Manevitch, A., Khatchatouriants, A., Pappo, O., Hyam, E., Darash-Yahana, M., et al. 
(2003). Femtosecond infrared laser-an efficient and safe in vivo gene delivery system for 
prolonged expression. Mol Ther, 8(2), 342-350. 
Zhao, J., Bauman, W. A., Huang, R., Caplan, A. J., & Cardozo, C. (2004). Oxandrolone blocks 
glucocorticoid signaling in an androgen receptor-dependent manner. Steroids, 69(5), 357-
366. 
Zhao, Y., Dai, Z. P., Lv, P., & Gao, X. M. (2002). Phenotypic and functional analysis of human 
T lymphocytes in early second- and third-trimester fetuses. Clin Exp Immunol, 129(2), 
302-308. 
Ziegler, R. J., Bercury, S. D., Fidler, J., Zhao, M. A., Foley, J., Taksir, T. V., et al. (2008a). 
Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-
glucosidase to correct the biochemical and motor function deficits of presymptomatic and 
symptomatic Pompe mice. Hum Gene Ther, 19(6), 609-621. 
Ziegler, R. J., Bercury, S. D., Fidler, J., Zhao, M. A., Foley, J., Taksir, T. V., et al. (2008b). 
Ability of Adeno-Associated Virus Serotype 8-Mediated Hepatic Expression of Acid 
alpha-Glucosidase to Correct the Biochemical and Motor Function Deficits of 
Presymptomatic and Symptomatic Pompe Mice. Hum Gene Ther. 
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008). Analysis of AAV serotypes 1-9 
mediated gene expression and tropism in mice after systemic injection. Mol Ther, 16(6), 
1073-1080. 
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997). Multiply attenuated 
lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol, 15(9), 871-875. 
 
 
